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9General Introduction
Pharmacotherapy is an essential aspect of medical treatments for curing or ameliorating 
diseases, relieving symptoms or preventing future complications. To achieve an optimal 
outcome one should ensure that the right drug is prescribed and administered to the right 
patient for the right reason in the right dosage and form, via the right route, at the right 
time with the right documentation and the right monitoring.1 Unfortunately drug-related 
problems, defi ned as circumstances during drug treatment that actually or potentially 
interfere with the achievement of the optimal outcome do occur.2
Drug-relateD Problems
Drug-related problems include medication errors and adverse drug events. Defi nitions of 
these terms and their relationship are presented in fi gure 1.
Preventable adverse 
drug events
Medication errors
No harm
Adverse drug 
events
Adverse drug reactions
Drug-related problems
Figure 1: Drug-related problems and their relationships
Drug-related problems  Circumstances during drug treatment that actually or potentially interfere with the 
achievement of an optimal outcome.2
Medication errors  Any error in the process of prescribing, transcribing, dispensing or administering a 
drug, whether there are adverse consequences or not.4
Adverse drug events  An injury resulting from medical intervention related to a drug.13
Preventable
adverse drug events An adverse drug event resulting from a medication error.85
Adverse drug reactions  A noxious and unintended response which occurs at doses normally used in humans 
for the prophylaxis, diagnosis, or therapy of disease, or for the modifi cation of physi-
ological function.9
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The publication of the report “To err is human” in 1999 showed that medication errors 
account for an increase in hospital costs of about $2 billion and over 7,000 deaths annu-
ally in the United States of America at that time.3 Since then, health care professionals 
increased their efforts to improve medication safety and studied the occurrence of drug-
related problems and their risk factors intensively, in particular in hospitalized patients.
medication errors and preventable adverse drug events
Medication errors are defined as any error in the process of prescribing, transcribing, dispens-
ing or administering a drug, whether there are adverse consequences or not.4 Errors occur 
when intended actions fail to proceed as intended (i.e. skill-based slips or memory-based 
lapses) or when the wrong plan is used to achieve the desired consequences (i.e. mistakes).5
A review on drug-related problems, published in 2007, indicated that about 6% of all 
medication orders prescribed to hospitalized patients, result in an error and most of these 
errors are made during prescribing and administering a drug.6 However, the prevalence 
varies highly, depending on the definition, detection method and setting.2, 6
It has been estimated that at most 10% of all medication errors result in patient harm, 
affecting 1% to 15% of hospitalized patients.6-8 This patient harm can vary from mild 
temporary discomfort to death. These harmful events caused by medication errors are 
referred to as preventable adverse drug events. For example, when penicillin is prescribed 
by mistake to a patient with a documented allergy for this drug, and the patient develops 
an anaphylactic reaction, this reaction could have been prevented by an electronic alert 
at the time of prescribing of the contra-indicated drug to this patient. Common other 
examples of medication errors that may result in preventable adverse drug events include 
overdoses of opiates leading to sedation or respiratory depression and lack of monitoring 
of anticoagulants leading to hemorrhage.7
adverse drug reactions
However, even without the existence of medication errors, the intrinsic toxicity of drugs 
can lead to patient harm. If, for example, the same penicillin is prescribed to a patient 
who has been treated before with this drug without any signs of allergy, the patient can 
develop an allergic reaction. Such noxious and unintended responses to drugs occurring 
at doses normally used are called adverse drug reactions9 and occur in about 7% to11% 
of hospitalized patients.2, 10
adverse drug events
Together, preventable adverse drug events and adverse drug reactions are called adverse 
drug events, which affect about 6% of hospitalized patients.11
It has been estimated in several studies that one quarter to more than half of the adverse 
drug events are related to medication errors.6, 7, 12-15 In primary care settings, where the 
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median prevalence of adverse drug events is 20%, about 16% of the events are thought to 
be preventable.16
In the Netherlands adverse drug events in hospitalized patients result in an excess length 
of stay of about 6 days and additional costs of more than €2500 per event.17 In addition, 
approximately 5% of acute hospital admissions in the Netherlands can be attributed to 
adverse drug events, of which about 40% are judged to be potentially preventable, resem-
bling the rates reported in the United States of America and Australia.15, 18
In comparison to medication errors, adverse drug events are more difficult to detect and 
assess. First, adverse drug events occur less frequently than medication errors. Second, a 
causality assessment using an algorithm is required to evaluate the likelihood that a drug 
was the causative agent of an observed event.9 Since this assessment can vary according to 
the professional background of the assessors, a consensus method, in which both pharma-
cists and physicians are involved, is recommended.19 Due to these difficulties medication 
errors are more often used as outcome to measure the effect of medication safety initiatives 
than (preventable) adverse drug events, assuming that a reduction of medication errors 
will subsequently lead to a reduction of adverse drug events. These safety initiatives are 
mainly targeted to identified risk factors for medication errors. However, risk factors for 
adverse drug events may (partly) differ from risk factors for medication errors, which 
would require different safety initiatives. Risk factors for the different types of drug-related 
problems have not been compared directly up to now.
risk FaCtors For Drug-relateD Problems
Knowledge on the origin of drug-related problems is a first step in reducing these prob-
lems. Therefore, risk factors for drug-related problems have been intensively studied. An 
overview of identified risk factors for drug-related problems is presented in table 1. In 
general, characteristics of the organization, the patient and the drug have all three been 
associated with the occurrence of drug-related problems.
Characteristics of the organization, including pharmacy services, have been associated 
with the occurrence of medication errors in particular.6, 20-22 The association of such or-
ganizational characteristics with (preventable) adverse drug events has not been assessed, 
except for ward type and lack of information about drugs or the patient.4, 7 On the other 
hand, patient characteristics, such as age6, 15, 23, 24 and the number of drugs used,6, 18, 24 have 
been mostly related with adverse drug events, reflecting a patient’s vulnerability to harm. 
Renal failure6, 18, 25 and liver failure23, 25 as comorbidity, requiring dose modifications or 
switching of contra-indicated drugs, have been associated with both medication errors 
and adverse drug events.
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Table 1: Risk factors for medication errors, preventable adverse drug events and adverse drug 
events (ADE)
Risk factor
Medication
error
Preventable
ADE ADE
Organizational characteristics
Ward ✓ 11,26 ✓ 6,11,23,84
Documentation and information
Errors in patient charts or nurses’ documentation ✓ 6
Lack of information about drugs or patients ✓ 6 ✓ 7,22
Knowledge and skills of health care professionals
Insufficient pharmacological knowledge ✓ 6
Insufficient training ✓ 20
Surgical specialists (versus medical specialists) ✓ 21
Residents (versus specialists) ✓ 21
Pharmacy services
Inadequate pharmacy services ✓ 6
Lack of standardization of the medication process ✓ 6
Lack of clinical pharmacists ✓ 6
Workload ✓ 6,20
Communication within a team ✓ 20,22
Patient characteristics
Female gender ✓ 6
Age ✓ 6,15,23,24
Weight ✓ 23
Increased length of stay ✓ 11 ✓ 6,11
Comorbidity
Renal failure ✓ 25 ✓ 6,18
Liver disease ✓ 25 ✓ 23
Impaired cognition ✓ 18
Enteral feeding tube ✓ 21
Thrombocytopenia ✓ 26
Number of comorbid conditions ✓ 11 ✓ 11,18,23, 84
Number of drugs and polypharmacy (≥5 drugs) ✓ 11 ✓ 6,11,18,24,84
Dependent living situation ✓ 18
Drug characteristics
Pharmacotherapeutic group
Drugs for gastrointestinal tract ✓ 21 ✓ 6,21
Anti-coagulants ✓ 6 ✓ 15,7 ✓ 6,84
Cardiovascular drugs ✓ 6 ✓ 15,7, 26 ✓ 6,26
Anti-infective agents ✓ 6 ✓ 7,15,17 ✓ 17,24
Antineoplastic agents ✓ 6 ✓ 15 ✓ 17
Drugs acting on the nervous system ✓ 21 ✓ 7,26 ✓ 6,24
Pharmaceutical dosage form ✓ 6,21 ✓ 23
Parenteral preparations ✓ 23
Inhalation, eye preparations, rectal preparations ✓ 21
Atypical dosage frequency ✓ 25
Continuation of pre-admission treatment ✓ 21
Hospital-initiated treatment ✓ 24
Weight-based dose calculation ✓ 6
✓ = Identified as risk factor. Abbreviations: ADE, adverse drug event.
13General Introduction
The pharmacotherapeutic group of the used drug seems to be the most important risk 
factor of the drug itself. Several drug classes, including anti-infective agents, drugs acting 
on the central nervous system, antineoplastic agents and anticoagulants have been related 
to medication errors and (preventable) adverse drug events, reflecting respectively the 
extrinsic and the intrinsic toxicity of these drugs.6, 7, 15, 17, 21, 24, 26
individuals with an intellectual disability: a population potentially at risk
The aforementioned risk factors are mostly addressed in hospitalized patients. Because 
a number of these risk factors, as described below, are pertinent in individuals with an 
intellectual disability in primary health care settings, this population may be especially at 
risk for drug-related problems.
First, they often suffer from multiple chronic morbid conditions requiring pharmaco-
therapy, including somatic diseases such as gastro-esophageal reflux disease,27 epilepsy,28 
and constipation29 as well as mental conditions, such as behavioral problems,30 anxiety31 
and depression.32 As a result, polypharmacy, defined as the concomitant use of five or 
more drugs, which has been identified as a risk factor for adverse drug events in the general 
population,18 occurs in up to 60% of the individuals with an intellectual disability.
Second, the life expectancy of adults with an intellectual disability is increasing and 
age-related frailty seems to start at a younger age than in the general population,33 possibly 
making them susceptible to inappropriate prescribing and adverse drug events.
Third, drugs acting on the central nervous system, associated with drug-related prob-
lems in the general population,6, 7, 21, 24, 26, are often prescribed to individuals with an 
intellectual disability for behavioral problems,30 notwithstanding limited evidence for this 
indication.34-36
Fourth, atypical symptoms of diseases and patients’ inability to communicate about 
disease, complicate diagnosing, prescribing and evaluating pharmacotherapy,37, 38 possibly 
leading to drug-related problems including undertreatment,39 overtreatment40 and dispro-
portionate continuation of pharmacotherapy without a clear indication.30
Finally, living in a residential care setting and impaired cognition, both known to be 
associated with adverse drug events requiring hospitalization in the general population,18 
are pertinent in individuals with an intellectual disability.
Despite the presence of these risk factors, the prevalence of drug-related problems in 
individuals with an intellectual disability is largely unknown.
interventions to reDuCe Drug-relateD Problems
Although risk factors related to patient characteristics or their pharmacotherapy have been 
identified, risk stratification approaches to identify patients at risks are disputed to be pro-
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ductive.26 Therefore, interventions to reduce drug-related problems are mainly focused on 
improvements at the organizational level, including the design of the medication process 
and clinical pharmacy services. One critical element of a safe organization is a blame-free 
error reporting system, used to monitor error rates, learn from experiences and to identify 
risk factors for errors and measures to diminish them.3 To increase the dissemination of 
knowledge obtained by these reporting systems, nationwide reporting systems have been 
developed in several countries.41
Besides, optimization of the pharmaceutical care process, such as a closed-loop system 
combining computerized physician order entry with barcode assisted dispensing and 
administering, could reduce the occurrence of drug-related problems. 42 Since this thesis 
focuses primarily on prescribing errors, computerized order entry will be discussed in 
some more detail.
Computerized physician order entry and clinical decision support systems 
(Cpoe/Cdss)
Computerized physician order entry in combination with clinical decision support sys-
tems, alerting physicians on potential drug-related problems during prescribing, has been 
shown to reduce the frequency of medication errors compared to handwritten prescribing. 
CPOE in combination with basic CDSS used currently in the Netherlands, providing 
support on dosing, drug-drug interactions, duplicate therapy and allergies, is less effec-
tive in reducing therapeutic prescribing errors, which are most strongly associated with 
preventable adverse drug events.43 This probably explains why the effect of CPOE on the 
reduction of preventable adverse drug events is less clear.44
In order to reduce pharmacotherapeutic errors and preventable adverse drug events, 
more advanced clinical decision support, combining medication data with biochemical 
results and patient history in so-called clinical rules, is being developed. In addition, these 
clinical rules can facilitate the early detection of adverse drug reactions.
Clinical rules are partly derived from electronic trigger tools, developed in the past to 
monitor adverse drug events.45-47 Examples of such rules include dose adjustments for 
patients with renal failure, requirement of additional drug therapy to prevent adverse drug 
reactions and abnormal biochemical values indicating toxicity.45-49 A defined validation 
process of these rules can result in an increase in the sensitivity and the specificity of the 
alerts,50 preventing alert fatigue, which is another disadvantage of basic CDSS.51
active participation of a clinical pharmacist
Another strategy to reduce drug-related problems is to integrate clinical pharmacists in the 
medical team on the ward. Because clinical pharmacists can combine current diagnoses, 
laboratory values, medical history, and prescribing guidelines with the actual pharma-
cotherapy of a patient they are able to reduce drug-related problems. Indeed, previous 
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studies have shown that participation of clinical pharmacists in the medical team can 
reduce prescribing errors, adverse drug events, length of stay and costs.52, 53 However, 
the contribution of a clinical pharmacist in addition to CPOE/CDSS has not been well 
established. Besides, limited personnel resources may hamper participation of clinical 
pharmacists on all wards on a daily basis, necessitating selection of patients at risk for 
drug-related problems using clinical rules.54
medication review
Previous studies have shown that medication review, defined as a systematic assessment 
of an individual’s pharmacotherapy that aims to evaluate and optimize medication,55 
performed by the physician and pharmacist, together with the patient, can reduce the 
number of drug-related problems, in particular in older patients with polypharmacy in 
the general population.55-59 Recently, a systematic tool to reduce inappropriate prescrib-
ing has been developed in the Netherlands for older patients with polypharmacy to 
facilitate medication reviews in this specific population.60 In this tool the Screening Tool 
to Alert doctors to Right Treatment (START) and the Screening Tool of Older Peoples’ 
Prescriptions (STOPP) are included to ease the detection of drug-related problems.61, 62 
In hospitalized patients, these START/STOPP criteria significantly reduced drug-related 
problems, which sustained during follow up for six months after discharge.63
Although a multidisciplinary annual medication review is demanded by the Dutch 
Healthcare Inspectorate in care organizations for individuals with an intellectual disability, 
studies on the effect of medication review in this population are scarce. Recently, a Dutch 
study showed that medication review reveals drug-related problems in 80% of individuals 
with an intellectual disability using at least one psychotropic drug.40 
In general, evidence for the contribution of pharmacists to patient care in this population 
is surprisingly scarce. O’Dwyer et al. reviewed all studies on pharmacists’ contributions to 
the care for individuals with an intellectual disability published between 1994 and 2014.64 
They were able to include only eight studies performed in this period. The results of these 
studies point in the same direction, namely that collaboration between pharmacists and 
healthcare providers, caregivers and patients with an intellectual disability can improve 
patient care. Effective improvements include a reduction in administration errors in 
patients with an enteral feeding tube by education of caregivers, reduction of prescribing 
rates of psychotropic drugs by consulting service (including medication review), increas-
ing patients knowledge on medication use by pharmacist counselling, and improvements 
in drug handling in organizations.64
16 Chapter 1
aCCePtanCe oF PharmaCists’ interventions
The organizational interventions to reduce drug-related problems, all result in the detec-
tion of potential drug-related problems in individual patients. For relevant problems that 
actually require a change in pharmacotherapy or additional monitoring, the clinical phar-
macist will contact the responsible physician (on the ward, by telephone or electronically) 
to propose an intervention for the individual patient to resolve the problem. To actually 
reduce drug-related problems, physicians need to implement recommendations that are 
clinically relevant for the patient. The reported acceptance rate of pharmacists’ interven-
tions varies between 52% and 98%, depending on setting, the method of detecting drug-
related problems and the means of communicating the interventions.65-76 The type of the 
underlying drug-related problem, the pharmacotherapeutic group of the drug involved, 
the type of interventions and the medical specialty of the ward have also been associated 
with the acceptance rate.67, 72, 77, 78 Most of the interventions in these studies were proposed 
by pharmacists that were integrated in the medical team on the ward, whereas in daily rou-
tine a substantial part of the interventions are proposed from the central pharmacy, at least 
in the Netherlands and surrounding countries in continental Europe. In order to improve 
pharmacy services and further decrease drug-related problems, detailed knowledge on the 
acceptance rate of interventions from these central pharmacy services and understanding 
of the factors that influence the acceptance rate and physicians’ reasons for non-acceptance 
is essential.
Summarizing, drug-related problems occur frequently in hospitalized patients and numer-
ous risk factors have been identified. However, an effective risk stratification method to 
identify patients at risk has not yet been developed.26 Besides, the studied interventions 
to reduce drug-related problems focus mainly on one intervention, whereas multi strategy 
approaches, combining CPOE/CDSS, clinical rules and active participation of clinical 
pharmacists, are usually operated in synergy in clinical practice.
Individuals with an intellectual disability may be especially at risk for drug-related 
problems, but the exact scope of these problems, associated risk factors and effective 
interventions need to be studied in this population.
aims anD outline oF this thesis
The main objectives of this thesis are to identify determinants for medication errors and 
patients at risk for adverse drug events (part I) and to evaluate the effect of clinical phar-
macists’ interventions to optimize pharmacotherapy (part II) in both hospitalized patients 
and individuals with an intellectual disability.
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part i determinants for medication errors and adverse drug events
In the first part of this thesis, determinants for medication errors are identified in hospital-
ized patients and individuals with an intellectual disability. Besides, a potential electronic 
trigger to detect adverse drug events in an early stage is studied.
In chapter 2 we compare the risk factors associated with medication errors resulting in 
patient harm with the risk factors for medication errors without harm in hospitalized 
patients, in order to assess whether these two types of drug-related problems share the 
same origin.
Older individuals with an intellectual disability may be especially at risk for prescribing 
errors, but data on the prevalence of prescribing errors are lacking in this population. 
Therefore, we study the occurrence of prescribing errors as well as determinants for these 
errors in this specific population in chapter 3.
Adverse drug events are not only difficult to assess in research, even in daily clinical prac-
tice health care professionals do not always recognize adverse drug events.45, 79, 80 However, 
the physician may have a suspicion before an adverse drug events becomes manifest. This 
so called “gut feeling” is a well-known phenomenon in medicine and leads to an increase 
in diagnostic procedures.81-83 Therefore, in chapter 4 we explore the association between 
the number of biochemical tests and the manifestation of adverse drug events .
part ii Clinical pharmacists’ interventions to optimize pharmacotherapy
The second part of this thesis focuses on possible interventions by clinical pharmacists to 
optimize pharmacotherapy in hospitalized patients and individuals with an intellectual 
disability.
Both implementation of CPOE/CDSS as well as active participation of clinical pharmacists 
can reduce drug-related problems in hospitalized patients. In chapter 5 the contribution 
of medication review by a clinical pharmacist to the detection of drug-related problems in 
addition to CPOE/CDSS is assessed.
The applicability of medication review using a systematic tool to reduce inappropriate 
prescribing in individuals with an intellectual disability and polypharmacy is evaluated in 
a pilot study, that is presented in chapter 6.
Physicians’ acceptance of pharmacists’ interventions for individual patients, identified 
by CPOE/CDSS, to reduce drug-related problems in daily clinical practice is studied in 
chapter 7. Subsequently, the experiences of physicians with pharmacists’ interventions, 
including their self-reported reasons for acceptance and non-acceptance are addressed in 
chapter 8.
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In the summarizing discussion, chapter 9, the main results are summarized and critically 
reviewed in a wider perspective. We will conclude with recommendations for patient care 
to optimize pharmacotherapy, based on the results of our studies, and some unresolved 
issues that require future research
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abstraCt
objective
To compare determinants for medication errors leading to patient harm with determinants 
for medication errors without patient harm.
methods
A two-way case-control design was used to identify determinants for medication errors 
without harm (substudy 1) and determinants for medication errors causing harm (sub-
study 2). Data of patients admitted to five internal medicine wards of two Dutch hospitals 
during five months were collected prospectively by chart review. Medication errors were 
detected and classified by two pharmacists. Consensus between five pharmacists was 
reached on the causal relationship between medication errors and patient harm. Data 
analysis was performed by multivariate logistic regression.
Results
We included 7286 medication orders, of which 3315 without errors (controls), and 5622 
medication errors without harm (cases substudy 1) and 102 medication errors causing 
harm (cases substudy 2) were identified.
Hospital, ward and the therapeutic class anti-infectives were associated with both 
medication errors without harm (hospital odds ratio (OR) 1.40; 95% confidence interval 
(CI) 1.21-1.63), TweeSteden hospital (TSh) geriatrics OR 2.03; 95% CI 1.73-2.38, TSh 
general internal medicine OR 1.44; 95% CI 1.23-1.69 and anti-infectives OR 1.28; 95% 
CI 1.06-1.56) and medication errors with harm (hospital OR 4.91; 95% CI 3.02-7.79, 
TSh geriatrics OR 5.76; 95% CI 2.52-13.15, TSh general internal medicine OR 6.51; 
95% CI 2.82-15.02 and anti-infectives OR 4.20; 95% CI 2.24-7.90).
Conclusions
This study shows that organizational determinants (hospital, ward) are comparable for 
medication errors with and without harm. For conclusions on patient- and medication 
related determinants studies with larger sample sizes are needed.
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introDuCtion
The prevalence of medication errors in hospitals is about 6% of all medication orders 
and approximately 10% of all medication errors is estimated to result in patient harm.1 
Whether or not a medication error results in patient harm depends on whether the er-
ror reaches the patient and when it does, on the intrinsic toxicity of the drug and the 
susceptibility of the patient to adverse events. Also, certain types of medication errors are 
more likely to cause patient harm than others, e.g. therapeutic prescribing errors result in 
harm more often than administrative prescribing errors do.2-5
Despite the fact that not all medication errors lead to patient harm, the impact of the 
problem of adverse drug events (ADEs) induced by such errors is rather large. The report 
“To err is human” showed that in the United States 2% of all admitted patients is harmed 
as a result of a medication error and that 7000 patients die from medication errors annu-
ally.6 This report has led to a renewed interest of health care professionals in improving 
medication safety. Such improvements can be achieved by effective interventions targeted 
at identified risk factors that contribute to unsafe practices and potential patient harm.
Whereas preventing actual patient harm is the ultimate goal of such medication safety 
initiatives, medication errors are often used as a surrogate outcome measure, because these 
occur more frequently and are easier to detect. However, the validity of this surrogate end 
point has not been established and it is unknown whether the risk factors associated with 
medication errors causing patient harm are the same as the risk factors associated with 
medication errors that do not cause harm. Therefore, we performed a study to compare 
the determinants for medication errors resulting in patient harm and the determinants for 
medication errors not resulting in harm.
methoDs
design and setting
The design of the current study is a two-way case-control study. In a first substudy (1st 
way) medication orders with errors not leading to patient harm (cases) were compared to 
medication orders without errors (controls). This first substudy aimed to identify determi-
nants for medication errors not leading to patient harm. In the second substudy (2nd way) 
medication orders with errors leading to patient harm (cases) were again compared to the 
same medication orders without errors (controls) to identify determinants for medication 
errors leading to patient harm. Subsequently, determinants that were identified in the first 
substudy were compared with determinants identified in the second substudy.
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This study is part of the POEMS study on the effect of a Computerized Physician Order 
Entry (CPOE) system on Medication Safety and associated costs.5, 7, 8 The POEMS study 
is a prospective intervention study, performed in two medical wards (one geriatric and one 
general internal medicine ward) of the 600 bed teaching hospital “TweeSteden” (TSh) in 
Tilburg and Waalwijk and three medical wards (two general internal medicine wards and 
one gastroenterology/rheumatology ward) of the 1300 bed University Medical Center in 
Groningen (UMCG), the Netherlands. The current study uses data of the period before the 
introduction of the CPOE-system. The process of medication ordering and administration 
consisted of a hand-written system: physicians prescribed medication orders on charts and 
nurses transcribed these medication orders on administration charts. Therefore, clinical 
decision support could not be provided to physicians at the time of prescribing medication.
patients
From July through November 2005 all patients admitted to the study wards for more than 
24 hours were included. Patients received written information about the study after which 
they could object to inclusion. A waiver of the Medical Ethical Committee was obtained 
for this study, as the study fell within the boundaries of normal hospital care and routine 
of quality improvement and assurance.
data collection
During ward visits the investigators prospectively extracted patients’ characteristics (age, 
sex, weight and length) and data on diseases (medical history, reasons for admission and 
diagnoses) and adverse events (i.e. untoward medical occurrences which do not have to 
have a causal relationship with the treatment9) from medical records. Medication orders 
issued during hospitalisation were collected by reviewing medication order charts and ad-
ministration charts. For ethical reasons, the physician was informed in case of potentially 
life threatening errors that were discovered during the process of data collection. These 
errors were not excluded from the study.
Classification of prescribing and transcribing errors
Medication errors were identified and categorized by two pharmacists according to the 
classification scheme for medication errors developed by the Dutch Association of Hos-
pital Pharmacists.10 During a pilot phase in the UMCG the two pharmacists were trained 
together to extract and classify medication errors uniformly. The classification distinguishes 
prescribing, transcribing, dispensing, administering and “across settings” errors. In this study 
only prescribing and transcribing errors were recorded. Prescribing errors are subdivided 
into administrative errors (errors on readability, patient data, ward and prescriber data, drug 
name, dosage form and route of administration), dosing errors (errors on strength, frequency, 
dosage, length of therapy and directions for use) and therapeutic errors (interactions, contra-
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indications, incorrect mono-therapy, duplicate therapy and errors on therapeutic drug 
monitoring or laboratory monitoring). Inappropriate drug choices were not actively assessed 
and were only taken into account when they were obvious. Transcribing errors are defined as 
errors in the process of interpreting, verifying and transcribing of medication orders.
The severity of all medication errors was assessed according to the index of the National 
Coordinating Council for Medication Error Reporting and Preventing (NCC MERP), 
which categorises medication errors into nine categories (A-I) based on severity of related 
patient outcomes (table 1).11 In this study, medication errors were divided into errors that 
did not lead to patient harm (NCC MERP category B up to D) and errors that did lead 
to harm (NCC MERP category E up to I).
patient harm
Patient harm was defined as a preventable adverse drug event (pADE) which is an adverse 
drug event (ADE) that occurred due to a medication error with a possible or probable 
causal relationship with the medication error. To assess this relationship an algorithm was 
developed, based on the NCC MERP index and the Yale algorithm.5, 11, 12 Our combined 
algorithm was described in detail and validated in a previous publication.5 The Yale al-
gorithm (table 2) assesses the causality of the association between a drug and an adverse 
event. In our algorithm the first three items of the Yale algorithm were used: knowledge 
about the relation between the drug and the event, the presence of underlying clinical con-
ditions which could be responsible for the event and the timing of the event. The causal 
relations between all medication errors made and the adverse events extracted from the 
medical records were assessed by five pharmacists. After individual assessment consensus 
was reached for all cases on both causality and severity. The causal relationship could be 
Table 1: NCC MERP Categories
Category Content
A No harm Circumstances or events that have the capacity to cause error
B An error occurred but the error did not reach the patient
C An error occurred that reached the patient but did not cause patient harm
D An error occurred that reached the patient and required monitoring to confirm 
that it resulted in no harm to the patient and/or required intervention to 
preclude harm
E Patient 
harm
An error occurred that may have contributed to or resulted in temporary harm 
to the patient and required intervention
F An error occurred that may have contributed to or resulted in temporary harm 
to the patient and required initial or prolonged hospitalization
G An error occurred that may have contributed to or resulted in permanent 
patient harm
H An error occurred that required intervention necessary to sustain life
I An error occurred that may have contributed to or resulted in the patient’s death
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defined as unlikely (score < 0), possible (score ≥ 0 and ≤ 3) or probable (score = 4). An 
event was defined as patient harm when consensus was reached on a possible or probable 
relationship with the medication error. Earlier we described the interobserver reliability on 
the presence of a preventable ADE and the severity of the preventable ADE assessed with 
the combined algorithm.5
determinants
Determinants for medication errors or (preventable) ADEs that were identified in previ-
ous studies were included, provided that the data could be extracted from medical records 
or medication orders.1-4, 13-23 Potential determinants of medication errors with and without 
patient harm that were studied were organizational characteristics (hospital, ward, transfer 
from another hospital ward or care institution, length of stay and readmission to study 
ward during study period), patient characteristics (gender, age, renal impairment (defined 
as creatinine clearance ≤ 50 ml/min during hospitalization) and the number of medication 
orders per patient during hospital stay), characteristics of the medication order (weekday 
of prescription, dosage frequency less than once daily and route of administration) and 
the therapeutic area of the medication (identified by Anatomical-Therapeutic- Chemical 
(ATC) code).
data analysis
All data were processed with MS Access 2003 and analysed with SPSS version 16.0.
Table 2: Simplified Yale algorithm (JAMA 1979;242:623-632)
+1 0 -1 Score
Axis 1 Adverse event is well accepted 
as ADR to
suspected drug.
Adverse event is not 
well known or drug 
is new.
Adverse event previously 
unreported as ADR to 
well-known drug.
Axis 2 a) No good alternative 
candidate
(score +2)
b) Otherwise unexplained 
exacerbation or recurrence of 
underlying illness
(score +1)
Alternative 
candidate(s) exist, 
but no good ones.
Good alternative 
candidate.
Axis 3 Timing as expected for ADR for 
this adverse event - drug pair.
Timing equivocal or 
non-assessable
Timing inconsistent for 
ADR for this adverse event 
- drug pair (score -2)
Total score
Score < 0: ADR is unlikely
Score ≥ 0 and ≤ 3: ADR is possible
Score = 4: ADR is probable
Abbreviations: ADR, adverse drug reaction
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Determinants for medication errors that did not lead to patient harm were identified 
by comparing medication orders containing these errors with medication orders without 
errors (substudy 1). Determinants for medication errors that resulted in patient harm 
were identified by comparing medication orders containing these errors with medication 
orders without errors (substudy 2). Univariate logistic regression analysis was performed 
with the medication order as unit of analysis. Multiple errors could have been made in one 
medication order and analysis was performed for each medication error separately.
For determinants that were statistically significantly associated (p<0.05) with errors in 
the univariate analysis, a multivariable logistic regression analysis was performed using 
a manual stepwise forward logistic regression model. Determinants were consecutively 
entered into the model and when they changed the beta coefficient with at least 10% their 
contribution was considered relevant and the determinant remained in the model. Crude 
and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. 
Determinants that were significantly associated with medication errors without harm in 
substudy 1 were compared to determinants for medication errors leading to patient harm 
identified in substudy 2.
Admissions 
n=592 
 
Female: 55%      
Age (mean ± SD): 65.5 ± 19.2 years 
Length of stay on study wards (mean ± SD): 14.6 ± 12.5 days 
 
Total medication orders 
n=7286 
Controls 
Medication orders without errors  
n=3315 
Cases (substudy 1) 
Medication errors  
without harm 
n=5622  
Cases (substudy 2) 
Medication errors  
with harm 
n=102 
 
Medication orders with errors 
n=3971  
Medication errors 
n=5724  
Figure 1: Patient characteristics, medication orders and medication errors
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results
During data collection 558 patients were included and four patients were excluded from 
the study due to objection to inclusion. Since 28 patients were re-admitted once and three 
patients were re-admitted twice, 592 admissions were included in the study. During these 
admissions 7286 medication orders were prescribed of which 3315 contained no error 
(controls). In the other 3971 medication orders a total of 5724 medication errors were 
identified of which 5622 did not cause patient harm (cases substudy 1) and 102 resulted 
in patient harm (cases substudy 2) (Figure 1). Nine medication errors were considered 
serious enough to require an intervention by the investigators to preclude harm. These 
errors were classified as errors that did not result in patient harm, but which required 
interventions to preclude harm (NCC MERP category D).
Table 3: Organisational characteristics associated with medication errors with and without patient harm 
after univariate logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1) Medication errors with harm (substudy 2)
Controls 
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases 
n (%)
OR 95% CI ORadj 95% CI
Hospital
TSh (UMCG is reference) 1459 (44.0) 3468 (61.7) 2.05 1.88-2.24 1.401 1.21-1.63 81 (79.4) 4.91 3.02-7.97 4.912 3.02-7.97
Ward
UMCG General internal medicine 732 (22.1) 904 (16.1) ref ref 7 (6.9) ref ref
UMCG Gastroenterology/ 
rheumatology
1124 (33.9) 1250 (22.2) 0.90 0.79-1.02 0.933 0.79-1.08 14 (13.7) 1.30 0.52-3.24 1.734 0.68-4.41
TSh Geriatrics 796 (24.0) 2250 (40.0) 2.29 2.02-2.60 2.033 1.73-2.38 49 (48.0) 6.44 2.90-14.30 5.764 2.52-13.15
TSh General internal medicine 663 (20.0) 1218 (21.7) 1.49 1.30-1.70 1.443 1.23-1.69 32 (31.4) 5.05 2.21-11.51 6.514 2.82-15.02
Transfer from: (n=8255/ n=3056)
Home (ref) 1566 (52.7) 3175 (60.1) ref ref 56 (59.6) ref
Another hospital ward 254 (8.5) 446 (8.4) 0.87 0.73-1.02 0.685 0.58-0.81 9 (9.6) 0.99 0.48-2.02
Care institution 1151 (38.7) 1663 (31.5) 0.71 0.65-0.79 0.865 0.78-0.96 29 (30.9) 0.71 0.45-1.11
Length of stay (days, mean ± SD)* 19.2 ± 15.5 22.2 ± 17.0 1.01 1.01-1.02 1.026 1.01-1.02 20.4 ± 11.7 1.00 0.99-1.02
Readmission 233 (7.0) 360 (6.4) 0.91 0.76-1.07 8 (7.8) (7.8) 1.13 0.54-2.35
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio; TSh, 
TweeSteden hospital; UMCG, University Medical Center Groningen; ref, reference
1: Ward, transfer and day of prescription contributed significantly to the model
2: No confounding factors were identified
3: Transfer, length of stay, age group, renal impairment, number of medication orders, day of prescription and  
pharmacotherapeutic area contributed significantly to the model
4: Age and pharmacotherapeutic area contributed significantly to the model
5: Hospital, ward and length of stay contributed significantly to the model
6: Number of medication orders contributed significantly to the model
* Analyzed as a continuous variable
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Details of the univariate and multivariate analysis of organizational characteristics, patient 
characteristics, characteristics of the medication order and the therapeutic area are pre-
sented in Tables 3-6.
After multivariate analysis, the following determinants were significantly associated 
with medication errors without patient harm: hospital, ward, transfer of patient, length 
of hospital stay, number of medication orders per patient during hospital stay, weekday of 
the prescription, route of administration and the therapeutic classes cardiovascular tract, 
genitourinary system and hormonal system, hormonal systemic therapy, anti-infectives, 
musculoskeletal system, nervous system and respiratory tract. Of these determinants the 
following were also statistically significantly associated with medication errors with harm: 
hospital, ward and therapeutic class anti-infectives.
All other determinants that were statistically significantly associated with medication 
errors without harm (transfer of patient, length of hospital stay, number of medication 
orders per patient, day of prescription, route of administration and the other therapeutic 
Table 3: Organisational characteristics associated with medication errors with and without patient harm 
after univariate logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1) Medication errors with harm (substudy 2)
Controls 
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases 
n (%)
OR 95% CI ORadj 95% CI
Hospital
TSh (UMCG is reference) 1459 (44.0) 3468 (61.7) 2.05 1.88-2.24 1.401 1.21-1.63 81 (79.4) 4.91 3.02-7.97 4.912 3.02-7.97
Ward
UMCG General internal medicine 732 (22.1) 904 (16.1) ref ref 7 (6.9) ref ref
UMCG Gastroenterology/ 
rheumatology
1124 (33.9) 1250 (22.2) 0.90 0.79-1.02 0.933 0.79-1.08 14 (13.7) 1.30 0.52-3.24 1.734 0.68-4.41
TSh Geriatrics 796 (24.0) 2250 (40.0) 2.29 2.02-2.60 2.033 1.73-2.38 49 (48.0) 6.44 2.90-14.30 5.764 2.52-13.15
TSh General internal medicine 663 (20.0) 1218 (21.7) 1.49 1.30-1.70 1.443 1.23-1.69 32 (31.4) 5.05 2.21-11.51 6.514 2.82-15.02
Transfer from: (n=8255/ n=3056)
Home (ref) 1566 (52.7) 3175 (60.1) ref ref 56 (59.6) ref
Another hospital ward 254 (8.5) 446 (8.4) 0.87 0.73-1.02 0.685 0.58-0.81 9 (9.6) 0.99 0.48-2.02
Care institution 1151 (38.7) 1663 (31.5) 0.71 0.65-0.79 0.865 0.78-0.96 29 (30.9) 0.71 0.45-1.11
Length of stay (days, mean ± SD)* 19.2 ± 15.5 22.2 ± 17.0 1.01 1.01-1.02 1.026 1.01-1.02 20.4 ± 11.7 1.00 0.99-1.02
Readmission 233 (7.0) 360 (6.4) 0.91 0.76-1.07 8 (7.8) (7.8) 1.13 0.54-2.35
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio; TSh, 
TweeSteden hospital; UMCG, University Medical Center Groningen; ref, reference
1: Ward, transfer and day of prescription contributed significantly to the model
2: No confounding factors were identified
3: Transfer, length of stay, age group, renal impairment, number of medication orders, day of prescription and  
pharmacotherapeutic area contributed significantly to the model
4: Age and pharmacotherapeutic area contributed significantly to the model
5: Hospital, ward and length of stay contributed significantly to the model
6: Number of medication orders contributed significantly to the model
* Analyzed as a continuous variable
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classes) showed no association with medication errors with harm in the univariate analysis 
already, had insufficient cases per category to analyze the association or showed a different 
trend in the odds ratio. No determinants for medication errors leading to harm were 
identified that had not been identified as determinant for medication errors without harm.
DisCussion
This study is the first study on the comparison of determinants for medication errors 
with and without consequent patient harm. Hospital, ward and the therapeutic class of 
anti-infectives were shown to be determinants for both types of medication errors.
In this study relatively few medication errors causing patient harm were identified, 
despite the collection of more than 7000 medication orders during five months of daily 
ward visits. This main limitation of our study may explain why many of the determinants 
that were identified in the multivariate analysis for medication errors without harm, were 
non-significant in the univariate analysis for medication errors with harm.
Table 4: Patient characteristics associated with medication errors with and without patient harm after 
univariate logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1) Medication errors with harm (substudy 2)
Controls
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases 
n (%)
OR 95% CI ORadj 95% CI
Female gender (male is reference) 1780 (53.7) 2990 (53.2) 0.98 0.90-1.07 47 (46.1) 0.74 0.50-1.10
Age (years, mean ± SD)* 67.1 ± 17.8 70.8 ± 16.8 1.01 1.01-1.02 1.001 1.00-1.01 74.1 ± 14.8 1.03 1.01-1.04 1.012 1.00-1.03
<50 years 605 (18.3) 778 (13.8) ref ref 9 (8.8) ref ref
50 to 64 years 668 (20.2) 882 (15.7) 1.03 0.89-1.19 1.003 0.85-1.18 12 (11.8) 1.21 0.51-2.89 1.354 0.56-3.26
65 to 79 years 1053 (31.8) 1859 (33.1) 1.38 1.21-1.56 0.993 0.84-1.17 38 (37.3) 2.43 1.17-5.05 1.774 0.81-3.90
≥ 80 years 989 (29.8) 2103 (37.4) 1.65 1.45-1.88 1.023 0.85-1.23 43 (42.2) 2.92 1.42-6.04 1.744 0.76-4.02
Renal impairment 1700 (51.3) 3176 (56.5) 1.23 1.13-1.34 1.035 0.92-1.16 61 (59.8) 1.41 0.95-2.11
Number of medication orders
(mean ± SD)*
18.2 ± 10.7 19.2 ± 17.0 1.01 1.00-1.01 0.996 0.99-1.00 18.3 ± 9.1 1.00 0.98-1.02
Polyfarmacy (>4) 3253 § (98.1) § 5534 (98.4) 1.20 0.86-1.66 103§ (99.0)§ 1.99 0.27-14.52
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio
1: Hospital, ward, length of stay and pharmacotherapeutic area contributed significantly to the model
2: Hospital contributed significantly to the model
3: Hospital, ward, transfer, length of stay, renal impairment, number of medication orders, day of prescription,  
route of administration and pharmacotherapeutic area contributed significantly to the model
4: Hospital, ward and pharmacotherapeutic area contributed significantly to the model
5: Hospital, ward, transfer, length of stay, age, number of medication orders, day of prescription, route of  
administration and pharmacotherapeutic area contributed significantly to the model
6: Hospital, ward, transfer, length of stay, day of prescription, route of administration and pharmacotherapeutic 
 area contributed significantly to the model
* Analyzed as a continuous variable
§ Dummy variables included
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The determinants hospital and ward point in the same direction, namely that errors 
(either with or without harm) probably occur more often in the TSh than in the UMCG. 
Thus, even after correction for case-mix, it remains likely that the personnel or local 
processes influence the prevalence of errors, irrespective of the outcome.
Therefore, it may be concluded that for these organizational determinants, medication 
errors are an acceptable surrogate outcome measure for patient harm. This corresponds 
with findings of previous studies separately showing that organizational determinants are 
linked to respectively medication errors and pADEs. 2, 4, 14, 16, 19, 21
Differences between the two hospitals and wards might be explained by differences in 
training of the physicians.1, 16, 19, 21, 24, 25 The UMCG is a university tertiary care teaching 
hospital while the TSh is a secondary care teaching hospital, where less education may lead 
to more errors.
Due to the limited power of our study for medication errors leading to harm, definite 
conclusions on determinants that are more patient- or medication-related can not be 
drawn, with the possible exception of anti-infectives. The association between anti-infec-
tives and errors might be explained by the fact that choosing the right anti-infective for an 
Table 4: Patient characteristics associated with medication errors with and without patient harm after 
univariate logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1) Medication errors with harm (substudy 2)
Controls
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases 
n (%)
OR 95% CI ORadj 95% CI
Female gender (male is reference) 1780 (53.7) 2990 (53.2) 0.98 0.90-1.07 47 (46.1) 0.74 0.50-1.10
Age (years, mean ± SD)* 67.1 ± 17.8 70.8 ± 16.8 1.01 1.01-1.02 1.001 1.00-1.01 74.1 ± 14.8 1.03 1.01-1.04 1.012 1.00-1.03
<50 years 605 (18.3) 778 (13.8) ref ref 9 (8.8) ref ref
50 to 64 years 668 (20.2) 882 (15.7) 1.03 0.89-1.19 1.003 0.85-1.18 12 (11.8) 1.21 0.51-2.89 1.354 0.56-3.26
65 to 79 years 1053 (31.8) 1859 (33.1) 1.38 1.21-1.56 0.993 0.84-1.17 38 (37.3) 2.43 1.17-5.05 1.774 0.81-3.90
≥ 80 years 989 (29.8) 2103 (37.4) 1.65 1.45-1.88 1.023 0.85-1.23 43 (42.2) 2.92 1.42-6.04 1.744 0.76-4.02
Renal impairment 1700 (51.3) 3176 (56.5) 1.23 1.13-1.34 1.035 0.92-1.16 61 (59.8) 1.41 0.95-2.11
Number of medication orders
(mean ± SD)*
18.2 ± 10.7 19.2 ± 17.0 1.01 1.00-1.01 0.996 0.99-1.00 18.3 ± 9.1 1.00 0.98-1.02
Polyfarmacy (>4) 3253 § (98.1) § 5534 (98.4) 1.20 0.86-1.66 103§ (99.0)§ 1.99 0.27-14.52
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio
1: Hospital, ward, length of stay and pharmacotherapeutic area contributed significantly to the model
2: Hospital contributed significantly to the model
3: Hospital, ward, transfer, length of stay, renal impairment, number of medication orders, day of prescription,  
route of administration and pharmacotherapeutic area contributed significantly to the model
4: Hospital, ward and pharmacotherapeutic area contributed significantly to the model
5: Hospital, ward, transfer, length of stay, age, number of medication orders, day of prescription, route of  
administration and pharmacotherapeutic area contributed significantly to the model
6: Hospital, ward, transfer, length of stay, day of prescription, route of administration and pharmacotherapeutic 
 area contributed significantly to the model
* Analyzed as a continuous variable
§ Dummy variables included
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infection could be more difficult than choosing drugs for other indications. Moreover, the 
dosage of most anti-infectives must be adjusted according to the patient’s renal function, 
so dosage errors are made more easily. Theoretically it seems likely that for medication 
errors leading to patient harm, specific determinants may be identified that reflect either 
the vulnerability of the patient to experience pADEs or the intrinsic toxicity of the medi-
cation. Anti-infectives, for example, have a great intrinsic toxicity and are prescribed to 
acutely ill patients, who are very susceptible for ADEs. This might explain the association 
between anti-infectives and ADEs. 1-3, 14, 17, 19, 22, 23 Again, the determinants identified in 
our study for medication errors without harm were identified in other studies, both for 
medication errors (identified determinants were number of medication orders per patient, 
Table 5: Characteristics of the medication order associated with medication errors with and without patient 
Tharm after univariate logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1)
Medication errors with harm 
(substudy 2)
Controls
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases 
n (%)
OR 95% CI
Day of prescription (n=8899/3398)
Monday 631 (19.1) 959 (17.1) ref ref 18 (17.8) ref
Tuesday 559 (17.0) 871 (15.5) 1.03 0.89-1.19 1.031 0.88-1.20 15 (14.9) 0.94 0.47-1.88
Wednesday 557 (16.9) 971 (17.3) 1.15 0.99-1.33 1.101 0.94-1.27 21 (20.8) 1.32 0.70-2.51
Thursday 530 (16.1) 951 (17.0) 1.18 1.02-1.37 1.081 0.93-1.26 20 (19.8) 1.32 0.70-2.53
Friday 587 (17.8) 1120 (20.0) 1.26 1.09-1.45 1.221 1.05-1.41 18 (17.8) 1.08 0.55-2.09
Saturday 203 (6.2) 352 (6.3) 1.14 0.93-1.40 1.281 1.04-1.57 7 (6.9) 1.21 0.50-2.94
Sunday 230 (7.0) 378 (6.7) 1.08 0.89-1.31 1.171 0.96-1.43 2 (2.0) 0.31 0.07-1.32
Weekend (weekdays are
reference)
433 (13.1) 730 (13.0) 0.99 0.87-1.13 9 (8.9) 0.65 0.32-1.29
Dosage frequency < once daily 84 § (2.5) § 163 (2.9) 1.16 0.89-1.52 1 § (1.0) § 0.37 0.05-2.71
Route of administration
Oral 2346 (70.8) 3701 (65.8) ref ref 72 (70.6) ref
Topical 35 (1.1) 94 (1.7) 1.70 1.15-2.52 2.132 0.99-4.62 1 (1.0) 0.93 0.13-6.89
Inhalation 66 (2.0) 209 (3.7) 2.01 1.52-2.66 1.172 0.71-1.92 4 (3.9) 1.98 0.70-5.57
Dermal 19 (0.6) 123 (2.2) 4.10 2.52-6.67 3.312 1.31-8.41 0 (0) †
Parenteral 758 (22.9) 1121 (19.9) 0.94 0.84-1.04 1.042 0.91-1.18 23 (22.5) 0.99 0.61-1.59
Rectal 62 (1.9) 280 (5.0) 2.86 2.16-3.79 3.192 2.33-4.37 2 (2.0) 1.05 0.25-4.38
Transdermal 29 (0.9) 55 (1.0) 1.20 0.76-1.89 0.912 0.52-1.57 0 (0) †
Sublingual 0 (0) 39 (0.7) † † 0 (0) †
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio ref, reference
1: Hospital, ward, length of stay, route of administration and pharmacotherapeutic area contributed significantly  
to the model
2: Hospital, ward, transfer, length of stay, number of medication orders, day of prescription and  
pharmacotherapeutic area contributed significantly to the model
† Statistical analysis not possible due to insufficient data
§ Dummy variables included
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route of administration and pharmacotherapeutic area1, 18, 20) and for (preventable) ADEs 
(identified determinants were among others number of medication orders per patient and 
therapeutic area1, 14, 17, 19, 20, 22, 23). However, none of these previous studies compared the 
determinants for medication errors without harm with the determinants for medication 
errors leading to patient harm.
A number of explanations for identified associations between specific determinants and 
the risk of medication errors without harm can be given. First of all, transfer of patients 
from home was associated with medication errors without harm in this study. Because no 
medication reconciliation was performed at admission, errors can be made more easily 
when patients are admitted from home, compared to transfers between hospital wards or 
Table 5: Characteristics of the medication order associated with medication errors with and without patient 
Tharm after univariate logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1)
Medication errors with harm 
(substudy 2)
Controls
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases 
n (%)
OR 95% CI
Day of prescription (n=8899/3398)
Monday 631 (19.1) 959 (17.1) ref ref 18 (17.8) ref
Tuesday 559 (17.0) 871 (15.5) 1.03 0.89-1.19 1.031 0.88-1.20 15 (14.9) 0.94 0.47-1.88
Wednesday 557 (16.9) 971 (17.3) 1.15 0.99-1.33 1.101 0.94-1.27 21 (20.8) 1.32 0.70-2.51
Thursday 530 (16.1) 951 (17.0) 1.18 1.02-1.37 1.081 0.93-1.26 20 (19.8) 1.32 0.70-2.53
Friday 587 (17.8) 1120 (20.0) 1.26 1.09-1.45 1.221 1.05-1.41 18 (17.8) 1.08 0.55-2.09
Saturday 203 (6.2) 352 (6.3) 1.14 0.93-1.40 1.281 1.04-1.57 7 (6.9) 1.21 0.50-2.94
Sunday 230 (7.0) 378 (6.7) 1.08 0.89-1.31 1.171 0.96-1.43 2 (2.0) 0.31 0.07-1.32
Weekend (weekdays are
reference)
433 (13.1) 730 (13.0) 0.99 0.87-1.13 9 (8.9) 0.65 0.32-1.29
Dosage frequency < once daily 84 § (2.5) § 163 (2.9) 1.16 0.89-1.52 1 § (1.0) § 0.37 0.05-2.71
Route of administration
Oral 2346 (70.8) 3701 (65.8) ref ref 72 (70.6) ref
Topical 35 (1.1) 94 (1.7) 1.70 1.15-2.52 2.132 0.99-4.62 1 (1.0) 0.93 0.13-6.89
Inhalation 66 (2.0) 209 (3.7) 2.01 1.52-2.66 1.172 0.71-1.92 4 (3.9) 1.98 0.70-5.57
Dermal 19 (0.6) 123 (2.2) 4.10 2.52-6.67 3.312 1.31-8.41 0 (0) †
Parenteral 758 (22.9) 1121 (19.9) 0.94 0.84-1.04 1.042 0.91-1.18 23 (22.5) 0.99 0.61-1.59
Rectal 62 (1.9) 280 (5.0) 2.86 2.16-3.79 3.192 2.33-4.37 2 (2.0) 1.05 0.25-4.38
Transdermal 29 (0.9) 55 (1.0) 1.20 0.76-1.89 0.912 0.52-1.57 0 (0) †
Sublingual 0 (0) 39 (0.7) † † 0 (0) †
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio ref, reference
1: Hospital, ward, length of stay, route of administration and pharmacotherapeutic area contributed significantly  
to the model
2: Hospital, ward, transfer, length of stay, number of medication orders, day of prescription and  
pharmacotherapeutic area contributed significantly to the model
† Statistical analysis not possible due to insufficient data
§ Dummy variables included
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other affiliated care institutions when actual medication is exchanged in a specified way 
between health care professionals.
Prolonged length of stay increased the risk of a medication error without harm. In the 
handwritten system the medication orders have to be transcribed again by nurses on a new 
administration chart when an old chart is completed, which can cause transcribing errors, 
which may explain this increased risk of medication errors.
After correcting for confounding factors, an increasing number of medication orders 
decreases the risk of medication errors without harm slightly. This is not consistent with 
previous studies and can possibly be explained by extra attention of physicians to patients 
who use more drugs.15 Medication orders prescribed on Friday and Saturday were at risk 
for medication errors without harm, which can be explained by a higher workload and less 
knowledge about the patient’s condition, because of staff changes and fewer physicians be-
ing present.4, 16, 19, 21 With dermal preparations, directions for use, for example the site of 
Table 6: Therapeutic areas associated with medication errors with and without patient harm after univariate 
logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1) Medication errors with harm (substudy 2)
Controls
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases
n (%)
OR 95% CI ORadj 95% CI
Therapeutic area (ATC-code)
Gastrointestinal tract (A) 835 (25.2) 1166 (20.7) ref ref 20 (19.6) ref ref
Blood system (B) 478 (14.4) 691 (12.3) 1.04 0.89-1.20 1.131 0.95-1.33 14 (13.7) 1.22 0.61-2.44 1.22 0.60-2.45
Cardiovascular tract (C) 716 (21.6) 831 (14.8) 0.83 0.73-0.95 0.821 0.71-0.94 10 (9.8) 0.58 0.27-1.25 0.48 0.22-1.03
Dermatologicals (D) 24 (0.7) 124 (2.2) 3.70 2.37-5.78 1.451 0.59-3.53 0 (0) † †
Genitourinary system and
sex hormones (G)
40 (1.2) 35 (0.6) 0.63 0.40-1.00 0.591 0.36-0.96 1 (1.0) 1.04 0.14-7.97 0.84 0.11-6.51
Hormonal systemic therapy (H) 126 (3.8) 249 (4.4) 1.42 1.12-1.79 1.631 1.26-2.10 1 (1.0) 0.33 0.04-2.49 0.37 0.05-2.77
Anti-infectives (J) 264 (8.0) 454 (8.1) 1.23 1.03-1.47 1.281 1.06-1.56 23 (22.5) 3.64 1.97-6.73 4.202 2.24-7.90
Cancer therapy (L) 47 (1.4) 47 (0.8) 0.72 0.47-1.08 0.811 0.49-1.35 0 (0) † †
Musculo-skeletal system (M) 86 (2.6) 172 (3.1) 1.43 1.09-1.89 1.621 1.20-2.20 2 (2.0) 0.97 0.22-4.22 1.08 0.25-4.75
Nervous system (N) 537 (16.2) 1415 (25.2) 1.89 1.65-2.16 1.851 1.60-2.14 25 (24.5) 1.94 1.07-3.53 1.622 0.89-2.98
Antiparasitic products, insecticides 
and repellents (P)
13 (0.4) 5 (0.1) 0.28 0.10-0.78 0.401 0.14-1.18 0 (0) † †
Respiratory tract (R) 104 (3.1) 324 (5.8) 2.23 1.76-2.83 2.301 1.54-3.43 5 (4.9) 2.01 0.74-5.46 2.15 0.78-5.94
Sensory organs (S) 28 (0.8) 68 (1.2) 1.74 1.11-2.73 0.921 0.38-2.21 1 (1.0) 1.49 0.19-11.51 1.56 0.19-12.50
Various (V) 13 (0.4) 36 (0.6) 1.98 1.05-3.76 1.111 0.51-2.42 0 (0) † †
Unknown 4 (0.1) 5 (0.1) 0.90 0.24-3.34 1.021 0.23-4.59 0 (0) † †
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio; ref, reference
1: Hospital, ward, transfer, length of stay, day of prescription and route of administration contributed significantly to the model
2: Hospital, ward and age contributed significantly to the model
† Statistical analysis not possible due to insufficient data
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application, were often missing on the prescription. This is an explanation for the high 
number of errors without harm.18
For all of the determinants that were associated with medication errors without harm, 
it can be suggested that most of these errors were administrative errors which result in 
patient harm less often than therapeutic errors.7
Although most of the determinants identified in this study can not be influenced by 
health care professionals directly to prevent patient harm, they give a first impression of 
risk departments, risk processes and risk medication and they are suitable to provide an 
answer to the main study aim. However, future studies should also focus on determinants 
that are more likely to be influenced by health care professionals.
Besides the small sample size of medication errors leading to harm, this study has several 
other limitations. First, only five wards in two hospitals were studied, so the results cannot 
be generalized to other medical specialties, wards or hospitals. Second, the medication 
ordering was done in the context of a handwritten-system. Implementation of a comput-
Table 6: Therapeutic areas associated with medication errors with and without patient harm after univariate 
logistic regression (odds ratios) and multivariate logistic regression (adjusted odds ratios)
Potential determinant
Medication errors without harm (substudy 1) Medication errors with harm (substudy 2)
Controls
n (%)
Cases 
n (%)
OR 95% CI ORadj 95% CI
Cases
n (%)
OR 95% CI ORadj 95% CI
Therapeutic area (ATC-code)
Gastrointestinal tract (A) 835 (25.2) 1166 (20.7) ref ref 20 (19.6) ref ref
Blood system (B) 478 (14.4) 691 (12.3) 1.04 0.89-1.20 1.131 0.95-1.33 14 (13.7) 1.22 0.61-2.44 1.22 0.60-2.45
Cardiovascular tract (C) 716 (21.6) 831 (14.8) 0.83 0.73-0.95 0.821 0.71-0.94 10 (9.8) 0.58 0.27-1.25 0.48 0.22-1.03
Dermatologicals (D) 24 (0.7) 124 (2.2) 3.70 2.37-5.78 1.451 0.59-3.53 0 (0) † †
Genitourinary system and
sex hormones (G)
40 (1.2) 35 (0.6) 0.63 0.40-1.00 0.591 0.36-0.96 1 (1.0) 1.04 0.14-7.97 0.84 0.11-6.51
Hormonal systemic therapy (H) 126 (3.8) 249 (4.4) 1.42 1.12-1.79 1.631 1.26-2.10 1 (1.0) 0.33 0.04-2.49 0.37 0.05-2.77
Anti-infectives (J) 264 (8.0) 454 (8.1) 1.23 1.03-1.47 1.281 1.06-1.56 23 (22.5) 3.64 1.97-6.73 4.202 2.24-7.90
Cancer therapy (L) 47 (1.4) 47 (0.8) 0.72 0.47-1.08 0.811 0.49-1.35 0 (0) † †
Musculo-skeletal system (M) 86 (2.6) 172 (3.1) 1.43 1.09-1.89 1.621 1.20-2.20 2 (2.0) 0.97 0.22-4.22 1.08 0.25-4.75
Nervous system (N) 537 (16.2) 1415 (25.2) 1.89 1.65-2.16 1.851 1.60-2.14 25 (24.5) 1.94 1.07-3.53 1.622 0.89-2.98
Antiparasitic products, insecticides 
and repellents (P)
13 (0.4) 5 (0.1) 0.28 0.10-0.78 0.401 0.14-1.18 0 (0) † †
Respiratory tract (R) 104 (3.1) 324 (5.8) 2.23 1.76-2.83 2.301 1.54-3.43 5 (4.9) 2.01 0.74-5.46 2.15 0.78-5.94
Sensory organs (S) 28 (0.8) 68 (1.2) 1.74 1.11-2.73 0.921 0.38-2.21 1 (1.0) 1.49 0.19-11.51 1.56 0.19-12.50
Various (V) 13 (0.4) 36 (0.6) 1.98 1.05-3.76 1.111 0.51-2.42 0 (0) † †
Unknown 4 (0.1) 5 (0.1) 0.90 0.24-3.34 1.021 0.23-4.59 0 (0) † †
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 95 %CI, 95% confidence interval; ORadj , adjusted odds ratio; ref, reference
1: Hospital, ward, transfer, length of stay, day of prescription and route of administration contributed significantly to the model
2: Hospital, ward and age contributed significantly to the model
† Statistical analysis not possible due to insufficient data
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erized physician order entry system with clinical decision support could change the risk 
factors for medication errors. Third, risk factors for medication errors and consequent 
harm could differ between continuation of pre-admission treatment and hospital-initiated 
drugs. Because it wasn’t necessary to define pre-admission treatment in the POEMS-study 
and medication reconciliation was not performed, this determinant could not be included 
in this study either. However, precribing errrors and transcribing errors in medication 
orders for continuation of pre-admission treatment were assessed. Finally, only prescribing 
and transcribing errors were considered in this study. To provide a full overview of the 
potential determinants for medication errors with and without harm distribution errors, 
administration errors and “across settings” errors should also be studied.
The main strength of this study is the epidemiological approach to identify risk factors 
by calculating odds ratios, whereas many other studies used error frequencies. Moreover, 
we established the actual outcome of the medication error instead of the potential harm 
an error could cause which many other studies did and our study is the first comparing 
determinants for medication errors without and with patient harm.
Future research with a larger sample size of medication errors leading to patient harm is 
recommended. These future studies should also take into account other types of medica-
tion errors and include more organizational determinants (such as the use of electronic 
prescribing) and patient related factors (like the reason for admission and comorbidities).
To conclude, medication errors resulting in harm and medication errors without harm 
have some determinants in common, which are mainly at the organizational level. There-
fore, the present study gives a first direction about the validity of medication errors as a 
surrogate outcome measure when looking at these organizational aspects. More determi-
nants could possibly be identified in studies with larger sample sizes, which may identify 
specific patient- and medication-related determinants for medication errors leading to 
patient harm.
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abstraCt
background
Prescribing pharmacotherapy for older individuals with an intellectual disability (ID) is a 
complex process, possibly leading to an increased risk of prescription errors. 
objective
The objectives of this study were (1) to determine the prevalence of older individuals with 
an intellectual disability with at least one prescription error and (2) to identify potential 
risk factors for these prescription errors (age, gender, body mass index (BMI), frailty index, 
level of intellectual disability and living situation). 
methods
The study population consisted of 600 older (≥50 years) individuals with an ID using 
one or more drugs who were randomly selected from the study cohort of the Healthy 
Ageing and Intellectual Disability (HA-ID) study. The medication used at the time of 
measurement was screened for errors by a hospital pharmacist/clinical pharmacologist 
and a Master’s student pharmacy using consensus methodology. Participants with one or 
more prescription errors were compared to participants without prescription errors by 
multivariate logistic regression to identify potential risk factors. 
Results and conclusions
The prevalence of individuals with one or more prescription errors was 47.5% (285 of 600 
individuals; 95% confidence interval (CI) 43-52%). Relevant errors, defined as errors that 
actually do require a change of pharmacotherapy, were identified in 26.8% of the individu-
als (161 of 600 individuals; 95% CI 23-30%). Higher age (adjusted odds ratio (ORadj) 
1.03; 95% CI 1.01-1.06), less severe intellectual disability (moderate: ORadj 0.48; 95% 
CI 0.31-0.74 and severe: ORadj 0.56; 95% CI 0.32-0.98), higher BMI (ORadj 1.04; 95% 
CI 1.01-1.08), higher frailty index (0.39-0.54: ORadj 2.4; 95% CI 1.21-4.77 and ≥0.55: 
ORadj 3.4; 95% CI 1.03-11.02), polypharmacy (ORadj 8.06; 95% CI 5.59-11.62) and use 
of medicines acting on the central nervous system (ORadj 3.34; 95% CI 2.35-4.73) were 
independently associated with the occurrence of prescription errors. Interventions targeted 
to high risk patients should be designed and implemented to improve pharmacotherapy in 
older individuals with an intellectual disability.
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introDuCtion
Inappropriate prescribing of pharmacotherapy occurs in about 20 to 40% of older indi-
viduals in the general population.1-3 Polypharmacy, i.e. concomitant use of five or more 
drugs, is also very common among these older people1, 4 and has been identified as a risk 
factor for the occurrence of prescription errors.1
The life expectancy of older individuals with an intellectual disability (ID) is increasing 
and age-related frailty seems to start at a younger age.5 As a result, polypharmacy is very 
common among individuals with an intellectual disability aged 50 years and older. For ex-
ample, antipsychotics, that have been associated with inappropriate prescriptions in older 
individuals in general1, are frequently used by individuals with an ID to treat psychiatric 
diseases and behavioral problems.6 Additionally, chronic somatic diseases, such as epilepsy7 
and gastro-esophageal reflux disease8, frequently require pharmacotherapy. Other factors 
that may increase the complexity of prescribing drugs to older individuals with an ID 
are the often atypical symptoms of disease9; the impaired ability to communicate about 
disease and effectiveness of pharmacotherapy9; and the limited evidence for treatment of 
mental and behavioral problems with psychotropic drugs.10
As a result, older individuals with an ID may be especially at risk of prescription errors. 
However, the prevalence of prescription errors and risk factors for such errors have not 
been established in this population. Therefore, the objectives of this study were (1) to de-
termine the prevalence of older individuals with an intellectual disability with at least one 
prescription error and (2) to identify potential risk factors for these prescription errors.
methoDs
design
A cross-sectional study was performed to determine the prevalence of older individuals 
with an intellectual disability with at least one prescription error and to identify potential 
risk factors for these errors.
setting and study population
The included research population in this study consisted of older individuals with an ID 
using one or more medicines who participated in the study titled “Healthy Ageing and 
Intellectual Disability” (HA-ID).11
The cohort from the Erasmus MC HA-ID study 11 consists of 1050 clients with an ID, 
defined as an intelligence quotient of 70 and lower, aged 50 years and older, from three 
Dutch care organizations (Abrona, Huis ter Heide; Ipse de Bruggen, Zwammerdam; Ama-
rant, Tilburg). The included population varies in ID level, living situation, mobility and 
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level of care. The population in the HA-ID study is considered representative for the total 
population of older individuals with an ID using formal ID services in the Netherlands.11
For the current study 187 individuals with prescription errors and 187 controls were 
necessary to be able to detect odds ratios of at least 2, with alpha=0.05 and power=0.8. To 
obtain these numbers 600 individuals were randomly selected from the HA-ID cohort.
Since this study did not affect patient integrity, a waiver from the Medical Ethics Com-
mittee was obtained.
data collection
The cross-sectional data of the HA-ID study were collected between March 2009 and 
March 2010. Participant characteristics (gender, age, level of intellectual disability, body 
mass index (BMI), living situation), medical data on co-morbidities and actual medi-
cation orders were obtained from the care-providing organizations and the responsible 
physician (i.e. a general practitioner or a specialized physician for individuals with an ID) 
or measured by the investigators of the HA-ID study.11
The frailty index indicates the increased vulnerability of an individual to adverse health 
outcomes. We created a frailty index for older individuals with ID based on the procedure 
described by Searle et al.12
Frailty was assessed considering a list of 51 deficits, including age-related risk factors 
(such as falling, weight loss and hospitalization), morbidity (such as cancer, asthma/
COPD, diabetes mellitus and heart failure) and disabilities (such as being unable to dress, 
bath or walking stairs).13 The presence of these deficits was obtained from the medical 
records or measured by the investigators of the HA-ID study.11 Subsequently, the frailty 
index was expressed as a ratio of present deficits to the total number of deficits considered 
(i.e. 51), resulting in a frailty index between 0 (no deficits) and 1 (all deficits are present). 
In the general older population aged 70 years and over a frailty index of 0 to 0.15 is most 
common.12
definition and classification of prescription errors
Prescription errors were defined as prescriptions that were not in concordance with cur-
rent standards. To facilitate the detection of prescription errors, the current prescribing 
standards were summarized into a so called ‘Good Prescribing Practice (GPP) for older 
individuals with an ID’. A draft version of the GPP was written by a Master’s student 
pharmacy on the basis of literature and guidelines from the Netherlands´ Society of 
Physicians for People with Intellectual Disabilities14, the Dutch College of General Prac-
titioners15 and the Dutch Institute for Healthcare Improvement.16 As these guidelines 
also consider off-label prescribing, for example the use of antipsychotics for behavioral 
problems, evidence-based off-label prescribing was included in our GPP as well. A focus 
group, consisting of five specialized physicians for individuals with an ID and a hospital 
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pharmacist/ clinical pharmacologist reached consensus on the completeness and the cor-
rectness of this draft version, resulting in a final version of the GPP. For prescriptions 
not covered by the GPP, general handbooks on pharmacotherapy were used to assess 
concordance with current standards.
Prescription errors were categorized into three classes according to the classification 
system for medication errors developed by the Dutch Association of Hospital Pharma-
cists17, namely administrative errors (such as incomplete or illegible orders), dosing errors 
and therapeutic errors. Because the original orders were no longer available for this study, 
administrative errors could not be assessed. Dosage errors and therapeutic errors were 
categorized into subtypes that are defined in table  1. Because we could not assess the 
handling of interactions and contra-indications by the physician, we regarded interac-
tions and contra-indications that required additional monitoring as potentially relevant 
errors that can be managed by the physician. Besides, lacking of a maximum daily dose 
for medication used “as needed” and drug-drug interactions that require a specific time-
window between the intake of the drugs were assessed as potentially relevant errors as 
well. All other errors were defined as relevant errors, i.e. errors that actually did require 
a change of pharmacotherapy. Since our GPP also covered off-label prescribing to this 
specific population, off-label prescriptions that were in concordance with the GPP were 
not considered as errors.
detection of prescription errors
A Master’s student gained insight into pharmacotherapy for this population by composing 
the GPP and was trained to detect and classify errors by a hospital pharmacist.
Subsequently, medication orders were independently screened by the Master’s student 
Pharmacy and a hospital pharmacist/clinical pharmacologist to identify prescription er-
rors. In case of any discrepancies, these two assessors reached consensus on the presence of 
errors. In case consensus could not be reached a second experienced hospital pharmacist, 
assessed the error and made a final decision on the presence of an error.
statistical analysis
Data were analyzed using IBM SPSS Statistics 17.0. To test the representativeness of the 
study sample, Chi-square analysis was used to test differences between the study par-
ticipants and the total HA-ID study population in gender, age, level of ID, body mass 
index, frailty index and living situation. Descriptive statistics were used to determine the 
prevalence of individuals with one or more prescription errors and the prevalence of indi-
viduals with one or more relevant prescription errors (aim 1). Univariate logistic regression 
analyses were performed to identify potential risk factors for all prescription errors and for 
relevant errors (aim 2). Potential risk factors that were studied included patient character-
istics (age, gender, level of ID, BMI and frailty index), living situation (centralized setting 
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Table 1: Classification of prescription errors and examples of detected errors.
Type of error Relevant Definition Example of a detected error
Dosage errors
Dosage too 
low
Yes The drug is not being effective at 
producing the desired response in the 
prescribed dose
Sofradex eardrops 3 times a 
day 2 drops instead of 3-4 
times a day 3 drops
Dosage too 
high
Yes Too much of a drug is prescribed or the 
patient is at risk of developing a new 
medical condition because too much of 
the correct drug is being taken
Maprotilin 2 times a day 50 
mg, while maximum dose for 
elderly is 75 mg a day
No maximum 
daily dosage 
for ‘as needed’ 
prescriptions
Potentiallya The prescribed drug should be used 
“ as needed” (pro re nata) but the 
required maximum daily dosage is 
lacking on the prescription
Arcoxia 90mg as needed
Therapeutic errors
Additional 
drug therapy 
required
Yes The patient has a medical condition 
that requires the initiation of new 
or additional drug therapy or is at 
high-risk of developing a new medical 
condition for which additional drug 
therapy is indicated
Dipyridamole lacking as 
secondary prevention after a 
cerebrovascular accident
Unnecessary 
drug therapy
Yes The patient is undergoing drug therapy 
that is unnecessary given his or her 
present condition
Furosemide use without a 
diagnosis of heart failure
Interaction Yes A combination of two or more drugs 
administered to a patient that can 
result in a modification of the effect of 
at least one drug
Concomitant use of 
prednisone and acetylsalicylic 
acid without gastric 
protection
Contra-
indication
Yes A drug that is undesired because of the 
medical condition of the patien
Haloperidol use in a person 
with Parkinson’s disease
Duplicate 
therapy
Yes The use of two or more drugs with the 
same ATC classification
Concomitant use of 
mesalazine generic product 
and brand product
Pseudo 
duplicate 
therapy
Yes The use of two or more drugs with 
similar pharmacodynamic properties, 
which can lead to adverse drug events
Concomitant use of 
nitrazepam and oxazepam
Interaction 
needing 
monitoring
Potentiallya A combination of two or more drugs 
that requires additional monitoring to 
prevent adverse events
Concomitant use of 
levothyroxine and 
acenocoumarol requires 
additional monitoring of 
international normalized ratio
Time 
interaction
Potentiallya A combination of two or more drugs 
that requires a specified time-window 
between administrations of the drugs
Simultaneous use of calcium 
carbonate and alendronate 
requires a time-window of two 
hours between alendronate 
and calcium carbonate
Contra-
indication 
needing 
monitoring
Potentiallya The medical condition of the patient 
requires additional monitoring during 
treatment with a drug
Risperidone used in a patient 
with epilepsy requires 
alertness for an increase of 
seizure frequency
a These errors were considered as potentially relevant, assuming correct handling of the error by the physician.
ATC classification = anatomical therapeutical chemical classification system
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versus community based), and medication characteristics (total number of medicines and 
number of drugs acting on the central nervous system (anatomical therapeutical chemical 
classification N)). Potential risk factors that showed a significant association (p<0.1) in the 
univariate analysis were entered in a multivariate model, using a stepwise enter method. 
When a potential risk factor changed the ß-coefficient with at least 10% its contribution 
was considered significant. Crude and adjusted odds ratios with 95% confidence intervals 
were calculated. Independent variables were checked for multicollinearity, using Pearson’s 
correlation coefficient. For highly correlated determinants (>0.400) only one potential 
risk factor was included in the multivariate model.
results
study population
Of the 1050 individuals with an ID included in the HA-ID study, 820 persons used 
one or more medicines at the time of inclusion of which 600 were randomly selected. In 
total 2773 prescriptions of these randomly selected individuals were screened for errors. 
Characteristics of the selected individuals and differences between this sample and the 
HA-ID cohort are presented in table 2. Individuals in centralized settings were slightly 
overrepresented in our sample. Probably, individuals living in a centralized setting have 
more complex disorders requiring pharmacotherapy. The frailty index significantly dif-
fered between our sample and the original cohort, but the difference was very small and 
not considered to be clinically relevant.
Table 2 Characteristics of the study population and representativeness for HA-ID cohort
Characteristic Study population Cohort p-value
Age (years), mean ± SD 61.8 ± 8.2 61.6 ± 8.0 n.s.
Body Mass Index, mean ± SD 27.5 ± 5.4 27.2 ± 5.2 n.s.
Frailty Index 0.3 ± 0.1 0.3 ± 0.1 p=0.047
Female gender 297 (49.5) 511 (48.7) n.s.
Level of ID
Mild ID 136 (22.7) 254 (24.2) n.s.
Moderate ID 301 (50.2) 506 (48.2) n.s.
Severe ID 152 (25.3) 263 (25.7) n.s.
Living situations
Centralized setting 365 (60.8) 557 (53.0)
Community based 234 (39.0) 483 (46.0) p=0.004
n.s. = not statistically significant
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prevalence of prescription errors
In total 446 errors, including 195 relevant errors, were identified. The Master’s student 
Pharmacy and the hospital pharmacist/clinical pharmacologist reached consensus on all 
errors. Frequencies of the different subtypes of identified errors are presented in table 3. 
Most prescription errors involved drugs acting on the nervous system (43.2% of the 
prescriptions with one or more errors) and cardiovascular drugs (17.5% of the prescrip-
tions with one or more errors). Prescription errors were identified in 285 out of the 600 
randomly selected individuals, resulting in a prevalence of individuals with one or more 
prescription errors of 47.5 % (95% confidence interval (CI) 43-52%). Relevant prescrip-
tion errors were identified in 161 individuals, resulting in a prevalence of 26.8% (95% 
CI 23-30%).
potential risk factors for prescription errors
Details of the univariate and multivariate analysis to identify potential risk factors for 
prescription errors are presented in table  4. Table  5 shows the results of the analysis 
for relevant errors. Frailty index and polypharmacy showed a high correlation (0.435). 
Therefore, these variables were not included together in the multivariate analysis to pre-
vent multicollinearity. First, the contribution of frailty index to the model was tested. If 
frailty index contributed significantly to the model, polypharmacy was not included in the 
Table 3 Subtypes of identified errors
Type of error
All prescription errors
n=446
n (%)
Relevant errors
n=195
n (%)
Dosage errors
Dosage too low 5 (1.1) 5 (2.6)
Dosage too high 54 (12.1) 54 (27.7)
No maximum daily dosage
for ‘as needed’ prescriptions
68 (15.3) -
Therapeutic errors
Additional drug therapy required 34 (7.6) 34 (17.4)
Unnecessary drug therapy 50 (11.2) 50 (25.6)
Interaction 1 (0.2) 1 (0.5)
Contra-indication 11 (2.5) 11 (5.6 )
Duplicate therapy 3 (0.7) 3 (1.5)
Pseudo-duplicate therapy 34 (7.6) 34 (17.4)
Interaction needing monitoring 81 (18.2) -
Time interaction 34 (7.6) -
Contra-indication needing monitoring 71 (15.9) -
55Prescription errors and intellectual disability
model. If frailty index did not contribute to the model, the contribution of polypharmacy 
was subsequently tested.
Higher age, less severe intellectual disability, polypharmacy and use of drugs acting on 
the nervous system showed a significant independent association with both all prescrip-
tion errors and relevant errors. Higher BMI and frailty index were associated with all 
prescription errors only.
Table 4: Potential risk factors associated with all prescription errors (potentially relevant and relevant 
errors) after univariate logistic regression (odds ratio) and multivariate logistic regression (adjusted 
odds ratio)
Potential risk factor
Controls
n=315
n (%)
Cases
n=285
n (%) OR 90% CI ORadj 95% CI
Age (years, mean ± SD) 60.5 ± 7.3 63.2 ± 8.9 1.04 1.03-1.06 1.03a 1.01-1.06
Gender
Male 162 (51.4) 141 (49.5) ref. ref.
Female 153 (48.6) 144 (50.5) 1.08 0.83-1.42 - -
Level of ID
Mild ID 59 (19.0) 77 (27.6) ref. ref.
Moderate ID 176 (56.8) 125 (44.8) 0.54 0.39-0.77 0.48b 0.31-0.74
Severe ID 75 (24.2) 77 (27.6) 0.79 0.53-1.16 0.56b 0.32-0.98
Living situation
Centralized 181 (57.6) 184 (64.6) ref. ref.
Community based 133 (42.4) 101 (35.4) 0.75 0.57-0.99 0.94c 0.63-1.40
Body Mass Index (mean ± SD) 26.9 ± 4.9 28.1 ± 5.8 1.04 1.01-1.07 1.04d 1.01-1.08
Frailty Index
≤0,20 71 (23.2) 39 (14.3) ref. ref.
 0,21 - 0,38 172 (56.2) 124 (45.6) 1.31 0.90-1.92 1.11e 0.65-1.88
 0,39 – 0,54 55 (18.0) 83 (30.5) 2.75 1.78-4.25 2.40e 1.21-4.77
≥ 0,55 8 (2.6) 26 (9.6) 5.92 2.82-12.42 3.37e 1.03-11.02
Number of medicines
No polypharmacy 241 (76.5) 82 (28.8) ref. ref.
Polypharmacy (5 or more) 74 (23.5) 203 (71.2) 8.06 5.93-10.96 8.06d 5.59-11.62
Use of CNS medicines
None 164 (52.1) 70 (24.6) ref. ref.
1 or more 151 (47.9) 215 (75.4) 3.34 2.49-4.47 3.34d 2.35-4.73
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 90%CI, 90% confidence interval; 95%CI, 95% confidence interval; ORadj, adjusted 
odds ratio; ref, reference; CNS, central nervous system
a Body Mass Index and frailty index were included in the model
b Age, living situation and frailty index were included in the model
c Level of ID and frailty index were included in the model
d No confounding factors were identified
e Age, level of ID, living situation and Body Mass Index were included in the model
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DisCussion
This study, performed in a representative population, shows that prescription errors are 
frequently identified in older individuals with an intellectual disability. The prevalence of 
individuals with prescription errors in our population was 47.5% and relevant errors were 
identified in 26.8% of included individuals. Higher age, less severe intellectual disability, 
polypharmacy and use of drugs acting on the central nervous system showed a significant 
 Table 5: Potential risk factors associated with relevant prescription errors after univariate logistic 
regression (odds ratio) and multivariate logistic regression (adjusted odds ratio)
Potential determinant
Controls
n=439
n (%)
Cases
n=161
n (%) OR 90% CI ORadj 95% CI
Age (years, mean ± SD) 61.0 ± 7.8 63.7 ± 9.0 1.04 1.02-1.06 1.04a 1.01-1.07
Gender
Male 224 (51.0) 79 (49.1) ref. ref.
Female 215 (49.0) 82 (50.9) 1.08 0.80-1.46 - -
Level of ID
Mild ID 85 (19.7) 51 (32.3) ref. ref.
Moderate ID 231 (53.6) 70 (44.3) 0.51 0.35-0.73 0.46b 0.28-0.77
Severe ID 115 (26.7) 37 (23.4) 0.54 0.35-0.82 0.58b 0.30-1.10
Living situation
Centralized 264 (60.3) 101 (62.7) ref. ref.
Community based 174 (39.7) 60 (37.3) 0.90 0.66-1.23 - -
Body Mass Index (mean ± SD) 27.2 ± 5.1 28.4 ± 6.0 1.04 1.01-1.07 1.04c 1.00-1.08
Frailty Index
≤0.20 83 (19.7) 27 (17.3) ref. ref.
0.21 - 0.38 227 (53.8) 69 (44.2) 0.93 0.61-1.44 0.88d 0.49-1.56
0.39 - 0.54 90 (21.3) 48 (30.8) 1.64 1.03-2.62 1.76d 0.86-3.57
≥ 0.55 22 (5.2) 12 (7.7) 1.68 0.84-3.36 1.12d 0.37-3.37
Number of medicines
No polypharmacy 274 (62.4) 49 (30.4) ref. ref.
Polypharmacy (5 or more) 165 (37.6) 112 (69.6) 3.80 2.74-5.25 3.80e 2.58-5.59
Use of CNS medicines
None 194 (44.2) 40 (24.8) ref. ref.
1 or more 245 (55.8) 121 (75.2) 2.40 1.71-3.36 2.67f 1.71-4.16
Figures in bold are statistically significant
Abbreviations: OR, odds ratio; 90%CI, 90% confidence interval; 95%CI, 95% confidence interval; ORadj, adjusted 
odds ratio; ref, reference
a Body Mass Index and frailty index were included in the model
b Age, Body Mass Index and frailty index were included in the model
c Number of medicines was included in the model
d Age, level of ID, Body Mass Index were included in the model
e No confounding factors were identified
f Body Mass Index was included in the model
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association with both all prescription errors and relevant errors. Higher BMI and frailty 
index were associated with all prescription errors only.
The prevalence of prescription errors is comparable to the prevalence in older individuals 
in general: 20% in outpatients3 and 40% in care institutions.1 In our study administrative 
prescription errors and the duration of pharmacotherapy could not be assessed. Therefore, 
the actual prevalence of prescription errors in this specific population may even be higher.
Higher age, BMI and polypharmacy have been identified as risk factors for prescription 
errors in older individuals in the general population.1, 9 We expected that a more severe 
intellectual disability would be a risk factor for prescription errors due to difficulties in 
diagnosing health problems and dosing problems. However, individuals with moderate 
and severe ID experienced relatively less errors compared to individuals with a mild ID. 
Possibly, physicians prescribe drugs more carefully to individuals with a more severe ID, 
resulting in fewer errors. Besides, differences in knowledge or experience between physi-
cians could contribute to difference in errors. Individuals with a more severe ID are being 
treated in centralized settings, employing specialized physicians for people with intellec-
tual disabilities more often. These physicians are specialized in chronic multimorbidity of 
individuals with an ID. General practitioners, treating individuals living in a community 
based setting, have less experience with this specific population, which could result in 
more prescription errors. However, living situation was not associated with the occur-
rence of errors. Still, differences between individual physicians could have influenced the 
results. Unfortunately, characteristics of the prescribing physician could not be assessed in 
our study. Future studies should give more insight in the association between prescriber’s 
characteristics and prescription errors.
Our study has several limitations. First, data on medication used by included individu-
als have been transcribed on a case report form by the responsible physician. These data 
have been transferred to an electronic database. Both steps could result in transcribing 
errors. To prevent a false positive result, administrative errors, that could have been a 
result of these transcribing errors, were not included in this study. Second, the duration of 
pharmacotherapy, such as long-term use of antipsychotics, which is quite common in this 
population,18 could not be determined due to the cross-sectional design. As a result, the 
occurrence of prescription errors could be even higher in daily practice.
Third, information on the current health problems of the individuals, monitoring of po-
tential adverse drug events and the physician’s arguments to accept potential errors (such 
as contra-indications, drug-drug interactions, duplicate therapy and off-label prescribing 
not included in the GPP) were unknown in this study. Therefore, certain prescription 
errors might have been deliberately accepted by the physician or might have been man-
aged by intensive monitoring of the individual. We tried to resolve this problem to define 
relevant errors that do require a change of pharmacotherapy.
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Fourth, the consequences of prescription errors in terms of patient harm or healthcare 
costs could not be established in this study. Finally, the prescription errors in our study 
were assessed by pharmacists only. Because it is known that the assessment of errors can 
differ between pharmacists and physicians, the errors should have been assessed by a physi-
cian as well. 19
Despite these limitations, our study is the first study on the prevalence of prescription 
errors in older individuals with an ID and potential risk factors for these errors and we 
were able to investigate several risk factors, including the frailty index.
Future research should focus on the reasoning of the physician to prescribe certain 
drugs, handling of medication errors in daily practice and consequences of prescription 
errors in this specific population. Besides, the effects of interventions designed to reduce 
prescription errors, adverse drug events and healthcare costs should be established.
Given the results of our study we recommend physicians and pharmacists treating older 
individuals with an ID to be aware of potential prescription errors, especially for patients 
with risk factors. Besides, regular review of pharmacotherapy by a multidisciplinary group, 
including at least a physician and a pharmacist, is recommended to reduce medication 
errors.
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abstraCt
background
Adverse drug events (ADEs) in hospitalized patients might be preceded by a physician’s 
suspicion leading to increased ordering of biochemical tests.
objective
To investigate whether the number of biochemical tests performed is predictive for the 
occurrence of ADEs in order to use it as an electronic trigger.
methods
During five months patients admitted to four internal medicine wards of two hospitals 
in the Netherlandswere included in this cohort study. The total number of biochemi-
cal tests performed per day was counted and all tests were assigned to a predefined test 
group. ADEs were assessed retrospectively by pharmacists. For every day of the admission 
patients experiencing an ADE were compared with patients without ADEs on the same 
day (index date). Univariate and multivariate cox-regression analyses were performed us-
ing the number of biochemical tests performed in the two days before the ADE or index 
date as time-dependent variable. Primary outcome was the adjusted odds ratio for the 
association between the total number of biochemical tests and the occurrence of ADEs. 
Adjusted odd ratios for the number of tests per test group were the secondary outcomes.
Results
In this study 554 patients were included; ADEs were identified during 331 admissions 
(59.7%). Univariate analysis showed an association between the number of metabolic tests 
and the occurrence of ADEs (Hazard Ratio (HR) 1.21, 95% Confidence Interval (CI) 
1.01 -1.44), but in multivariate analysis the association was not statistically significant 
(HRadjusted 1.16, 95% CI 0.97 -1.38). Neither the total number of tests nor subsets of 
tests (electrolytes, renal function, liver function, hematological, hemostasis or other) were 
statistically significantly associated with ADEs.
Conclusion
In this study the number of biochemical tests could not be identified as a predictor for 
ADEs in hospitalized patients.
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introDuCtion
Up to sixty percent of hospitalized patients experience adverse drug events (ADEs)1, in-
cluding adverse drug reactions, which occur at doses normally used in man for treatment, 
prophylaxis, diagnosis or modification of physiological function2, as well as patient harm 
as a result of medication errors.
Since the majority of these ADEs (88%) are not preventable1, early detection and recog-
nition of ADEs in daily practice is essential to limit patient harm, prolongation of hospital 
stay and health care expenditures and to improve patients’ well-being. But unfortunately 
previous studies have shown that not all ADEs are recognized by the attending physi-
cian.3-5 Therefore, automated systems using electronic triggers have been developed to 
support the detection of ADEs.6, 7
Abnormal biochemical responses (also known as drug related hazardous conditions 
(DRHC)8) are an attractive approach to detect suspected ADEs at an early stage because 
the temporal gap between the biochemical response and the clinical manifestation of an 
ADE allows health care professionals to intervene and prevent further harm.9 Computer-
based monitoring using electronic data from the hospital information system, is an ex-
ample of a detection tool for this type of DRHCs .10 For example, Kane-Gill et al. defined 
a list of abnormal biochemical values, known to be associated with frequently used drugs 
on an intensive care unit. In this study 97% of the abnormal biochemical values that were 
related to a drug resulted in increased monitoring or changed drug regimens to prevent 
further harm.9
Besides the use of specific laboratory values as electronic triggers, the number of bio-
chemical tests may also be useful to detect DRHCs or ADEs at an early stage. Even when 
the physician did not diagnose a patient’s condition yet nor actually identified an ADE, 
he or she may have an uneasy feeling which makes him or her concerned about a pos-
sible adverse outcome. This suspicion, also described as “gut feeling” or “sense of alarm”, 
alerts the physician and leads to increased diagnostic procedures to clarify the patient’s 
condition and prevent serious problems.11-13 If this phenomenon also applies to initially 
subclinical or unrecognized ADEs, one may expect that the number of biochemical tests 
increases before an ADE is actually recognized, irrespective of the nature of the ADE. 
Consequently, the number of biochemical tests may be used as an electronic trigger to 
identify a patient at risk for ADEs before the ADE actually reveals and to target additional 
resources, like a multidisciplinary patient review, to these patients and improve patient 
safety.14-19 Therefore, the objective of this study was to investigate whether the number of 
biochemical tests increases before the manifestation of ADEs with the ultimate aim to use 
this information as an electronic trigger.
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methoDs
design
This study used data of a larger prospective intervention study on the effect of a Comput-
erized Physician Order Entry in combination with a Clinical Decision Support System for 
prescribing medication (CPOE/CDSS) on medication safety and associated costs.20 The 
current study is designed as a cohort study that uses data that were prospectively collected 
after the introduction of CPOE/CDSS.
setting
This study was performed in two internal medicine wards (one geriatric and one general 
internal medicine ward) of the 600 bed teaching hospital “TweeSteden” (TSh) in Tilburg 
and Waalwijk and two medical wards (one general internal medicine wards divided into 
two units, and one gastroenterology/rheumatology ward) of the 1300 bed University 
Medical Center in Groningen (UMCG), the Netherlands. CPOE/CDSS was introduced 
on one ward at a time and on each ward the study started eight weeks after the imple-
mentation (TSh general internal medicine June 2006, TSh geriatrics April 2006, UMCG 
general internal medicine August 2006, gastroenterology/rheumatology January 2008).
patients
During five months per ward all patients admitted to the study wards for more than 24 
hours were included. Patients who did not use medication during their admission were 
excluded from the current study. For patients that were admitted more than once during 
the study period, only the first admission was included to avoid the statistical complexities 
arising from dependence of observations. A waiver of the Medical Ethical Committee was 
obtained for this study, as the study fell within the boundaries of normal hospital care and 
routine of quality improvement and assurance. According to the Dutch Data Protection 
Act patients received written information about the study after which they could object to 
use of their medical data in this study.
data collection
During ward visits trained pharmacists prospectively extracted patients’ characteristics 
(age, sex, weight and length), data on diseases (medical history, reasons for admission 
and diagnoses), biochemical tests performed and adverse events (i.e. untoward medical 
occurrences which do not need to have a causal relationship with the treatment2) from 
medical records. Medication orders issued during hospitalization were collected by review-
ing CPOE/CDSS.
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biochemical tests
During admission the total number of biochemical tests performed per day was counted. 
Based on known associations between abnormal biochemical values and ADEs, all per-
formed tests were assigned to one of the following eight test groups: electrolytes (potassium, 
calcium, sodium, magnesium), metabolic (glucose, creatine kinase), renal function (creati-
nine, ureum, urine albumin), liver function (alkaline phosphatase, aspartate transaminase, 
alanine transaminase, gamma-glutamyl transpeptidase, lactate dehydrogenase, bilirubine, 
serum albumin), hematological (leukocytes, thrombocytes, hemoglobin, differentiation 
of leukocytes), hemostasis (prothrombin time, international normalized ratio, activated 
partial thromboplastin time), therapeutic drug monitoring (serum drug levels) or other 
(all other biochemical tests).3, 9, 21-23 Subsequently, the number of performed tests per test 
group per day was calculated.
adverse drug events
Adverse drug events include adverse drug reactions and patient harm resulting from 
medication errors (i.e. preventable adverse drug events) occurring during hospitalization. 
To determine adverse drug reactions (ADRs), the causal relation between all recorded 
adverse events and any drug taken by the patient was assessed by two pharmacists after 
the data collection period. Consensus was evaluated using the first three items of the 
Yale algorithm, also known as the Kramer scale24: knowledge about the relation between 
the drug and the event, the presence of underlying clinical conditions which could be 
responsible for the event (using the collected data on diseases and diagnoses) and the 
timing of the event, as we previously described in detail.1 Following this algorithm, the 
causal relationship between an event and a drug could be defined as unlikely (score < 0), 
possible (score ≥ 0 and ≤ 3) or probable (score = 4). Only events with a possible or prob-
able relationship with drug treatment were included in the analysis.
Preventable adverse drug events (pADEs) were defined as adverse drug events with a 
possible or probable causal relationship with a medication error. This causal relationship 
was assessed in consensus between five pharmacists following the same Yale algorithm
All ADEs were classified according to the WHO Adverse Reaction Terminology on the 
level of system organ class.2 Critical terms, defined as “events referring to, or possibly being 
indicative for, serious disease states, which have been regarded as particularly important to 
follow up”2, were marked.
statistical analysis
Patients’ age was categorized based on the quartiles of our population. Reason for admis-
sion was classified according to the International Classification of Diseases ICD-10.25 
Length of stay was calculated and for every single day of a patient’s admission the number 
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of drugs was counted separately. Drugs used at the first day of admission were categorized 
according to Anatomical Therapeutic Chemical (ATC) classification system.
Patients were included in the analysis until the occurrence of an ADE, discharge from 
hospital or death, whichever occurred first. For every day of the admission patients ex-
periencing an ADE on that specific day were compared with patients without ADEs on 
the same day (index date) using Cox-regression analysis. Using this predictive model, 
data beyond the index date may not be used in the analysis, meaning that a patient that 
experienced an ADE after this day is considered a control until the ADE occurred. For 
example, a patient who experienced an ADE on the fifth day of admission was included in 
the analysis as a control on day one to four.
Univariate Cox-regression analysis was performed using the total number of biochemical 
tests carried out in the two days before the ADE or index date as time-dependent variable. 
For patients with an ADE on the second day of the admission and their controls only the 
number of tests of the first day of admission, including tests performed in the emergency 
room, was included. Patients experiencing an ADE on the first day of admission were 
excluded from the analysis.
Sub analyses were performed for the number of tests per test group. Variables that were 
associated with ADEs in a previous analysis of our study data were included as potential 
confounders: gender, age (categorized into quartiles), ward and number of drugs.1 Because 
the Cox-regression analysis uses longitudinal data, the number of drugs, which can change 
during admission, is counted for every day of the admission separately and included in the 
analysis as a continuous variable, both for patients with ADEs and patients without ADEs. 
Crude hazard ratios with 95% confidence intervals were calculated.
In the multivariate Cox-regression analysis potential confounders that were statistically 
significantly associated with the occurrence of ADEs in the univariate analysis (p<0.05) 
were entered into a multivariate model to calculate adjusted hazard ratios with 95% 
confidence intervals. The assumption of proportional hazards in the multivariate Cox-
regression models was verified by studying the associations of the effect of each variable 
regarding the relation with time, i.e. by including interaction terms with time (day of 
admission) in the Cox regression models. A sample size was not calculated, as the expected 
effect size could not be estimated due to the lack of previous studies on this subject.
All statistical analyses were performed using SPSS version 21 (IBM Software).
results
During the study period 603 patients were admitted to the study wards, of which 16 
patients were excluded because they did not use any medication during admission. Four 
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other patients were excluded due to missing data (biochemical laboratory results or date 
of adverse drug event) and 29 readmissions were excluded. None of the patients objected 
to use of their data for this study. In total 554 patients were included in our analysis. 
Characteristics of the included patients and admissions are presented in table 1.
Table 1: Characteristics of patients (n=554)
Patient characteristics
Patients with 
ADEs
n=331
n (%)
Patients without 
ADEs
n=223
n (%)
All patients
(n=554)
n (%)
Age, years (median, range) 77 (16-100) 61 (17-96) 71 (16-100)
Female gender 203 (61.3) 112 (50.2) 315 (56.9)
Reason for admission (ICD10)
Diseases of the digestive system (K) 60 (18.1) 76 (34.1) 136 (24.5)
Diseases of the circulatory system (I) 39 (11.8) 10 (4.5) 49 (8.8)
Symptoms, signs and abnormal clinical 
and laboratory findings (R)
32 (9.7) 16 (7.2) 48 (8.7)
Neoplasms (C) 21 (6.3) 23 (10.3) 44 (7.9)
Endocrine, nutritional and metabolic 
diseases (E)
20 (6.0) 18 (8.1) 38 (6.9)
Diseases of the genitourinary system (N) 27 (8.2) 9 (4.0) 36 (6.5)
Other 108 (32.6) 55 (24.7) 163 (29.4)
Unknown 24 (7.3) 16 (7.2) 40 (7.2)
Length of stay (median, range) 14 (3-100) 6 (1-38) 10 (1-100)
Ward
1 78 (23.6) 122 (54.7) 200 (36.1)
2 100 (30.2) 51 (22.9) 151 (27.3)
3 120 (36.3) 11 (4.9) 131 (23.6)
4 33 (10.0) 39 (17.5) 72 (13.0)
Number of drugs at admission (median, range) 6 (0-22) 4 (0-17) 5 (0-22)
Use of therapeutic group, according to ATCa
Alimentary tract and metabolism (A) 218 (65.9) 138 (61.8) 356 (64.3)
Blood and blood forming organs (B) 190 (75.4) 90 (40.4) 280 (50.5)
Cardiovascular system (C) 180 (54.4) 94 (42.2) 274 (49.5)
Systemic hormonal preparations (H) 77 (23.3) 40 (17.9) 117 (21.1)
Anti-infectives for systemic use (J) 89 (26.9) 53 (23.8) 142 (25.6)
Musculo-skeletal system (M) 50 (15.1) 39 (17.5) 89 (16.1)
Nervous system (N) 180 (54.3) 86 (38.9) 266 (48.9)
Respiratory system (R) 59 (17.8) 27 (12.1) 86 (15.5)
Other (D,G,L,P,S,V and unknown)b 95 (28.7) 56 (25.1) 151 (27.3)
ICD10= International Classification of Diseases; ATC= Anatomical Therapeutic Chemical (ATC) classification sys-
tem
a number of patients that used one or more drugs from the specific class at admission
b D= Dermatologicals, G= Genito-urinary system and sex hormones, L= Antineoplastic and immunomodulating 
agents, P= Antiparasitic products, insecticides and repellents, S= Sensory organs, V= Various
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Adverse drug events were identified during 331 admissions (59.7%) and 18 (5.4%) of 
these events were considered preventable adverse drug events. Details of the identified 
ADEs are presented in table 2. Gastro-intestinal disorders (29.3%), psychiatric disorders 
Table 2: Details of identified adverse drug events (n=331)
Details of adverse drug events
Adverse 
drug 
reactions
n = 313
n (%)
Preventable 
adverse drug 
events
n = 18
n (%)
Total
n = 331
n (%)
Nature of event, according to system-organ class
Gastro-intestinal system disorders 92 (29.4) 5 (27.8) 97 (29.3)
Psychiatric disorders 46 (14.7) 1 (5.6) 47 (14.2)
Nervous system disorders 38 (12.1) 1 (5.6) 39 (11.8)
Respiratory system disorders 24 (7.7) - - 24 (7.3)
Metabolic and nutritional disorders 14 (4.5) 2 (11.1) 16 (4.8)
Cardiovascular disorders 15 (4.8) 1 (5.6) 16 (4.8)
Other 84 (26.8) 8 (44.4) 92 (27.8)
Critical adverse drug events 35 (11.2) 5 (27.8) 40 (12.1)
Hypoglycaemia 5 5
International normalised ratio increased 3 2 5
Hypertension 4 4
Phlebitis 4 4
Coagulation time increased 2 2
Collaps 2 2
Hallucinations 2 2
Hyperkalaemia 1 1 2
Melaena 2 2
Pulse abnormal 2 2
Othera 8 2 10
Pharmacotherapeutic group related to ADE, according to 
ATC classification
Alimentary tract and metabolism (A) 56 (17.9) 2 (11.1) 58 (17.5)
Blood and blood forming organs (B) 19 (6.1) 5 (27.8) 24 (7.3)
Cardiovascular system (C) 76 (24.3) 4 (22.2) 80 (24.2)
Systemic hormonal preparations (H) 16 (5.1) - - 16 (4.8)
Anti-infectives for systemic use (J) 27 (8.6) 2 (11.1) 29 (8.8)
Musculo-skeletal system (M) 7 (2.2) 2 (11.1) 9 (2.7)
Nervous system (N) 96 (30.7) 3 (16.7) 99 (29.9)
Respiratory system (R) 12 (3.8) - - 12 (3.6)
Other (G,L,S)b 4 (1.3) - - 4 (1.2)
ATC= Anatomical Therapeutic Chemical (ATC) classification system
a Other critical adverse drug events include cheyne stokes respiration, delirium, epistaxis, hypokalemia, interna-
tional normalized ratio decreased, leucopenia, renal function abnormal, restless legs, stridor, wheezes
b G= Genito-urinary system and sex hormones, L= Antineoplastic and immunomodulating agents, S= Sensory 
organs
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(14.2%) and nervous system disorders (11.8%) were the most common ADEs. 40 ADEs 
were defi ned as critical terms, including hypoglycaemia, increased international normal-
ized ratio, phlebitis and hyperkalaemia.
Median time to occurrence of the ADE was 3 days (range 1-21 days). Th e risk of an ADE 
was highest on day 2 and decreased with increased length of stay after day 2 (fi gure 1).
Th e prior number of tests according to admission day and whether or not an ADE had 
occurred is shown in fi gure 2. Th is fi gure shows that patients with and without an ADE do 
not consistently diff er with respect to the prior total number of biochemical tests.
Univariate regression analysis of potential important factors regarding the occurrence 
of adverse drug events showed signifi cant relations with gender (p=0.006), age (p<0.001) 
and the number of drugs (p<0.001). Th ere were also signifi cant diff erences between the 
four wards studied (p<0.001). Th erefore, in all evaluations of the number of biochemical 
tests the analyses were adjusted for gender, age, ward and the number of drugs.
Univariate Cox-regression analysis of the occurrence of an ADE and the total number 
of biochemical tests showed no signifi cant relation (Hazard Ratio (HR) 1.00; p=0.506). 
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Figure 1: Graph showing the risk of an adverse drug event for each day of admission
The numbers of patients at risk at the various days are shown at the bottom. After day 14 only 4 of the remaining 
patients had an ADE (during a total of 147 patient admission days after day 14).
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Also in multivariate analysis no signifi cant relation was found. Th e adjusted hazard ratio 
associated with an increase of one additional test was 1.01 (95% Confi dence Interval (CI): 
1.00-1.01; p=0.258), see table 3.
Results of the univariate and multivariate Cox-regression analyses for the numbers of 
biochemical tests grouped according to type of test are presented in table 4. In univariate 
analysis only the number of metabolic tests showed an association with the occurrence of 
ADEs (HR 1.21, 95% CI 1.01-1.44, p=0.037, meaning that for every additional meta-
bolic test performed, the risk of an ADE increases with 21%). However, after correction 
for gender age, number of drugs and ward in the multivariate analysis, the signifi cance of 
the association was lost (HRadjusted 1.16, 95% CI 0.97 -1.38, p=0.112).
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Figure 2: Prior number of biochemical tests performed for patients with and without an adverse 
drug event (ADE) for admission day 2 to 14
At each day of admission the median value of the total number during the two days before the indicated day is 
shown according to whether or not an ADE had occurred at the day indicated (closed circles: ADE, open squares: 
no ADE). The bars represent the ranges. The numbers below the horizontal axis at each day of admission represent 
the numbers of patients at risk without an ADE at the indicated day / number of cases with an incident ADE at 
the indicated day.
To further clarify the fi gure, at admission day 8 for example, there were 108 patients still at risk for an ADE. Five of 
these patients developed an ADE at this particular day, and 103 did not. For these two groups the median values 
of the total number of tests during the preceding two days (days 6 and 7) was 11 and 6, respectively.
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Table 3: Results of multivariate Cox regression analysis regarding the incidence rate of adverse drug 
events according to various factors
Variable Hazard ratio 95% Confidence Interval p-value
Total nr of biochemical tests 1.01a 1.00-1.01 0.258
Gender 1.20 0.94-1.53 0.152
Age category 0.021b
 ≤ 52 yrs (n=137) reference - - 
 53-70 yrs (n=135) 0.83 0.57-1.23 0.353 
 71-81 yrs (n=143) 0.87 0.59-1.28 0.478 
 ≥82 yrs (n=139) 1.34 0.90-1.98 0.145 
Number of drugs 1.10c 1.07-1.13 <0.001
Wardd <0.001b
 1 (n=200) reference - - 
 2 (n=151) 1.89 1.35-2.66 <0.001 
 3 (n=131) 2.47 1.72-3.55 <0.001 
 4 (n=72) 0.88 0.57-1.36 0.566 
aEffect per additional test
bOverall p-values
cEffect per additional drug
dWards are ranked according to the number of patients
Table 4: Associations between number of biochemical tests and adverse drug events after univari-
ate (hazard ratio) and multivariate (adjusted hazard ratio) cox regression analysis
Number of biochemical tests Hazard ratio (CI95) p Hazard ratioadj (CI95) p-value
Number of tests per test group
Electrolytes 1.02 (0.95 - 1.08) 0.642 1.04 (0.96 - 1.11)c 0.347
Metabolic 1.21 (1.01 - 1.44)a,b 0.037 1.16 (0.97 - 1.38)c 0.112
Renal function 1.04 (0.95 - 1.13) 0.435 1.05 (0.96 - 1.16)c 0.277
Liver function 0.99 (0.96 - 1.02) 0.567 1.03 (1.00 - 1.07)c 0.085
Hematology 0.99 (0.94 - 1.05) 0.766 1.02 (0.96 - 1.08)c 0.538
Hemostasis 0.91 (0.76 - 1.08) 0.286 0.99 (0.83 - 1.18)c 0.916
Therapeutic drug 
monitoring
1.14 (0.66 - 1.96) 0.647 0.90 (0.51 - 1.57)c 0.703
Other 1.01 (1.00 - 1.02) 1.00 (0.99 - 1.02)c 0.552
CI95 = 95% confidence interval, HRadj = adjusted hazard ratio
a statistically significant (p<0.05)
b The risk of an adverse drug event increases with 21 % for every additional metabolic test performed.
c Adjusted for gender, age, number of drugs, and ward.
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DisCussion
Our study shows that the number of biochemical tests is not higher for hospitalized 
patients with an ADE than for patients without an ADE in the 2 days prior to the ADE.
In univariate analysis a larger number of metabolic tests showed an increased risk of 
ADEs. Metabolic tests include glucose and creatine kinase measurements. Disturbances of 
serum glucose levels are frequently caused by drugs such as corticosteroids or blood glu-
cose lowering drugs. To diagnose these ADEs measurement of serum glucose is performed. 
Therefore patients whose serum glucose is frequently measured may be patients at risk 
of hyperglycaemia or hypoglycaemia. The same argumentation holds for creatine kinase, 
which is often determined when myopathy is suspected if patients use a statin. However, 
the significance of the relation was lost in multivariate analysis.
The most common ADEs in this cohort were relatively mild gastro-intestinal disorders, 
psychiatric disorders and nervous system disorders. These ADEs do not have a clear rela-
tion with certain biochemical values and are not diagnosed or evaluated by biochemical 
values. This may partly explain why we did not find an association between the number 
of tests and ADEs, irrespective of their nature. More serious ADEs for which we expected 
an association with biochemical values, such as renal failure, liver failure or blood cell 
disorders, were uncommon in our population. Due to the low prevalence of events per 
class of ADE, associations between number of tests and specific classes of ADEs could not 
be assessed.
In addition, in our cohort the median time to occurrence of an ADE after admission 
was relatively short. This corresponds with previous results of Hurwitz et al. who showed 
that the occurrence of ADRs is highest during the first or first two days of hospital admis-
sion.19 These ADRs could be related to starting new drugs at admission, which is a risk 
factor for ADRs.17
During the first days of an admission the mean number of tests performed was also 
higher in our study, probably to clarify the patient’s condition. These tests may have 
outnumbered the biochemical tests that were requested as a result of the physician’s 
suspicion. Besides, the number of tests performed can vary between different physicians, 
according to their specialty or experience. In the studied hospitals (a teaching hospital 
and a university hospital) mainly residents are responsible for test ordering in the studied 
hospitals (a teaching hospital and a university hospital), which may result in inappropriate 
and avoidable test requests, especially by junior trainees.26 This phenomenon might have 
influenced our results as well.
The analysis in this study was based on the assumption that a physician will have a 
suspicion one or two days before an ADE becomes manifest. However, the number of 
tests could also be argued to increase immediately after an ADE appears. If future research 
should confirm this increase and its predictive value, electronic monitoring of the number 
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of tests may be useful to identify patients that experience an ADE at an early stage in order 
to prevent further harm.
This study has three main limitations. First, ADEs were assessed retrospectively based on 
physicians’ notes and nurses’ notes. Therefore, it is possible that the physician did not have 
any suspicion and as a consequence did not perform additional diagnostic procedures. 
Second, the results of the biochemical tests were not taken into account in this study, 
whereas previous studies have shown that abnormal biochemical values can be used as a 
predictor to identify patients at risk of an ADE.3, 9, 27 Third, we could not discriminate 
between ADEs and other possible cause of increases of biochemical tests, such as worsen-
ing of underlying conditions or the manifestation of other conditions, such as nosocomial 
infections. In addition, data on comorbid conditions nor severity of the disease state were 
taken into account in this study. Unfortunately, we were not able to include any of these 
potential confounders in our longitudinal analysis. However, because we did not find an 
association between the number of tests and the occurrence of ADEs, correction for these 
confounders would be unlikely to affect our results or conclusion.
This study is the first study on a potential association between the number of biochemi-
cal tests and ADEs. Because we found no significant associations between the number of 
performed biochemical tests and the occurrence of ADEs the total number of biochemical 
tests cannot be used for computerized detection of hospitalized patients that may develop 
an ADE. However, some other options to use the number of tests as an electronic trigger 
should be explored. For example, the relation between specific types of tests and more 
serious types of ADEs, changes in trends of ordering tests for each patient with a suspected 
ADE, and the possible increase of performed tests immediately after an ADE is identified 
should be studied, taking into account other reasons for increases in biochemical tests.
To conclude, in this study the number of biochemical tests could not be identified as a 
predictor for ADEs in hospitalized patients. Automated detection of adverse drug events 
at an early stage should thus be focused on other parameters.
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abstraCt
background
Both clinical pharmacists and computerized physician order entry systems with clinical 
decision support (CPOE/CDSS) can reduce drug-related problems (DRPs). However, the 
contribution of a clinical pharmacist in addition to CPOE/CDSS has not been established 
in a prospective study.
objective
To determine which DRPs can be identified by a clinical pharmacist in a setting with 
routine use of CPOE/CDSS.
methods
In this observational prospective follow-up study a clinical pharmacist reviewed the phar-
macotherapy of patients admitted to surgical and neurological wards in a teaching hospital 
in the Netherlands to identify DRPs (i.e. medication errors and adverse drug events) and 
discussed the relevance of identified problems and interventions to resolve these with the 
responsible physician. Acceptance of the proposed interventions and the presence of alerts 
in CPOE/CDSS were assessed. Primary outcome was the proportion of DRPs identified 
by the clinical pharmacist that also triggered a CPOE/CDSS alert. Differences between 
the DRPs that generated an alert and those that did not were expressed as relative risks 
or analyzed with Chi square statistics or Mann–Whitney U tests. Primary outcome was 
the proportion of drug-related problems identified by the clinical pharmacist that also 
generated an alert in the CPOE/CDSS.
Results
During 1206 medication reviews, 442 potential DRPs were identified; 286 (65%) DRPs 
were considered relevant and 247 (56%) of the proposed interventions were accepted. A 
CPOE/CDSS alert was generated for 35 (8%) of the DRPs the clinical pharmacist identi-
fied. The only difference between problems that triggered an alert and those that did not 
was the class of the DRP (indication 23% vs. 36%, effectiveness 23% vs. 13%, safety 23% 
vs. 10% and pharmaceutical care issues 31% vs. 42%, p = 0.02). CPOE/CDSS triggered 
623 additional alerts that were handled during routine pharmacy service.
Conclusions
As most DRPs identified by a clinical pharmacist were not detected in daily clinical prac-
tice by CPOE/CDSS, a clinical pharmacist contributes to reducing DRPs. The sensitivity 
of CPOE/CDSS to detect certain classes of problems should be optimized.
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introDuCtion
Problems associated with pharmacotherapy, including adverse drug events and medication 
errors, occur frequently in hospitalized patients.1-3 Since the report “To err is human” 
showed the impact of these drug-related problems on morbidity, mortality, and health-
care expenditures more than a decade ago, improving medication safety has become an 
important goal for health care professionals.3 However, even in hospitals with a heavy 
programmatic focus on safety, adverse drug events still occur in a considerable proportion 
of admitted patients.4, 5
Organizational factors (such as local workflows; procedures regarding ordering, dis-
pensing, and administration of medication; and knowledge and training of personnel) 
have been associated with the occurrence of drug-related problems.2, 6-11 One of such 
organizational factors, namely use of health information technologies, can contribute to 
a reduction of these drug-related problems.6, 12 This has been shown for computerized 
physician order entry in combination with a clinical decision support system (CPOE/
CDSS). The basic CPOE/CDSS used in the Netherlands is mainly effective in preventing 
medication errors, particularly administrative prescribing errors (such as incomplete or 
illegible orders), dosing errors and transcription errors and has a high sensitivity for iden-
tifying drug-drug interactions.6, 13-20 However, basic CPOE/CDSS is not able to detect all 
pharmacotherapeutic errors, which are more likely to result in adverse drug events,20, 21 
and generates a substantial amount of alerts that are not clinically relevant, resulting in 
alert fatigue.19, 22
Clinical pharmacists can combine current diagnoses, laboratory values, medical history, 
and prescribing guidelines with the current pharmacotherapy of a patient. As a result a 
clinical pharmacist could possibly detect more therapeutic errors and adverse drug events 
than CPOE/CDSS. Although active participation of clinical pharmacists on the ward has 
been shown to improve medication safety,23-32 the contribution of a clinical pharmacist in 
addition to CPOE/CDSS has not yet been established in a prospective study.
This study was designed to determine which drug-related problems can be identified by a 
clinical pharmacist in a setting with routine use of CPOE/CDSS and whether problems 
that were also identified by CPOE/CDSS differed from those that were only identified by 
the clinical pharmacist.
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methoDs
design and setting
We performed an observational prospective follow-up study from November 2009 to July 
2010 on two surgical and two neurological wards in St. Elisabeth hospital, a 600-bed 
teaching hospital in Tilburg, the Netherlands. We selected surgical wards for this study, 
because surgical patients have been shown to be at risk of drug-related problems.33, 34 The 
neurological wards were selected to compare surgical wards with medical wards.
In this hospital the process of medication ordering and administration consists of a 
system for computerized physician order entry and barcode-assisted medication admin-
istration (Theriak Medication Management®, Theriak ehf, Tilburg, The Netherlands). 
The integrated basic clinical decision support system, based on the Dutch national drug 
database G-standard® (Z-Index, The Hague, The Netherlands), generates intrusive alerts 
(pop-ups) for overdosing, duplicate therapy, and allergies at the time of prescribing.35 
Drug-drug interactions are always visible for the physician during and after prescribing, 
but these do not trigger intrusive alerts during prescribing to prevent alert fatigue.22 
Routine central pharmacy service consisted of on-call duty for consultations and central 
handling of drug-drug interactions and overridden CPOE/CDSS alerts by pharmacy tech-
nicians and pharmacists. Alerts are primarily assessed by pharmacy technicians following 
local procedures as part of their daily routine. They can accept alerts that are not clinically 
relevant for the individual patient (for example drug-drug interactions considering pre-
admission pharmacotherapy or dosage alerts for dosages that are according to guidelines 
or handbooks), send an information leaflet to the ward (for example to advise additional 
monitoring) or submit the alert to a pharmacist.
patients
Patients included in this analysis had at least one potential drug-related problem (as as-
sessed by the clinical pharmacist). This study fell within the boundaries of normal hospital 
care and routine of quality improvement and therefore did not need Medical Ethics ap-
proval in the Netherlands.
drug-related problems
Drug-related problems were defined as circumstances that involve a patient’s drug treat-
ment that actually or potentially interfere with the achievement of an optimal outcome. 
These include medication errors (defined as any error in the process of prescribing, 
dispensing or administering a drug, whether there are adverse consequences or not) as 
well as adverse drug events (defined as any injury related to the use of a drug).9, 36 The 
classification of drug-related problems (table 1) is derived from the classification recently 
described in detail by Leendertse et al.37 which was based on the work of Strand et al..38 
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Table 1: Classification of drug-related problems and pharmaceutical care issues
Class
Drug-related 
problem Definition Example
Indication Additional drug 
therapy required
The patient has a medical condition or is experiencing symptoms that 
require the initiation of new or additional drug therapy or is at high-risk 
of developing a new medical condition for which additional drug therapy 
is indicated.
- Laxative indicated during 
opioid use (severity E)
Unnecessary drug 
therapy
The patient is undergoing drug therapy that is unnecessary given his or 
her present condition.
- Continuation of treatment 
with acetazolamide (initiated 
in intensive care unit) without 
clear indication (severity E)
Effectiveness Ineffective drug 
therapy
The drug is not being effective at producing the desired response. The 
patient is not experiencing the intended positive outcome from a certain 
regimen, or the intended outcome is not reached. Or an alternative drug 
therapy has a higher probability of producing the desired outcome.
- Butylscopolamine 
suppositories for abdominal 
spasms (absorption after 
rectal administration is less 
than 3%) (severity C)
Dosage too low The patient has a medical condition for which too little of the correct 
drug is being taken to produce the desired beneficial outcome, or the 
patient is at risk of developing a new medical condition because too 
little of the correct drug is being taken to expect a beneficial outcome. 
The patient’s drug concentration in the body can be below the desired 
therapeutic range, or the timing of prophylaxis can be inadequate for 
the patient. Or, dose, interval and duration can be inadequate for the 
patient, or drug, dose, route or formulation conversions were inadequate 
for the patient.
- Prophylactic dose of 
low molecular weight 
heparin prescribed instead 
of therapeutic dose for 
atrial fibrillation during 
temporary cessation of oral 
anticoagulants (severity G)
Safety Adverse drug 
event
The patient has a medical condition, or is experiencing symptoms, or is 
at risk of developing a medical condition which is an undesired effect and 
is related to the drug therapy. This can be an idiosyncratic reaction to the 
drug, an allergic reaction to the drug, or a pharmacologically expected 
reaction to the drug, possibly due to a medication error.
- Use of oxybutynin could 
have contributed to delirium 
(severity E)
Dosage too high The patient has a medical condition for which too much of the correct 
drug is being taken, or the patient is at risk of developing a new medical 
condition because too much of the correct drug is being taken. The 
patient’s drug concentration in the body can be above the desired 
therapeutic range, or the drug dose can be escalating too rapidly, or 
there can be drug accumulation from chronic administration or dose, 
interval, and duration can be inadequate for the patient, or drug, dose, 
route or formulation conversions were inadequate for the patient.
- Colchicine 0.5 mg every 
8 hours for a patient with a 
glomerular filtration rate of 
22 ml/min. Recommended 
dose given this glomerular 
filtration rate is 0.5 mg every 
12 hours (severity F)
Drug use Drug use problem The patient is unable or unwilling to take a drug regimen that a health 
care provider has clinically judged to be appropriately indicated, 
adequately efficacious and able to produce the intended outcomes 
without any undesired effects, or drug therapy is not optimally 
convenient.
- Use of amlodipine 5 mg 
twice daily; 10 mg once daily 
would be more convenient 
for the patient (severity A)
Pharmaceutical 
Care
Monitoring An intermittent series of observations in time, carried out to determine 
the effectiveness, safety, and adherence to drug therapy.
- Monitor digoxin serum 
levels for a patient with a 
decreased renal function 
(severity D)
Drug-drug 
interaction
A combination of two or more drugs administered to one patient that can 
result in a modification of the effect of at least one drug.
- Folic acid once weekly and 
methotrexate once weekly 
prescribed on the same day, 
while administration on the 
same day is contra-indicated 
(severity E)
Contra-indicated 
drug
A drug that is undesired because of the medical condition of the patient. - Prescription for codeine, 
while it was explicitly contra-
indicated due to somnolence 
(severity E)
Lifestyle The lifestyle of the patient that could interfere with effective and safe 
drug therapy, or that could result in non-adherence.
- Did not occur in current 
study
Duplicate therapy The use of two or more drugs with the same ATC classification* and/
or with similar pharmacodynamic properties, which can lead to adverse 
drug events.
- Combination of low dose 
aspirin and coumarin without 
indication for combination 
(severity G)
Discrepancy with
pre-admission 
pharmacotherapy
Unintended discrepancy between pre-admission pharmacotherapy and 
in-hospital treatment, including unintended discontinuation of a pre-
admission drug therapy.
- Unintended discontinuation 
of latanoprost eye drops 
for glaucoma at admission 
(severity E)
Based on Leendertse et al.37 and Strand et al.38
ATC classification = Anatomical Therapeutic Chemical (ATC) classification system
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Because discrepancies can occur between pre-admission pharmacotherapy and in-hospital 
treatment, this problem was added to the classification.39
data collection
To identify drug-related problems that required an intervention, a clinical pharmacist 
reviewed pharmacotherapy of all patients in the study wards weekly, on a set day, until 
discharge of the patients. Current medical diagnoses, laboratory results, medical history 
and medication history were taken into account.
For each patient, the relevance of identified potential drug-related problems and 
proposed interventions to ameliorate them were discussed with the attending physician. 
Subsequently, the clinical pharmacist assessed the acceptance of the proposed interven-
tions for relevant drug-related problems, as well as the presence and pharmacy handling 
of alerts in the CPOE/CDSS. Additionally, the number and type of CPOE/CDSS alerts 
for reviewed medication orders of included patients that were handled by routine central 
pharmacy service were extracted from CPOE/CDSS.
Patients’ characteristics (age and sex) and relevant medical data (reason for admission, 
medical history, and laboratory results) were extracted from medical records.
severity of drug-related problems
The index of the National Coordinating Council for Medication Error Reporting and 
Prevention (NCC MERP), which had been designed to classify medication errors into 
nine classes based on severity of related patient outcomes, was adapted to assess the sever-
ity of all drug-related problems in terms of their potential to cause patient harm had they 
not been averted (table 2).40 Each problem was retrospectively assessed separately by two 
hospital pharmacists/ clinical pharmacologists and one medical specialist (a surgeon for 
surgical cases and a neurologist for neurological cases). Consequently, the three raters 
reached consensus on severity for all cases. 41
outcomes
Primary outcome was the proportion of drug-related problems identified by the clinical 
pharmacist that also generated an alert in the CPOE/CDSS. Secondary outcomes were the 
differences between drug-related problems that were detected by the clinical pharmacist 
only and drug-related problems that also generated an alert in the CPOE/CDSS. The 
differences looked for were the class, severity, relevance and acceptance of proposed inter-
ventions as well as patient characteristics (gender, age, number of drugs during admission 
and number of drugs at time of medication review, medical specialty, and length of stay 
on study ward).
85Drug-related problems identified by a clinical pharmacist
In order to describe the routine pharmacy service for the included patients, the number 
and type of CPOE/CDSS alerts handled by the central pharmacy service that were not 
identified or not considered relevant by the clinical pharmacist are also described.
data analysis
All data were analyzed with SPSS version 17.0. To identify differences between drug-
related problems that were detected only by the clinical pharmacist and those that were 
also detected by CPOE/CDSS chi-square tests were performed for categorical nominal 
variables. Continuous variables were analyzed with Mann–Whitney U tests. A p-value less 
than 0.05 was considered statistically significant for both tests.
Results
The clinical pharmacist performed 1206 medication reviews and detected at least one 
drug-related problems during 276 reviews. In total 442 possible drug-related problems 
were identified concerning 251 admissions of 228 patients (17 patients were admitted at 
least twice). Of the identified problems 286 (65%) problems were deemed relevant for 
the individual patient and 247 (56%) of the 442 proposed interventions were accepted 
by the physicians. Among the 195 (44%) rejected interventions were those proposed for 
problems that were not relevant according to the physician (n=156). Besides, 39 interven-
Table 2: Severity categories for drug-related problems
Category Content
A Non-relevant 
problem
A drug-related problem that is not relevant for the given patient
B Relevant problem, 
no patient harm
A drug-related problem that will not reach the patient
C A drug-related problem occurred that may reach the patient but will 
not cause patient harm
D A drug-related problem that may reach the patient and will require 
monitoring to confirm that it resulted in no harm to the patient and/
or required intervention to preclude harm
E Relevant problem, 
patient harm
A drug-related problem that may contribute to or result in 
temporary harm to the patient and required intervention
F A drug-related problem that may contribute to or result in 
temporary harm to the patient and may require initial or prolonged 
hospitalization
G A drug-related problem that may contribute to or result in 
permanent patient harm
H A drug-related problem that may require intervention necessary to 
sustain life
I A drug-related problem that may contribute to or result in the 
patient’s death
Reference: National Coordinating Council for Medication Error Preventing and Reporting. NCC MERP 
Index for Categorizing Medication Errors.40
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tions for relevant problems were rejected, mainly because the patient had already been 
discharged or would be discharged soon (n=9) or because the drug therapy had been 
initiated by another specialist (n=8).
Examples of identified drug-related problems and their severity are presented in table 1. 
Of the 442 possible drug-related problems identified by the clinical pharmacist, 35 (8%) 
problems generated a CPOE/CDSS alert. Details on patient characteristics, relevance of 
drug-related problems and the acceptance of interventions are presented in figure 1.
Table 3 shows the frequency of different classes of identified drug-related problems. The 
most common drug-related problems identified by the clinical pharmacist were unneces-
sary drug therapy (21%), requirement of additional drug therapy (14%) and discrepancy 
with pre-admission pharmacotherapy (14%).
Table  4 presents the characteristics of drug-related problems detected by the clinical 
pharmacist only and problems that also triggered an alert. There was a significant differ-
ence between the classes of drug-related problems that were detected by the clinical phar-
macist only and the classes of problems that also generated a CPOE/CDSS alert (p=0.02). 
Problems concerning indication (36% versus 23%) and pharmaceutical care issues (42% 
versus 31%) were more frequently identified by the clinical pharmacist only. Problems 
regarding effectiveness (23% versus 13%) or safety issues (23% versus 10%) generated a 
CPOE/CDSS alert more often. The severity, proportion of relevant problems, acceptance 
Patients
n = 228
Female: 46%     
Age, median (range): 70 years (18-100)
Admissions
n= 251
Surgery: n= 194
Neurology: n= 57
Length of stay, median (range): 12 days (0-146)
Number of drugs, median (range): 15 (2-48)
No CPOE alert
n = 407
Potential drug-related problems
n= 442 
Relevant drug-related 
problem
n = 261                
CPOE-alert
n = 35
Acceptance of proposed 
interventions
n = 24
Acceptance of proposed 
interventions
n = 223
Relevant drug-related 
problem
n = 25
Figure 1: Patient characteristics and drug-related problems
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of proposed interventions, and patient characteristics did not significantly differ between 
drug-related problems that did generate a CPOE/CDSS alert and those that did not.
During routine pharmacy service, CPOE/CDSS generated 623 alerts for actual medica-
tion orders of included patients that were not identified or not considered relevant by the 
clinical pharmacist. Of these 415 (67%) were drug-drug interactions, 207 (33%) were 
dosage alerts and 1 (0%) was an allergy (figure 2). Pharmacy technicians assessed 76% 
of the alerts as non-relevant alerts according to local procedures. Most common reported 
reasons for acceptance of the alert by the technicians were the following: dosage is con-
form guidelines and pharmacotherapeutic handbooks (n=166), drug-drug interactions for 
continuation of pre-admission therapy (n=73) and alert is not relevant for the individual 
patient considering the dose of the drug or co-medication (n=35). An information leaflet, 
containing recommendations to prevent patient harm, was sent to the ward for 15% of the 
alerts and 9% of the alerts were submitted to a hospital pharmacist. The hospital pharma-
cist proposed an intervention, such as change in drug therapy or additional monitoring, 
to the responsible physician for 10 of those 56 alerts of which 7 were considered relevant 
by the physician.
Table 3: Frequency of classes of identified drug-related problems
Class
Subclass of drug-related 
problem
Problems detected by
Total
n=442
n (%)
Clinical 
pharmacist
only
n=407
n (%)
Clinical 
pharmacist and 
CPOE
n=35
n (%)
Indication Additional drug therapy 
required
54 (13) 7 (20) 61 (14)
Unnecessary drug therapy 91 (22) 1 (3) 92 (21)
Effectiveness Ineffective drug therapy 9 (2) 2 (6) 11 (3)
Dosage too low 44 (11) 6 (17) 50 (11)
Safety Adverse drug event 16 (4) 3 (9) 19 (4)
Dosage too high 23 (6) 5 (14) 28 (6)
Drug use Drug use problem 16 (4) 3 (9) 19 (4)
Pharmaceutical Care Monitoring 34 (8) 0 (0) 34 (7)
Drug-drug interaction 3 (1) 2 (6) 5 (1)
Contra-indicated drug 5 (1) 1 (3) 6 (1)
Lifestyle 0 (0) 0 (0) 0 (0)
Duplicate therapy 52 (13) 2 (6) 54 (12)
Discrepancy with
pre-admission 
pharmacotherapy
60 (15) 3 (9) 63 (14)
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Table 4: Characteristics of drug-related problems detected by a clinical pharmacist only (n=407), 
versus drug-related problems detected by a clinical pharmacist and CPOE/CDSS (n=35)
Characteristic of drug-related problem
Problems detected by
Statistics
Clinical 
pharmacist
only
n=407
n (%)
Clinical 
pharmacist 
and CPOE
n=35
n (%)
Class of drug-related problem p = 0.02a
Indication 145 (36) 8 (23)
Effectiveness 53 (13) 8 (23)
Safety 39 (10) 8 (23)
Pharmaceutical care issues 170 (42) 11 (31)
Severity of drug-related problem p = 0.24a
Non-relevant problem 149 (37) 8 (23)
Relevant problem, no harm 105 (26) 10 (29)
Relevant problem, harm 153 (38) 17 (49)
Relevant drug-related problem according to physician 261 (64) 25 (71) p = 0.39a
Acceptance of proposed interventions 223 (55) 24 (69) p = 0.12a
Therapeutic area of drug-related problem Not applicableb
Gastro-intestinal tract (A) 53 (13) 2 (6)
Blood system (B) 55 (14) 2 (6)
Cardiovascular tract (C) 52 (13) 11 (31)
Dermatologicals (D) 2 (1) 0 (0)
Genitourinary systems and sex hormones (G) 6 (2) 0 (0)
Hormonal systemic therapy (H) 8 (2) 2 (6)
Anti-infectives (J) 51 (13) 1 (3)
Cancer therapy (L) 2 (1) 0 (0)
Musculo-skeletal system (M) 28 (7) 2 (6)
Nervous system (N) 99 (24) 11 (31)
Anti-parasitic products, insecticides and repellents (P) 3 (1) 0 (0)
Respiratory tract (R) 30 (7) 4 (11)
Sensory organs (S) 13 (3) 0 (0)
Various (V) 5 (1) 0 (0)
Female gender 172 (43) 20 (57) p = 0.09a
Age (years; median, IQR) 72 (17) 71 (22) p = 0.73c
Number of drugs during admission (median, IQR) 16 (10) 15 (5) p = 0.29c
Number of drugs at time of medication review (median, 
IQR)
12 (6) 12 (6) p = 0.55c
Length of stay (days; median, IQR) 10 (14) 9 (12) p = 0.52c
Medical ward
Surgery (versus neurology) 314 (77) 30 (86) p = 0.24a
IQR = interquartile range; RR = relative risk; 95%CI = 95% confidence interval
Figures in bold are statistically significant
a Chi-square test
b Chi-square test could not be applied, due to low observed count and expected count <5 in many cells
c Mann–Whitney U test
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DisCussion
To our knowledge, this is the first study looking at the effect of a clinical pharmacist on 
the identification of drug-related problems in addition to routine use of CPOE/CDSS. It 
shows that a clinical pharmacist can identify drug-related problems that are not detected by 
basic CPOE/CDSS. This is consistent with previous findings that drug-related problems 
still occur after implementation of CPOE/CDSS20, 23, 42, 43 and that a clinical pharmacist 
can improve medication safety in different health care settings.27, 44
Only 8% of the drug-related problems identified by the clinical pharmacist generated 
a CPOE/CDSS alert. Problems that did generate an alert and those that did not dif-
fered only with respect to the class of the drug-related problem. The clinical pharmacist 
identified many problems regarding indication (mainly unnecessary drug therapy) and 
pharmaceutical care (especially discrepancies with pre-admission pharmacotherapy and 
requirement for additional monitoring). By contrast, the CDSS, that covers basic prin-
ciples of support only, generated relatively more alerts for problems concerning safety (e.g. 
overdosage), effectiveness (e.g. underdosage) and drug-drug interactions. This is in line 
with our expectations since the system is not programmed to identify problems regarding 
indication and pharmaceutical care issues other than drug-drug interactions and allergies.
Currently, more sophisticated CDSSs that use clinical rules to detect pharmacothera-
peutic errors are being developed and implemented in the Netherlands.17, 45, 46 Examples 
of such clinical rules are the following: prescription of a drug which requires dosage 
adjustment for a patient with renal failure, no laxative prescribed in conjunction with 
CPOE/CDSS alerts handled during routine 
pharmacy services
n=623
Non-relevant alert
n = 472 (76%)
Primary assessment by a pharmacy 
technician
Assessment by a hospital 
pharmacist
n=56 (9%)
Non-relevant alert
n = 46
Intervention required
n = 10
Information leaflet
sent to ward
n = 95 (15%)
Relevant alert  
according to physician
n = 7
Figure 2: Handling of additional CPOE/CDSS alerts during routine pharmacy services
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opioid use and no ulcer protection prescribed to a patient >70 years who uses an NSAID. 
Van Doormaal et al. reported that 39% of the dosing and therapeutic errors detected 
by a retrospective medication review by a pharmacist were detected by a small set of 
clinical rules. When these clinical rules were combined with CPOE/CDSS this proportion 
increased to 66%.19 However, we believe that a clinical pharmacist may still contribute 
to the reduction of drug-related problems even when more clinical rules are used. For 
example by reviewing a patients complete pharmacotherapy to identify unnecessary drugs 
or certain adverse drug reactions, which will probably not be completely possible with 
CPOE/CDSS or clinical rules in the near future.
For patients in our study, CPOE/CDSS generated many additional alerts that the 
clinical pharmacist did not identify or did not consider relevant. Most of these alerts 
were handled by pharmacy technicians during routine central pharmacy care and did not 
require an intervention. Only about 10% of CPOE/CDSS alerts needed assessment by a 
pharmacist and even for these alerts an intervention was not always required, suggesting 
that CPOE/CDSS has a low positive predictive value to identify drug-related problems 
that require an intervention. In contrast, the majority of the problems identified by the 
clinical pharmacist, who focused on problems that required an intervention, were consid-
ered relevant by the attending physician. As a result, most of the proposed interventions to 
ameliorate the problems were accepted, suggesting that a clinical pharmacist identifies and 
averts more clinically relevant drug-related problems than basic CPOE/CDSS.
Our study has four limitations. The first is that only patients with one or more identified 
drug-related problems according to the clinical pharmacists were included in the analysis, 
which means that CPOE/CDSS alerts for patients without any drug-related problems 
according to the clinical pharmacist were not included. Consequently, we could not calcu-
late the specificity and sensitivity to identify drug-related problems by medication review 
and by CPOE/CDSS alerts or the positive and negative predictive values.
Second, neither the actual reduction of patient harm by the clinical pharmacist nor the 
cost-effectiveness of this intervention was assessed.
Third, the clinical pharmacist was aware of the limitations of basic CDSS and could 
have focused more on problems that are not detected by CPOE/CDSS. But as the aim 
of our study was to identify which drug-related problems can be identified by a clinical 
pharmacist in a setting with routine use of CPOE/CDSS, we feel this fact represents the 
way a clinical pharmacist operates in real life and thus generates results that are representa-
tive for daily routine.
Fourth, because organizational characteristics have been shown to be a determinant 
for drug-related problems, these results cannot be extrapolated to other medical special-
ties or hospitals with a differently organized pharmaceutical care or to hospitals using 
other CPOE/CDSSs. Main strength of this study is that the discussion with the attending 
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physician yielded information about the clinical relevance of the identified problems and 
the acceptance of the proposed interventions for individual patients.
Future studies should focus on optimizing the sensitivity and specificity of CPOE/
CDSSs incorporating clinical rules to detect clinically relevant drug-related problems by 
combining data from different electronic health records. Furthermore, the contribution 
of clinical pharmacists in addition to these advanced systems should be assessed, as well as 
their cost-effectiveness and potential to reduce actual harm.
To identify and avert drug-related problems routine hospital pharmacy service should 
be much more patient-focused than drug-focused. It should consist of medication recon-
ciliation at admission, central handling of CPOE/CDSS alerts, a defined set of clinical 
rules, and medication review by a clinical pharmacist and the attending physician. Besides, 
advanced health information technologies that help physicians, clinical pharmacists and 
other health care professionals to identify patients at risk of drug-related problems should 
be designed and implemented. These technologies should fit into clinical workflow and 
minimize alerts for problems that are not clinically relevant and do not require an inter-
vention.
To conclude, a clinical pharmacist can identify many additional drug-related problems in 
a setting with routine use of CPOE/CDSS. On the other hand CPOE/CDSS generates 
many alerts that are not considered relevant. These findings should be used to develop 
more advanced CDSSs to identify drug-related problems. Given the type of drug- related 
problems identified by clinical pharmacists when compared to CDSS, clinical pharmacists 
may still provide additional value even in settings using more advanced CDSSs.
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abstraCt
background
A Systematic Tool to Reduce Inappropriate Prescribing (STRIP), which includes the 
Screening Tool to Alert doctors to Right Treatment (START) and the Screening Tool of 
Older Peoples’ Prescriptions (STOPP), has recently been developed in the Netherlands for 
older patients with polypharmacy in the general population. Active involvement of the 
patient is part of this systematic multidisciplinary medication review. Although annual 
review of pharmacotherapy is recommended for people with an intellectual disability 
(ID), a specific tool for this population is not yet available. Besides, active involvement 
can be compromised by ID. The objective of this observational pilot study was to evaluate 
the process of medication review using STRIP in adults with an ID living in a centralized 
or dependent setting and the identification of drug-related problems using this tool. 
method
The study was performed in three residential care organizations for ID. In each organization 
nine clients with polypharmacy were selected by an investigator (a physician in training 
to become a specialized physician for individuals with an ID) for a review using STRIP. 
Clients as well as their legal representatives (usually a family member) and professional 
caregivers were invited to participate. Reviews were performed by an investigator together 
with a pharmacist. First, to evaluate the process time-investments of the investigator and 
the pharmacist were described. Besides, the proportion of reviews in which a client and/or 
his legal representative participated was calculated as well as the proportion of professional 
caregivers that participated. Second, to evaluate the identification of drug-related problems 
using STRIP, the proportion of clients with at least one drug-related problem was calculated. 
Results
Mean time investment was 130 minutes for the investigator and 90 minutes for the pharma-
cist. The client and/or a legal representatives were present during 25 of 27 reviews (93%). All 
27 professional caregivers (100%) were involved. For every client included at least one drug-
related problem was identified. In total 127 drug-related problems were detected, mainly 
potentially inappropriate or unnecessary drugs. After six months, 15.7% of the interventions 
were actually implemented.
Conclusions
Medication review using STRIP seems feasible in adults with an ID and identifies drug-
related problems. However, in this pilot study the implementation rate of suggested 
interventions was low. To improve the implementation rate, the treating physician should 
be involved in the review process. Besides, specific adaptations to STRIP to address drug-
related problems specific for this population are required.
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introDuCtion
Polypharmacy, defined as the concomitant use of five or more drugs, can be indicated 
in case of multimorbidity, but it is also an important risk factor for undesired health 
outcomes in the general population, including adverse drug events1, hospitalizations2 and 
mortality.3 In our earlier work, published in this journal, we showed that polypharmacy is 
an important risk factor for clinically relevant prescription errors in older individuals with 
an intellectual disability (ID).4
Individuals with an ID are prone to polypharmacy due to the high prevalence of chronic 
comorbid conditions. These include somatic diseases, such as gastrointestinal disorders5-7 
and epilepsy7, the presence of cardiovascular risk factors8, 9, and mental conditions, such as 
behavioral problems, sleep disturbances10, anxiety11 and depression.12 In previous studies 
the prevalence of polypharmacy among individuals with an ID varied between 11% and 
60%, depending on the study population, definitions and study methods.13 Although 
different prescribing guidelines for the ID population acknowledge the risk of polyphar-
macy, clear recommendations to prevent or reduce polypharmacy are lacking or focus on 
psychotropic medication only.13
Besides polypharmacy, both impaired cognition and living in a residential care setting 
have been identified as independent risk factors for medication related hospital admis-
sions in the general population.2 As these risk factors are pertinent in the residential ID 
population, the Dutch Health Care Inspectorate demands an annual reassessment of 
pharmacotherapy by the physician, pharmacist, professional caregiver and the individual 
or his legal representative.14
In the Netherlands a multidisciplinary guideline has been developed for reviewing phar-
macotherapy in older persons with polypharmacy15, called the Systematic Tool to Reduce 
Inappropriate Prescribing (STRIP). This method comprises five steps: a pharmacothera-
peutic history, including experiences and expectations of the patient (1), an analysis of 
potential drug-related problems, in which the Screening Tool to Alert doctors to Right 
Treatment (START) and the Screening Tool of Older Peoples’ Prescriptions (STOPP) with 
adaptations to Dutch practice are being used (2)16, 17, proposing a pharmaceutical care plan 
by the physician and the pharmacist (3), concordance between physician and patient on 
the care plan (4), and follow-up (5). However, a validated instrument to perform a review 
in individuals with an ID is not available. A recent Dutch study performed by Scheifes 
et al. evaluated a comparable structured medication review (not including START and 
STOPP criteria) performed by pharmacists and psychiatrists in individuals with an ID 
and severe behavioral problems.18 This study showed that structured medication review is a 
valuable tool to identify drug-related problems and optimize pharmacotherapy. However, 
the authors noted that the participation of patients in the pharmaceutical anamnesis was 
problematic, that patients’ understanding of the questions about their pharmacotherapy 
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might be insufficient and that patients are prone to give socially desirable answers. It is 
known that in the ID-population atypical symptoms of diseases, which can be masked by 
the disability, and persons’ inability to communicate about disease complicate diagnos-
ing, prescribing and evaluating pharmacotherapy.19, 20 In addition, their knowledge on 
potential adverse drug reactions and alternatives to medication seems limited 21 and their 
capacity to consent with treatment is often impaired.22, 23 As a result, active involvement 
of adults with ID in the evaluation of their pharmacotherapy (step 1) and concordance 
(step 4) in a medication review using STRIP could be complicated as well, but ways to 
involve and empower individuals with ID despite these problems should be explored. 
Therefore, the objectives of this study were to evaluate the process of medication review 
using STRIP in adults with an ID living in a residential care setting and the identification 
of drug-related problems.
methoDs
design
A pilot study was performed to explore the process of medication review using STRIP in 
adults with an ID.
setting and study population
This study was performed in three Dutch residential care organizations for adults with 
an ID (DeSeizoenen (Oploo), Het Raamwerk (Noordwijkerhout), Pluryn (Nijmegen)). 
These organizations provide residential care, including reimbursed chronic specialized 
healthcare, provided by a team of certified physicians for individuals with an intellectual 
disability (ID-physicians), behavioral therapists, physiotherapists and other disciplines. 
Daily support and care, including administering medication, is given by a team of profes-
sionally trained caregivers. Until recently, professional training of these caregivers primarily 
focused at behavioral aspects and less on health and nursing. The treating ID-physician is 
responsible for the medical care, including pharmacotherapy. In the Netherlands, the legal 
representative of a client, who is usually a family member, needs to give consent to any 
changes in (medical) treatment. Preferably, the client agrees with the treatment as well.
Since this study did not affect patient integrity, a waiver from the Medical Ethics Com-
mittee was obtained.
data collection
The three different pharmacists connected to the care organizations selected all clients with 
polypharmacy, defined as the concomitant use of five or more drugs, from their organiza-
tion. In each care organization one of three investigators, who were physicians following 
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the 3-year specialist training to become an ID-physician, selected nine adults to obtain a 
sample with large diversity in age, level of disability and comorbid conditions. Selected 
clients, their legal representatives and professional caregivers received written information 
about the pilot study and were invited for an interview about their pharmacotherapy.
The medication reviews were performed in June 2013 (organization 1), July and Sep-
tember 2013 (organization 2) and October 2013 (organization 3). Gender, age and level 
of ID (mild, intelligence quotient (IQ) ≥55 to <70; moderate, IQ ≥35 to <55 and severe, 
IQ<35) of included adults were recorded by the investigators. Number and type of drugs 
(according to Anatomical Therapeutic Chemical (ATC) classification system) at time of 
the review were extracted from the records of the dispensing pharmacy.
The investigators did not have any responsibilities in patient care during the study.
the systematic tool to Reduce inappropriate prescribing (stRip)
The medication review process is described in detail in table 1. Reviews were performed by 
the investigator together with a pharmacist, following the steps described in the detailed 
description of the tool. The review included the Screening Tool to Alert doctors to Right 
Treatment (START) (appendix A) to identify potentially appropriate indicated drugs that 
should be started and the Screening Tool of Older Peoples’ Prescriptions (STOPP) (appen-
dix B) to identify potentially inappropriate or unnecessary drugs that should be withheld. 
Apart from the explicit START and STOPP criteria, additional drug-related problems were 
identified by the pharmacist or the investigator based on their professional judgement and 
Table 1: Reviewing pharmacotherapy according to the Systematic Tool to Reduce Inappropriate 
Prescribing
Description Performed by
Preliminary phase Collecting relevant data on pharmacotherapy, allergies, 
medical history, current diagnoses, laboratory results
Investigator
Step 1 During an interview with the client and/or his legal 
representative or his professional caregiver, the 
investigators collected information on the actual 
pharmacotherapy and the clients experiences and 
expectations.
Investigator
Step 2 Potential drug-related problems were identified using data 
obtained during the previous steps.
Pharmacist
Step 3 Composing a pharmaceutical care plan in which treatment 
goals, relevant drug-related problems and interventions 
were defined.
Investigator together 
with pharmacist
Step 4 Concordance with the client and/or his legal representative 
on the care plan.
Investigator
Step 5 Follow-up: Discussing the findings in a meeting with the 
treating ID-physician. Implementation of the suggested 
interventions to optimize pharmacotherapy was assessed 
directly, three and six months after the review process.
Investigator
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current guidelines on appropriate prescribing in ID24 or the general population.25, 26These 
additional drug-related problems were classified as potentially appropriate indicated 
drugs, potentially inappropriate or unnecessary drugs, drug use problems, monitoring 
issues and discrepancies (for example between the patient information, medical record 
and/or the pharmacy record).
Suggestions to improve pharmacotherapy were discussed with the treating ID-physician. 
Implementation of suggested interventions to change pharmacotherapy was assessed im-
mediately after the review, after three months and after six months by reviewing clients’ 
pharmacy records.
Financial consequences
Time invested by the investigator and the pharmacists was recorded during the review 
process. Costs related to their efforts were calculated using an hourly rate of €45 for the 
pharmacist, based on the maximum salary costs for employed pharmacists27 and €54 for 
the resident ID-physician (based on the maximum salary costs of an ID-physician).28
Medication-related costs/savings of interventions to resolve drug-related problems 
were calculated using the consumer reimbursement price published on the website of 
the National Health Care Institute.29 These prices are based on the pharmacist purchase 
price minus 6.82% clawback (a rate the pharmacist has to pay to the healthcare insurance 
company to compensate for purchase discounts with a maximum of €6.80 per prescrip-
tion) plus 6% value-added tax. The dispensing fee for the pharmacist is excluded in this 
price. The difference in costs for the prescribed drug before the intervention and the 
prescribed drug after the intervention was calculated for all interventions and the financial 
consequences were recalculated using 67% of these total cost differences, assuming an 
implementation rate of 67%. This assumption was based on previous studies in which the 
acceptance rates of pharmacists’ interventions in hospitalized patients varies between 56 
and 98%.30-35
Total financial consequences were calculated by summing the salary costs and the dif-
ference in drug costs. Costs for additional monitoring were excluded from this analysis.
Additionally, cost differences were calculated for every intervention partly or completely 
implemented that resulted in a change of pharmacotherapy six months after the review. 
Again, total financial consequences were calculated by summing the salary costs and the 
difference in drug costs.
outcomes
First, to evaluate the process of medication review using STRIP in the ID-population 
time-investments of the investigator and the pharmacist were described. Besides, the 
proportion of reviews in which a client and/or his legal representative participated was 
calculated as well as the proportion of professional caregivers that participated (based 
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on the requirement of the Dutch Health Care Inspectorate that these persons should be 
involved in medication review in individuals with an ID14).
Second, to evaluate the identification of drug-related problems using STRIP, the propor-
tion of clients with at least one drug-related problem was calculated. Additional outcomes 
in this evaluation were the number and types of drug-related problems identified, the 
implementation rate of suggested changes in pharmacotherapy directly, three months and 
six months after the review, the net savings on direct pharmaceutical costs assuming an 
implementation rate of 67% and the net savings of interventions that were partially or 
completely implemented six months after the review.
statistical analysis
Data were analyzed using IBM SPSS Statistics version 21.0. Descriptive statistics were 
used to determine the participation of adults with ID, their legal representatives and 
professional caregivers as well as the number and types of potential drug-related problems. 
Financial consequences were calculated using Microsoft Excel version 2010.
results
evaluation of the process of medication review using stRip
Study population
During this pilot-study 27 reviews were performed. Characteristics of the included clients 
are presented in table 2. For these clients a comparable structured medication review using 
STRIP had not been performed before. The median number of drugs used per client was 
10 (range 5-29), including as needed prescriptions. Twenty-one clients (77.8%) had at 
least one as needed prescription (median 1; range 0-7), mostly drugs acting on the central 
nervous system (13 clients) and drugs for the alimentary tract (8 clients).
Table 2: Characteristics of included clients (n=27)
Patient characteristics n (%)
Female gender 13 (48.1)
Age, years (median, range) 45 (18-80)
Level of intellectual disability
Mild 13 (48.1)
Moderate 9 (33.3)
Severe 5 (18.5)
Number of drugs (median, range) 10 (5-29)
Number of drug-related problems (median, range) 4 (1-12)
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Details on the drug use per pharmacotherapeutic group are presented in table 3. Almost 
all patients used drugs for the alimentary tract (26 clients) and drugs acting on the central 
nervous system (24 clients).
Time investment
The mean time investment of investigators per client was 30 minutes for the preliminary 
phase, 30 minutes for step 1, 40 minutes for step 3, 20 minutes for step 4 and 10 minutes 
for step 5. Mean total time investment for the investigators was 130 minutes. Mean time 
investments for the pharmacists was 60 minutes in step 2 and 30 minutes in step 3 and 
thus 90 minutes in total.
Involvement of clients, legal representatives and professional caregivers
In total 24 out of 27 (89%) clients were present during the medication review. Of the three 
clients that did not participate two had a mild disability and one had a severe disability. 
For two of these clients participation in the review was considered too stressful given their 
disabilities. The other client developed psychotic symptoms during the interview and left 
the interview early. The client and/or a legal representatives were present during 25 of 27 
reviews (93%). All 27 professional caregivers (100%) were involved.
identification of drug-related problems
Identified drug-related problems and implementation of interventions
For each client included at least one drug-related problem was identified and in total 127 
drug-related problems were identified. (table 4). During the review process 4 potentially 
Table 3: Use of drugs according to pharmacotherapeutic group
Pharmacotherapeutic groupa
Patients (n=27) using ≥ 1 drugs 
from class
n (%)
Alimentary tract and metabolism (A) 26 (96.3)
Blood and blood forming organs (B) 8 (29.6)
Cardiovascular system (C) 14 (51.9)
Dermatologicals (D) 11 (40.7)
Systemic hormonal preparations (H) 6 (22.2)
Anti-infectives for systemic use (J) 3 (11.1)
Musculo-skeletal system (M) 3 (11.1)
Nervous system (N) 24 (88.9)
Respiratory system (R) 5 (18.5)
Sensory Organs (S) 5 (18.5)
a According to Anatomical Therapeutic Chemical (ATC) classification system
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appropriate indicated drugs were identified by START in 4 clients (15% of our popula-
tion) and 18 potentially inappropriate or unnecessary drugs were identified by STOPP 
in 13 clients (48% of our population). Apart from the START and STOPP criteria, the 
pharmacist and the investigator identified 2 potentially appropriate indicated drugs, 81 
potentially inappropriate or unnecessary drugs, 6 drug-use problems, 15 monitoring is-
sues and 1 discrepancy. Examples of the identified problems are presented in table 4. In 
total 32 problems (25.4%) were related to drugs acting on the central nervous system, 
including potentially unnecessary drug therapy without a clear indication (n=13), poten-
tially inappropriate drug therapy due to the presence of an adverse drug reaction (n=6) or 
supratherapeutic dosage (n=4) and requirement of monitoring (n=4).
Implementation rate of suggested interventions
The implementation rate of the suggested interventions for the 127 problems is presented 
in table 5. Directly after the review 5 (3.9%) of the 127 interventions had been partially 
implemented. The implementation rate increased to 13.4% three months after the review. 
After six months, 20 out of 127 proposed interventions (15.7%) had been partially or 
completely implemented.
Table 4: Identified potential drug-related problems (n=127)
Potential drug-related 
problem n (%) Example
Potentially appropriate 
indicated drug (START)
4 (3.1) Oral anticoagulant indicated with chronic atrial 
fibrillation
Potentially appropriate 
indicated drug
2 (1.6) Laxative indicated for constipation; insulin indicated 
for diabetes mellitus type II poorly controlled with 
oral antidiabetic drugs
Potentially inappropriate or 
unnecessary drug (STOPP)
18 (14.1) Duplicate therapy with 4 antiepileptic drugs or 2 
antipsychotic drugs
Potentially inappropriate or 
unnecessary drug
81 (63.8) Underdose of vitamin D; ineffective drug (NSAID) 
prescribed for neuropathic pain; unnecessary drugs 
given the present condition, e.g. proton pump 
inhibitor, antihistamine, dermal preparations
Drug use problem 6 (4.7) Infrequent use of carbomer liquid eye gel to relieve 
dryness; infrequent use of cleansing enema for 
constipation
Monitoring 15 (11.8) Control of serum levels of antiepileptics or potassium 
level required; measuring of blood pressure is 
recommended
Discrepancy 1 (0.8) Use of hydrocortisone ointment by client is unknown 
to physician and pharmacist
Total 127 (100.0)
NSAID, non-steroidal anti-inflammatory drug
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Financial consequences
Mean time investment per review was 130 minutes for the investigator and 90 minutes 
for the pharmacist, resulting in a total of €184.50 salary costs per review and € 4981.50 
for 27 reviews.
From all 127 interventions medication-related costs/savings could be calculated for 88 
interventions. Apart from additional monitoring (n=15), medication-related costs/savings 
could not be calculated for 24 interventions because the specific drug, dose or frequency 
used or advised was unknown or the drug was not available on the website of the National 
Health Care Institute. The 88 interventions included in this analysis would result in a 
reduction of € 38,234.97 in medication related costs yearly. In case of an implementation 
rate of 67%; the net savings on pharmaceutical costs of the review process would be
€ 38,234.97*0.67- € 4981.50 = € 20,635.93. However, it should be mentioned that this 
benefit was strongly influenced by one drug-related problem, namely duplicate therapy 
of tadalafil and bosentan for pulmonary hypertension in one client. Discontinuation 
of one of these two drugs would result in a benefit of €30,773.87. Exclusion of this 
benefit would mean that the review process would yield ((€38,234.97-€30,773.87)*0.67) 
- €4981.50=€17.44.
For three of the 20 interventions that were at least partly implemented after six months 
the medication-related costs/savings could not be calculated (no specific drug was advised, 
the drug was not available on the website of the National Health Care Institute or the 
drug-related problem concerned a drug allergy that was not recorded in the pharmacy 
chart). The remaining 17 changes in pharmacotherapy that were actually implemented 
after six months resulted in a reduction of €2024.91 in yearly drug costs, meaning that for 
this scenario the costs for the review process are €4981.50 - €2024.91= €2956.59.
Table 5: Implementation rate of interventions (n=127) to resolve potential drug-related problems
Implementation
After review
n (%)&
After 3 months
n (%)&
After 6 months
n (%)&
Complete 3 (2.4) 13 (10.2) 14 (11.0)
Partly 2 (1.6) 4 (3.1) 6 (4.7)
Not implemented 90 (70.9) 76 (59.8) 73 (57.5)
Unknown* 28 (22.0) 28 (22.0) 28 (22.0)
Loss to follow-up# 4 (3.1) 6 (4.7) 6 (4.7)
& Percentages of total number of interventions (n=127)
* For example: monitoring of blood pressure control or serum drug levels could not be evaluated in this study
# Two clients died shortly after the review and were lost to follow-up
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DisCussion
In this pilot study we showed that the Systematic Tool to Reduce Inappropriate Prescribing 
can be used for adults with an ID to identify drug-related problems. Medication review 
using this tool requires substantial time investments from physicians and pharmacists. It 
should be mentioned that neither these physicians nor the pharmacists used STRIP for 
this specific population before this pilot study. When STRIP would be implemented as 
routine practice for the annual assessment of pharmacotherapy, both the physician and the 
pharmacist would gain experience in using this tool, resulting in a decrease in time invest-
ment. Moreover, a first medication review for a patient takes significantly more time, since 
the patient’s medical and pharmaceutical history need to be collected. When implement-
ing structured medication review in practice, one should consider delegating some tasks 
in the preliminary phase to other professionals, such as professional caregivers. In the only 
published study on medication review in adults with an intellectual disability and severe 
behavioral problems, time investments were substantially lower, namely one hour for the 
pharmacist and physician together.18 However, in this study the pharmaceutical history 
with the client was performed by the nurse. Besides, differences between settings, such 
as available data in the medical record, and training of the professionals could possibly 
explain these differences.
During almost all reviews the client and/or a legal representative were present and a 
high number of individuals with an ID in residential care were able to be involved in a 
systematic medication review. This may be explained by the fact that most participants 
had a mild to moderate degree of ID. Although the actual contribution of the clients to 
the identification of drug-related problems has not been systematically recorded in this 
study, the investigators mentioned the added value of involving the client, since clients 
spontaneously reported adverse events. Besides, investigators noted that the clients ap-
preciated being involved in the process, which possibly could improve their adherence 
to pharmacotherapy. In comparison, during home medication review by community 
pharmacists in older patients with polypharmacy using medication and clinical records 
as well as an interview with the patient, about one quarter of all drug-related problems, 
mostly adverse drug reactions, were identified during the interview,36 suggesting important 
contribution of the patients themselves.
All professional caregivers were involved in the process. They experienced the medi-
cation review process as useful. For example, the evaluation of actual use of as needed 
prescriptions showed that some of these drugs were not used at the right moment or were 
not used at all.
A total of 127 drug-related problems, mainly potentially unnecessary or inappropriate 
drugs, were detected and for all 27 included adults at least one drug-related problem 
was identified. In the previously mentioned study on structured medication review in 
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clients with severe behavioral problems, drug-related problems were identified in 80% of 
included clients, mostly potentially unnecessary drugs (i.e. drugs with no or an unclear 
indication).18 In previous studies performed in the general population in primary care 
settings or nursing homes using START and STOPP criteria, potentially appropriate 
indicated drugs were identified in 42 to 50% of the older patients and potentially inap-
propriate or unnecessary drugs in 27 to 60% of the older patients.37-39 In our pilot study, 
potentially appropriate indicated drugs according to START criteria were identified less 
often than in these studies. The proportion of clients with potentially inappropriate or 
unnecessary drugs according to STOPP criteria found in our study seems comparable 
to that in the general population, but a large number of the potentially inappropriate or 
unnecessary drugs were identified by other means than the STOPP criteria. This suggests 
that the actual prevalence of unnecessary or inappropriate drugs could even be higher than 
in the general population, emphasizing the need for adaptation of the STOPP criteria for 
the ID population. However, given the small sample size of our pilot study, no definite 
conclusions can be drawn from our study.
STRIP, including the START and STOPP criteria used in this systematic medication 
review, was designed for individuals aged 65 years and older in the general population. We 
used it for adults, aged 18 years and older, with an ID. Because age-related frailty starts 
at a younger age, around 50 years, in the ID-population40, 41 one could argue that START 
and STOPP criteria could be applicable to adults with ID from around 50 years and older. 
Although the median age in our pilot study was slightly below 50 years, relatively few 
problems were identified by the START or STOPP criteria. Future research in individuals 
with an ID should explore which items of the START and STOPP criteria are relevant 
for adults with an ID and which adaptations, in accordance with specific guidelines, such 
as the international guide to prescribing psychotropic medication for the management 
of problem behaviors,42 are necessary. For example, duplicate therapy of drugs acting 
on the central nervous system (e.g. two or more antiepileptics for epilepsy or two or 
more antipsychotics for behavioral problems) could be added to the STOPP-criteria and 
supplementation of vitamin D could be added to the START-criteria. Besides, one should 
focus on evaluating the effect and adverse events of chronic drug treatment and the actual 
use of “as needed” prescriptions. An adapted tool should especially emphasize evaluation 
of antipsychotics, which are used by up to 45% of individuals with an ID42 and require 
extensive monitoring on potential adverse drug reactions, including involuntary move-
ments and for the newer antipsychotics weight gain and metabolic syndrome.43 Moreover, 
there is a special need to evaluate the effectiveness and the actual reason for prescription 
of antipsychotics according to the international guidelines,42 since almost 80% of the 
antipsychotics are used longer than 10 years, often without a clear indication.44
In this study only 15.7% of the suggested interventions were at least partly implemented 
six months after the review (criterion 4), whereas Scheifes et al. reported an implementa-
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tion rate of 56.9%.18 Presence of an indication for a potentially unnecessary drug, change 
of physician, attention for the treatment relationship and early discharge were reported as 
reasons for not implementing interventions. However, the reason for not implementing 
was unknown in 18 of 44 not-implemented interventions. Moreover, acceptance rates of 
interventions based on START-criteria and STOPP-criteria above 90% have been reported 
in older hospitalized patients.45 The fact that the reviews in our study were performed by 
physicians, not being the treating physician, could have influenced the low implementa-
tion rate in our setting. Therefore, we recommend involvement of the treating physician 
in any medication review. Unfortunately, we did not assess physicians’ reasons for not 
implementing the suggested interventions. Since the interventions were proposed by a 
physician in training to become an ID-physician together with a pharmacist we believe the 
recommendations (e.g. discontinuation of potentially inappropriate or unnecessary drugs) 
were feasible in general. However, the treating physician could have argued that a recom-
mendation was not applicable to the specific patient; comparable to the physicians in the 
previously mentioned study, where the physicians did find an indication for potentially 
unnecessary drugs. Besides, attention for the treatment relationship or opinions of profes-
sional caregivers (especially on discontinuation of drugs for behavioral problems) could 
have played a role. In addition, preferences of clients or their legal representatives could 
have hindered implementation, since legal representative need to give consent to changes 
in pharmacotherapy in the Netherlands. Moreover, most clients visit different specialists 
because of their multimorbidity, and the treating physicians could have thought they 
were not able to implement changes to pharmacotherapy initiated by another specialist. 
However, in other settings, other barriers for implementing changes could exist, depend-
ing on the legal responsibilities, especially when clients have the right to make their own 
decisions when they are capable, as in England and Wales.23 It should be mentioned that 
physicians in general could be accountable for not following evidence-based guidelines, 
unless valid argumentation for disregarding evidence-based recommendations is well 
documented in the medical record.
Assuming an implementation rate of 67%, the review results in net savings on phar-
maceutical costs. However, looking at the changes in pharmacotherapy that were actu-
ally implemented, the medication review using STRIP did not result in net savings on 
pharmaceutical costs, as the salary costs were higher than the benefits in medication costs. 
This can be explained by the relatively few interventions that were actually implemented 
by the treating physician and the substantial time investments discussed earlier. Addition-
ally, we used the maximum salary costs for both the physician and the pharmacist as a 
worst case scenario, whereas actual salary costs may be lower. Since our study was a pilot 
study a sensitivity analysis was not performed for the financial consequences. Considering 
the presented example of duplicate therapy of tadalafil and bosentan, single drug-related 
problems could have major impact on the financial consequences. Therefore, future larger 
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studies should focus on the cost-effectiveness of medication review, including sensitivity 
analyses. However, probably comparable outliers (problems related to expensive drugs) 
will be identified in other studies.
This study has five main limitations. First, given the small sample size of this pilot study, 
no definite conclusions can be drawn on the prevalence of drug-related problems and the 
cost-effectiveness of STRIP. In addition, the clients were not randomly selected, which 
could have resulted in sampling bias. Therefore, the sample may not be representative for 
the population of adults with an ID in residential care settings.
Second, we did not assess inter-rater reliability between the three physicians or the three 
pharmacists. Given the absence of specific recommendations and guidelines on polyphar-
macy for the ID-population this inter-rater reliability may be a problem, which should be 
addressed in future studies.
Third, reviews were performed by investigators who were not the treating physicians. 
This might have influenced the implementation rate as well as the time investment and 
financial consequences. Fourth, we did not take into account actual harm caused by the 
drug-related problems and the reduction in patient harm by the review process. Finally, 
experiences of the clients, legal representatives, professional caregivers, physicians and 
pharmacists were not systematically studied.
Notwithstanding these limitations, to our knowledge this is one of the first studies on a 
systematic multidisciplinary medication review in adults with an ID with polypharmacy. 
Besides, the study was performed in three care organizations, improving the generaliz-
ability of the results.
To conclude, this pilot study shows that medication review using the Systematic Tool 
to Reduce Inappropriate Prescribing can be used in adults with an ID to identify drug-
related problems. In this pilot study the implementation rate of interventions was low. To 
improve the implementation rate, the treating physician should be involved in the review 
process. Future studies should focus on specific adaptations to STRIP (including START 
and STOPP criteria) for this population, the cost-effectiveness, reduction of actual patient 
harm and experiences of the clients, their legal representatives and involved professionals 
using this tool.
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Appendix A START criteria
Cardiovascular system
ACE inhibitor (or Angiotensin II receptor blocker) with chronic heart failure
ACE inhibitor (or Angiotensin II receptor blocker) with diabetes mellitus with proteinuria and life expectancy >10 years
ACE inhibitor (or Angiotensin II receptor blocker) following acute myocardial infarction
Statin therapy with history of coronary, cerebral, or peripheral vascular disease, following acute myocardial infarction or with 
diabetes mellitus and LDL > 2,5 mmol/l
Antihypertensive therapy with systolic blood pressure > 160 mm Hg
Diuretics with chronic heart failure
β-blocker with stable angina pectoris, following acute myocardial infarction or stable chronic heart failure (low dose)
Salicylate with chronic atrial fibrillation and contra-indication for oral anticoagulants, with chronic stable angina pectoris or 
following acute myocardial infarction
Salicylate and/or clopidogrel with history of coronary, cerebral or peripheral vascular disease and sinus rhythm
Oral anticoagulants with chronic atrial fibrillation
Respiratory system
Inhalation of short-acting β-2 agonist or anticholinergic agent for mild to moderate asthma or COPD
Inhalation of corticosteroids for moderate to severe asthma or COPD (GOLD III-V and predicted FEV1<50% with ≥2 
exacerbations per year)
Oxygen therapy with chronic respiratory failure
Central nervous system
Levodopa with Parkinson’s disease with functional limitations or handicaps
Antidepressants with depression (according to DSM IV-criteria)
Gastro-intestinal system
Proton pump inhibitor with severe gastro-oesophagal reflux disease or peptic stricture requiring dilatation
Proton pump inhibitor with NSAID plus history of peptic ulcer, age ≥ 70 years or age 60-70 years and concomitant use of 
oral anticoagulants, oral glucocorticosteroid, SSRI or salicylate
Proton pump inhibitor with low dose salicylate and age ≥ 60 years with history of peptic ulcer, ≥ 70 years and concomitant 
use of oral anticoagulants, oral glucocorticosteroid or SSRI or age ≥ 80 years
Fiber supplement with chronic symptomatic diverticulosis with obstipation
Musculoskeletal system
DMARD with active moderate to severe rheumatoid arthritis (>4 weeks)
Bisphosphonates in patients taking glucocorticosteroids >3 months
Calcium and vitamin D supplement in patients with osteoporosis or patients with risk at osteoporosis
Endocrine system
Metformin with type 2 diabetes mellitus
ACE inhibitor or Angiotensin II receptor blocker with diabetes mellitus and nefropathy
Antiplatelet therapy with diabetes mellitus and proven cardiovascular disease
Statin therapy with diabetes mellitus and cardiovascular risk factors
Other
Laxatives with opiod use
Adapted to the Dutch practice by Vermeulen Windsant-van den Tweel et al. 17 from Gallagher et al 16
ACE, angiotensin converting enzyme; LDL, low density lipoproteins; COPD, Chronic Obstructive Pulmonary Disease; 
FEV1, forced expiratory volume; DSM IV, Diagnostic and Statistical Manual of Mental Disorders; NSAID, non-steroidal 
anti-inflammatory drugs; SSRI, Selective serotonin re-uptake inhibitors; DMARD, disease modifying antirheumatic 
drug
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Appendix B STOPP criteria
Cardiovascular system
Digoxin >0,125 mg per day with impaired renal function
Loop diuretic for ankle edema only, without clinical sings of heart failure or for hypertension
Thiazide diuretic with a history of gout
Non-selective β-blocker (propranolol, carvedilol, oxprenolol, pindolol, labetalol, sotalol) with COPD
β-blocker in combination with verapamil
Diltiazem or verapamil with chronic heart failure NYHA class III or IV
Calcium channel blockers with chronic obstipation
Salicylates >160 mg per day or without coronary, cerebral or peripheral arterial symptoms or for dizziness not related to 
cerebrovascular disease
Dipyridamol as monotherapy for secondary cardiovascular prevention
Oral anticoagulants for longer than 6 months duration for first uncomplicated deep vein thrombosis or for longer than 12 
months duration for first uncomplicated pulmonary embolus
Platelet inhibitors or oral anticoagulants with bleeding disorders
Central nervous system
Tricyclic antidepressant with dementia, glaucoma, cardiac conduction diseases, obstipation, prostatism, history of urinary 
retention or with an opiate or calcium channel blocker
Long-acting benzodiazepines for longer than 1 month duration
Antipsychotics with parkinsonism or for longer than 1 month duration
Phenothiazines with epilepsia
Parasympathicolytic anti-Parkinson drugs for extrapyridamal effects of antipsychotics
SSRIs with non-iatrogenic hyponatremia in the previous two months
First generation antihistamines for longer than one week duration
Gastro-intestinal system
Loperamide or codein for diarrhea e.c.i. or for severe infectious gastro-enteritis
Metoclopramide with parkinsonism
Proton pump inhibitor for peptic ulcer disease at full therapeutic dose >8 weeks
Butylscopolamine with chronic obstipation
Respiratory system
Theophylline as monotherapy for COPD
Systemic instead of inhaled glucocorticosteroids for maintenance therapy of moderate-severe COPD
Ipratropium or tiotropium with glaucoma
Musculoskeletal system
NSAID with moderate to severe hypertension, heart failure, chronic renal failure, for mild joint pain in ostheoarthritis for 
longer than 3 months duration, for maintenance therapy of gout for longer than 3 months duration without contraindication 
or proven inefficacy for allopurinol
Glucocorticoids as monotherapy for rheumatoid arthritis or osteoarthritis for longer than 3 months duration
Colchicin for maintenance therapy of gout for longer than 3 months duration without contraindication or proven inefficacy of 
allopurinol
Urogenital system
Bladder antimuscarinic drugs with dementia, chronic glaucoma, chronic obstipation, chronic miction problems
Selective α1-blocker for men with daily incontinence or urinary catheter in situ for longer than 2 months duration
Endocrine system
Glibenclamide for type 2 diabetes mellitus
Neuroleptics, classic antihistamines, long-acting opiates and vasodilator drugs for patients with a history of orthostatic 
hypotension
Non-selective β-blocker (propranolol, carvedilol, oxprenolol, pindolol, labetalol, sotalol) with diabetes mellitus and frequent 
hypoglycemia (>1 episode per month)
Estrogen replacement therapy with history of breast cancer or history of thromboembolism or as monotherapy, without 
prostagens, in women with intact uterus.
Mobility
Benzodiazepines, neuroleptics, first generation antihistamines and long acting opiates for those prone to falls
Vasodilator drugs in those with postural hypotension
Pain
Opiates as long term first-line treatment for mild to moderate pain or with dementia
Other
Duplicate therapy
Adapted to the Dutch practice by Vermeulen Windsant-van den Tweel et al. 17 from Gallagher et al 16
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abstraCt
background
Detailed knowledge on the acceptance rate of pharmacists’ interventions in daily clini-
cal practice and determinants for acceptance in particular is important to optimize both 
pharmacotherapy and central pharmacy services.
objective
To determine the physicians’ acceptance rate of pharmacists’ interventions from central 
pharmacy services in routine daily hospital practice and to identify determinants for ac-
ceptance.
methods
A retrospective case-control study was performed in adult patients admitted to a university 
hospital in the Netherlands. Pharmacists’ interventions, based on alerts for drug-drug in-
teractions and drug dosing in patients with renal failure, recorded in the electronic medical 
record from January 2012 until June 2013 were extracted. The primary outcome was the 
proportion of accepted interventions, which was assessed by reviewing the computerized 
physician order entry system and electronic medical records. A mixed-effects logistic model 
was used to identify determinants for physicians’ acceptance as secondary outcome. 
Results
A total of 841 interventions relating to 623 patients were included. Drug-drug interactions 
(46.4%), supratherapeutic dosages (21.8%) and requirement of additional drug therapy 
(8.7%) were the most common underlying drug-related problems.
Physicians accepted 599 interventions, resulting in an acceptance rate of 71.2%. The 
mixed-effects logistic model showed that acceptance was significantly associated with the 
number of drugs (16 to ≤20 drugs ORadj 1.88; 95% CI 1.05-3.35, >20 drugs ORadj 2.90; 
95% CI 1.41-5.96, both compared to ≤10 drugs) and severity of the drug-related problem 
(drug-related problems without potential harm ORadj 6.36; 95% CI 1.89-21.38; drug 
related with potential harm OR 6.78; 95% CI 2.09-21.99, both compared to clinically ir-
relevant problems), and inversely associated with continuation of pre-admission treatment 
(ORadj 0.55; 95% CI 0.35-0.87).
Conclusion
The majority of pharmacists’ interventions from a central pharmacy setting are accepted 
by physicians and the probability for acceptance increases for patients with an increasing 
number of medication orders and for clinically relevant problems. Interventions regarding 
continued pre-admission treatment are less likely to be accepted.
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introDuCtion
Reviewing medication orders, using clinical decision support systems (CDSS) and clinical 
rules, in order to prevent drug-related problems is part of the daily routine of clinical 
pharmacists. In general, recommendations to optimize pharmacotherapy for clinically 
relevant drug-related problems are proposed to the attending physician. The physicians’ 
acceptance rate of these pharmacists’ interventions has been shown to vary between 52% 
and 98% in previous studies.1-14 This variation can probably be explained by differences in 
setting, such as the prescribing process (computerized or handwritten), the identification 
of potential drug-related problems (using CDSS or medication review) and the way of 
communicating the intervention (by telephone, during ward rounds and/or electroni-
cally recorded). Most of these studies dealt with recommendations proposed during ward 
rounds by clinical pharmacists who were, at least partly, integrated in the medical team 
on the ward. However, in daily routine practice a substantial number of interventions 
are proposed from the central pharmacy by telephone, at least in the Netherlands and 
surrounding countries in continental Europe.
In a recent French multicentre study on pharmacists’ interventions a subset of interven-
tions was proposed by pharmacists from the central pharmacy by telephone. The accep-
tance rate in this subset of interventions was 62%.3 However, interventions were extracted 
from a national database designed for documentation and classification of interventions 
during daily medication review. Since the number of interventions varied strongly between 
pharmacists, wards and hospitals, it is likely that not all interventions were documented.
Consequently, the acceptance rate of pharmacists’ interventions from the central phar-
macy and communicated by telephone is not exactly known. Besides, little is known about 
the characteristics that determine the acceptance of pharmacist’s interventions proposed 
during daily routine from the central pharmacy.
Further insight into the determinants for acceptance could facilitate optimizing the 
central pharmacy services aimed at reducing drug-related problems and improving phar-
macotherapy. Therefore, the objectives of this study were to determine the acceptance rate 
of pharmacists’ interventions proposed by telephone from the central pharmacy, and to 
identify determinants for acceptance.
methoDs
design and setting
This study was designed as a retrospective case-control study, performed in a university 
hospital in the Netherlands. In this hospital, medication is prescribed using a computerized 
physician order entry system (Medicator®, CSC-Isoft, Leiden, The Netherlands) combined 
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with a basic clinical decision support system, based on the Dutch national drug database 
G-standard® (Z-Index, The Hague, The Netherlands). This system generates intrusive 
alerts (pop-ups) during prescribing for overdosing, duplicate therapy, allergies and drug-
drug interactions during prescribing. Nevertheless, a substantial amount of these alerts 
are handled incorrectly or overridden unconsciously by physicians.15 Reviewing alerts for 
drug-drug interactions is part of the daily routine of pharmacists in our central pharmacy. 
Besides, a clinical rule is used to assess drug dosing in patients with renal failure. All 
medication orders of patients identified by this clinical rule are reviewed by a pharmacist. 
Subsequently, for all relevant drug-related problems a recommendation to resolve the 
specific problem is proposed to the physician by telephone. All these interventions are 
recorded in a special tab of the patient’s electronic medical record.
data collection
All interventions recorded in the electronic medical record during weekdays from January 
2012 until July 2013 resulting from drug-drug interactions and the clinical rule renal 
failure were included in this study. In exceptional cases, when the treating physician could 
not be contacted, interventions were communicated by e-mail. These interventions were 
excluded from this study. Interventions for patients admitted to intensive care units, are 
usually not proposed from the central pharmacy, since a clinical pharmacist is present on 
these wards.
Data on the intervention (date, weekday, number of days since drug-related problem 
arose), the underlying drug-related problem (group of drug involved according to the 
Anatomical Therapeutic Chemical (ATC) classification system and whether the drug was 
continued from pre-admission treatment or initiated during admission), characteristics of 
the patient involved (age, gender, renal failure (glomerular filtration rate < 50 ml/min), 
number of drugs at time of intervention, length of stay at time of intervention), charac-
teristics of the pharmacist (gender and status (resident versus certified clinical pharmacist) 
and medical specialty of the prescriber were recorded. All patient data were processed 
anonymously in a protected database. Since this study did not affect patient integrity, a 
waiver of the Medical Ethical Committee was obtained for this study.
drug-related problems and interventions
Drug-related problems were classified according to the classification of Strand et al.16, that 
was adapted by Leendertse et al.17 This classification differentiates drug-related problems 
regarding the indication (additional drug therapy required or unnecessary drug therapy), 
effectiveness (ineffective drug therapy or subtherapeutic dosage), safety (adverse drug 
event or supratherapeutic dosage), drug use problems, and pharmaceutical care issues 
(monitoring, drug-drug interactions, contra-indicated drug, lifestyle, duplicate therapy). 
We added discrepancies with pre-admission treatment and administrative prescribing er-
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rors (i.e. missing information on drug, dosage or administration route or duplicate orders) 
to this classification based on our clinical experience.
The severity of drug-related problems was assessed using the NCC-MERP index, clas-
sifying severity from clinically irrelevant problems (A), that have the capacity to cause 
problems, to problems that may contribute to or result in death (I).18 We grouped these 
categories into three classes, namely clinically irrelevant drug-related problems, drug-
related problems without potential harm, and drug-related problems with potential harm, 
varying from mild temporary discomfort to death. Because of the intervention, actual 
harm was prevented and therefore potential harm was assessed, by estimating the conse-
quences of the drug-related problem, in case the pharmacist would not have intervened. 
The assessment was performed by both a hospital pharmacist/clinical pharmacologist and 
a physician/clinical pharmacologist. After their independent assessment they discussed all 
discrepancies to reach consensus.
Interventions were classified according to the classification used by Bedouch et al.19 as 
drug choice (addition of a drug, discontinuation of a drug or drug switch), dose ad-
justment (increasing the dose, decreasing the dose), monitoring (which we subdivided 
into therapeutic drug monitoring, monitoring of biochemical parameters, recording an 
electrocardiogram and other types of monitoring) and optimization of administration 
(which we defined as optimization of administration times). Based on our experience we 
added an additional class with other expected interventions, including consulting another 
specialist, reconciliation of pre-admission treatment or administrative interventions.
outcomes
Primary outcome was the proportion of accepted interventions. Acceptance of interven-
tions regarding drug choice, dose adjustments or optimization of administration was 
assessed by reviewing the computerized physician order entry system. Acceptance was 
defined as implementation of the suggested change in pharmacotherapy within 24 hours. 
For interventions regarding monitoring clinical chemical parameters, serum drug levels or 
electrocardiogram the medical record was reviewed; interventions were considered as ac-
cepted when the suggested test was performed within 7 days. Monitoring of other adverse 
drug events, for example oedema, symptoms of heart failure or myalgia, could not be 
assessed in this study.
Characteristics of the intervention (type of intervention, day of the week and number 
of days since problem arose), the underlying drug-related problem (pharmacotherapeutic 
group of drug involved according to anatomical therapeutic chemical classification system 
(ATC), severity and continuation of pre-admission treatment), characteristics of the 
patient involved (gender, age, presence of renal failure (glomerular filtration rate < 50 ml/
min), number of drugs at time of intervention and length of stay at time of intervention), 
characteristics of the pharmacist (gender and status (resident versus certified hospital 
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pharmacist)) and the medical specialty of the prescriber (medical, surgical, intensive care 
or cardiology) were included as potential determinants for acceptance.
statistical analysis
Considering an expected acceptance rate of 60% and 15 potential predictors the minimum 
required sample size was 375 interventions.
Descriptive analyses were performed using IBM SPPS Statistics version 21. A logistic 
mixed-effects logistic model was performed with R statistical software version 3.2.2 
(www.r-project.org) to investigate associations between potential determinants and 
acceptance, while accounting for multiple interventions within the same patients. The 
advantage of using mixed-effect models is that they can deal with unbalanced datasets, 
namely when the number of available observations per patient, that could be measured 
at different time points, varies. To ease the interpretation of the results, the continuous 
variables age, number of drugs and length of stay were categorized into four categories, 
based on the quartiles of their frequencies. Adjusted odds ratios, corrected for the other 
covariates, with 95% confidence intervals were calculated. A p-value <0.05 was considered 
statistically significant.
results
A total of 841 interventions, involving 623 patients were included. Characteristics of 
these interventions and patients are presented in table 1. Drug-drug interactions (46.4%), 
supratherapeutic dosages (21.8%) and requirement of additional drug therapy (8.7%) 
Table 1: Characteristics of included patients and interventions included
n (%)
Patients 623 (100.0)
Gender
Female 263 (42.2)
Male 360 (57.8)
Age in years, median [range] 64.0 [18-91]
DRPs per patient, median [range] 1.0 [1-6]
Proposed interventions 841 (100.0)
Medical specialty prescriber, n (%)
Medical wards 449 (53.4)
Surgical wards 231 (27.5)
Intensive Care Units 1* (0.1)
Cardiology Units 160 (19.0)
* At the time of proposing the intervention the patient was transferred to an intensive care unit
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were the most common underlying drug-related problems (table 2). Interventions were 
proposed most frequently for problems related to anti-infective agents (33.9%), drugs 
acting on blood and blood forming organs (13.4%) and drugs for alimentary tract and 
metabolism (12.2%) (table 3).
After consensus between two clinical pharmacologists 569 (67.7%) drug-related prob-
lems were assessed as clinically relevant problems having potential to cause patient harm, 
whereas 253 (30.1%) of the problems were unlikely to cause harm; 19 (2.3%) problems 
were considered as clinically irrelevant.
Table 2: Drug-related problems underlying pharmacists’ interventions (n=841)
Class Subclass of drug-related problem n (%)
Indication Additional drug therapy required 73 (8.7)
Unnecessary drug therapy 3 (0.4)
Effectiveness Ineffective drug therapy 8 (1.0)
Dosage too low 45 (5.4)
Safety Dosage too high 183 (21.8)
Adverse drug event 8 (1.0)
Drug use Drug use problem 13 (1.5)
Pharmaceutical
Care
Drug-drug interaction 390 (46.4)
Contra-indication 64 (7.6)
Duplicate therapy 25 (3.0)
Monitoring 11 (1.3)
Discrepancy with pre-admission pharmacotherapy 8 (1.0)
Administrative prescribing errors 10 (1.2)
Total 841 (100.0)
Table 3: Pharmacotherapeutic drug group underlying pharmacists’ interventions (n=841)
Pharmacotherapeutic group* n (%)
Alimentary tract and metabolism (A) 103 (12.2)
Blood and blood forming organs (B) 113 (13.4)
Cardiovascular system (C) 69 (8.2)
Anti-infective agentsfor systemic use (J) 285 (33.9)
Antineoplastic and immunomodulating agents (L) 33 (3.9)
Musculo-skeletal system (M) 94 (11.2)
Nervous system (N) 86 (10.2)
Othera 58 (6.9)
Total 841 (100.0)
* According to Anatomical Therapeutic Chemical (ATC) Classification System
a Includes dermatologicals (D), genito-urinary system and sex hormones (G), systemic hormonal preparations (H), 
antiparasitic products (P) and respiratory system (R).
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Table 4: Mixed-effects model showing the association between potential determinants and acceptance of pharmacists’ interventions (n=769)§
Potential determinant ORadj 95% CI p-value
Characteristics of intervention
Sequential count of interventions per patient 1.00 0.77-1.31 0.976
Type of intervention
Addition of a drug ref.
Discontinuation of a drug 1.17 0.45-3.03 0.745
Drug switch 0.57 0.25-1.27 0.168
Increasing the dose 0.75 0.26-2.16 0.588
Decreasing the dose 0.81 0.33-2.01 0.653
Therapeutic Drug Monitoring 0.47 0.16-1.41 0.179
Monitoring of biochemical parameters 0.53 0.19-1.45 0.219
Recording an electrocardiogram 0.33 0.10-1.08 0.067
Optimization of administration times 1.06 0.33-3.57 0.930
Weekday of intervention
Monday ref.
Tuesday 2.34 0.88-6.20 0.087
Wednesday 1.24 0.69-2.22 0.473
Thursday 0.83 0.45-1.50 0.532
Friday 0.94 0.51-1.74 0.852
Number of days since problem arose 0.93 0.76-1.14 0.477
Characteristics of underlying drug-related problem*
Pharmacotherapeutic group of drug involved
Alimentary tract and metabolism (A) ref
Blood and blood system (B) 0.72 0.33-1.60 0.423
Cardiovascular system (C) 1.05 0.44-2.49 0.912
Anti-infectives for systemic use (J) 0.84 0.41-1.69 0.628
Antineoplastics and immunomodulating agents (L) 0.43 0.15-1.26 0.123
Musculo-skeletal system (M) 0.58 0.26-1.30 0.185
Nervous system (N) 0.65 0.27-1.52 0.320
Other# 0.57 0.23-1.41 0.220
Severity
Clinically irrelevant drug-related problem ref.
Relevant problem without potential harm 6.36 1.89-21.38 0.002
Relevant problem with potential harm 6.78 2.09-21.99 0.001
Continuation of pre-admission treatment (hospital-initiated treatment is reference) 0.55 0.35-0.87 0.010
Patient characteristics
Female gender 0.86 0.58-1.27 0.443
Age (years)
≤ 50 0.66 0.38-1.13 0.126
51 to ≤ 65 0.91 0.50-1.65 0.759
66 to ≤ 75 0.92 0.47-1.79 0.796
> 75
Presence of renal failure 1.10 0.70-1.73 0.676
Number of drugs
≤ 10 ref.
11 to ≤ 15 1.63 0.94-2.81 0.082
16 to ≤ 20 1.88 1.05-3.35 0.033
> 20 2.90 1.41-5.96 0.004
Length of stay (days)
≤ 1 ref.
2 to ≤ 3 0.65 0.38-1.12 0.123
4 to ≤ 8 0.98 0.54-1.76 0.936
> 8 0.80 0.44-1.46 0.461
Pharmacists’ characteristics
Female gender 1.53 0.89-2.60 0.122
Residents (certified hospital pharmacists are reference) 0.95 0.62-1.45 0.804
Medical specialty of prescriber
Medical ref.
Surgical 1.14 0.71-1.84 0.589
Cardiology 1.09 0.65-1.82 0.754
Figures in bold are statistically significant
OR, odds ratio; CI, confidence interval; ref, reference; DRP, drug-related problem
§ Excluding interventions for which acceptance could not be assessed (n=51). Subsequently, interventions with missing data 
(renal function (n=11) and continuation of pre-admission treatment (n=6)) and interventions for intensive care units (n=1) 
and intervention types “consulting another specialist” (n=2) or “administrative interventions” (n=1) were excluded from the 
mixed-effects model as well.
* According to Anatomical Therapeutic Chemical (ATC) Classification System
# Includes dermal preparations (D), genito-urinary system and sex hormones (G), systemic hormonal preparations (H), antipara-
sitic products (P) and respiratory system (R).
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599 of the 841 included interventions were accepted, resulting in a physicians’ accep-
tance rate of 71.2 %, whereas 191 (22.7%) interventions were not accepted and acceptance 
could not be assessed for 51 (6.1%) interventions.
The mixed-effects logistic model used to explore associations between potential deter-
minants and acceptance is presented in table 4. Physicians’ acceptance was significantly 
associated with the number of drugs (16 to ≤20 drugs ORadj 1.88; 95% CI 1.05-3.35, >20 
drugs ORadj 2.90; 95% CI 1.41-5.96) and severity of the drug-related problem (drug-
related problems without potential harm ORadj 6.36; 95% CI 1.89-21.38; drug related 
with potential harm ORadj 6.78; 95% CI 2.09-21.99), and inversely associated with 
continuation of pre-admission treatment (ORadj 0.55; 95% CI 0.35-0.87).
DisCussion
In this study physicians’ acceptance rate of pharmacists’ interventions was 71.2% and 
the number of medication orders at time of the intervention, the continuation of pre-
admission treatment and the severity of the underlying drug-related problem were statisti-
cally significant associated with acceptance.
Our acceptance rate is somewhat higher than the acceptance rate of 62% in a subset 
of interventions proposed by pharmacists from a central pharmacy reported in a large 
multicenter study.3 Others reported even lower acceptance rates of around 50%.6, 12, 13 The 
accurate assessment of the clinical relevance of potential drug-related problems by our 
pharmacists, illustrated by the small number of clinically irrelevant alerts, could be an ex-
planation for the higher acceptance rate found in our study. In addition, other differences 
in settings, such as the communication methods, the system for detecting the drug-related 
problems and physicians’ attitude towards pharmacists, could have contributed to the 
higher acceptance rate .
It should be noted that our acceptance rate is comparable with some reported acceptance 
rates of around 60% to 80% in settings with pharmacists integrated in the medical team 
on the ward.3, 13, 20 Therefore, central checking of CDSS alerts and clinical rules could be 
considered for settings with pharmacists on the ward, so the pharmacist on the ward can 
focus on other drug-related problems, such as adverse drug reactions.
In our study, the number of medication orders of a patient at time of the intervention 
was significantly associated with acceptance. Possibly, physicians have less overview of 
a patients’ complete pharmacotherapy when the number of medication orders increases 
and they are more inclined to accept an intervention. This suggests an added value of 
pharmacists for patients with polypharmacy, which is imaginable since polypharmacy is a 
well-known risk factor for drug-related problems.21
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Furthermore, the probability for acceptance decreases if the underlying drug had been 
initiated before admission, indicating that physicians may be reluctant to change medica-
tion initiated by another physician before admission, which could be explained by the 
physicians’ confidence in the expertise of their colleagues.
Our finding that interventions for drug-related problems assessed as clinically relevant 
by two clinical pharmacologists are more likely to be accepted, suggests that physicians do 
give careful consideration to the clinical relevance of a problem, based on their knowledge 
and experience, weighing the risks and benefits for the individual patient. Apparently, 
their judgement is in accordance with the assessment of the clinical pharmacologists when 
they decide not to accept the intervention. However, this finding was based on only 19 
interventions and should be interpreted with caution.
We did not find an association between any other characteristics of the intervention, the 
underlying problem, the patient or the prescriber. In addition, we found no difference in 
acceptance rates between pharmacy residents and certified hospital pharmacists. Probably, 
physicians are not aware of the status of the pharmacists, indicating that our residents 
are well trained to review pharmacotherapy, assess the clinical relevance of drug-related 
problems and propose interventions to physicians. However, the finding that some of the 
drug-related problems were assessed as clinically irrelevant, not requiring an intervention, 
according to clinical pharmacologists, shows variability between different professionals 
during the medication review process, despite of training and use of guidelines. Still, the 
small number of irrelevant interventions shows that our pharmacists are trained to assess 
the relevance of the majority of potential drug-related problems.
In contrast to our results, Bedouch et al showed a significant association between several 
therapeutic drug classes and acceptance.3 Besides, some previous studies have shown dif-
ferences in acceptance between surgical and medical wards.3, 8, 22 We were not able to 
reproduce these results, which can probably be explained by differences in setting and the 
smaller sample size of our study.
In our setting, interventions were discussed between the pharmacist and the physician 
by telephone. Subsequently, pharmacists recorded their interventions in the patient’s 
electronic medical record. Looking at the patients included in our study, the pharmacy 
tab  in their electronic medical records was viewed 5568 times in total; 96.9% of these 
were views by pharmacists and only 3.1% by physicians. This indicates that physicians 
decisions to accept interventions are based on the discussion, since they hardly viewed the 
recorded recommendations. Previously, it has been shown that interventions that are only 
recorded electronically are much less likely to be accepted than verbally communicated 
interventions.20 This is confirmed by a recent Spanish study, in which the authors found 
a lower acceptance rate of 53% for interventions that were communicated electronically.6 
These findings support the current process of proposing interventions for the studied 
drug-related problems by telephone from the central pharmacy.
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Our study has several main limitations. First, this study is retrospective and hence rea-
sons for non-acceptance were unknown. Physicians may have valid arguments to decline a 
recommendation, but we were not able to retrieve their argumentation.
Second, the proportion of the proposed interventions of the total CDSS alerts is un-
known. This proportion could vary between different pharmacists and settings and can 
influence the acceptance rate. For example, when a pharmacist decides to propose only the 
most urgent interventions the acceptance rate could increase.
Third, this study is performed in only one hospital and the results are difficult to ex-
trapolate to other hospitals, especially when the pharmacists are more integrated on the 
ward. 
Fourth, we were not able to include any characteristics of the prescriber, except for 
specialty, whereas physicians’ status (resident versus specialist) has been associated with 
acceptance previously.20
Despite these limitations, this is one of the first studies on the acceptance of pharma-
cists’ interventions and determinants for acceptance in a setting that is representative for 
settings with central pharmacy services.
Future research should focus on reasons for non-acceptance, for which prospective 
follow-up of interventions and exploring physicians’ reasons for non-acceptance is recom-
mended, with the ultimate goal to adapt interventions for specific problems according to 
the specialty of the prescriber. Furthermore, clinical consequences of non-acceptance in 
terms of patient harm, length of stay and pharmaceutical costs need to be studied.
To improve clinical pharmacy services, we recommend pharmacists and physicians in primary 
and secondary care to discuss their responsibilities on chronic pharmacotherapy during admis-
sion of a patient, based on our finding that physicians tend to decline interventions regarding 
medication initiated before admission. It is conceivable that non-urgent recommendations are 
discussed by the pharmacist with the patients’ general practitioner. In more urgent cases cases 
pharmacists should be aware of physicians’ declined propensity to accept recommendations 
and should use more convincing arguments during the discussion. Stronger arguments should 
also be used for patients with less than 10 drugs to increase the acceptance of interventions for 
these patients. On the other hand, pharmacists could more pro-actively review the complete 
pharmacotherapy of patients using more than 15 or 20 drugs, to detect more drug-related 
problems and optimize therapy together with the physician.
In conclusion, the majority of pharmacists’ interventions from a central pharmacy set-
ting are accepted by physicians and the probability for acceptance increases for patients 
with an increasing number of medication orders and for relevant drug-related problems. 
Interventions regarding continued pre-admission treatment are less likely to be accepted. 
To optimize central pharmacy services further insight into physicians’ reasons for non-
acceptance is necessary.
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abstraCt
background
During daily routine, clinical pharmacists propose changes in pharmacotherapy to reduce 
potential drug-related problems. To optimize physicians’ acceptance of these interventions 
understanding physicians’ barriers and facilitators for acceptance is essential.
objective
To explore physicians’ barriers and facilitators for acceptance of pharmacists’ interventions.
methods
An explorative study was conducted in a university hospital, using a short questionnaire. 
Randomly selected physicians, 12 residents and 12 specialists form both medical and 
surgical wards, were asked to estimate their acceptance rate of pharmacists’ interventions. 
Subsequently, they were questioned on their perceived barriers and facilitators for ac-
ceptance and their opinion on pharmacists’ interventions.
The mean self-reported acceptance rate was calculated and Mann–Whitney U tests were 
used to compare the rates between medical physicians and surgeons and between residents 
and specialists. Reported barriers and facilitators were classified into the categories knowl-
edge, attitude and behavior.
Results
Forty-eight interviews were conducted and forty-seven interviews were analysed. The 
mean reported acceptance rate was 88.3% (95% confidence interval (CI) 83.9-92.7). The 
reported acceptance rate differed significantly between medical physicians and surgical 
physicians (81.3% versus 96.4%, p<0.001), but not between residents and specialists 
(89.6% versus 86.6%, p=0.718).
In total 47 barriers and 40 facilitators for acceptance were mentioned, mostly related to 
physicians’ attitude. Inapplicability of a recommendation to the individual patient was the 
most frequently reported barrier (n=20) and confidence in the pharmacist was the most 
frequently reported facilitator (n=16).
Conclusion
In general, physicians report to accept the majority of pharmacists’ interventions. Most 
barriers and facilitators for acceptance were related to physicians’ attitude. To optimize the 
acceptance rate to eventually reduce drug-related problems, pharmacists need to take these 
barriers and facilitators into account.
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introDuCtion
Proposing changes in pharmacotherapy to physicians to reduce potential drug-related 
problems and optimize therapy is an important part of the daily routine of clinical phar-
macists. Previous studies have shown that between 52% and 98% of pharmacists’ interven-
tions for hospitalized patients are actually accepted by the physician.1-13 The nature of the 
underlying drug-related problem, the pharmacotherapeutic group of the drug involved, 
the type of intervention, characteristics of the physician (status and medical specialty), 
characteristics of the pharmacist (the integration of the pharmacist on the ward and status) 
and the way of communicating have been associated with the acceptance rate in previous 
studies.3, 11, 14, 15 However, physicians’ reasons to decline or accept a specific intervention 
for an individual patient have not been systematically addressed in these studies.
Since pharmacists’ interventions are mainly based on evidence-based guidelines, a 
comparison with the uptake of evidence in clinical care in general could be made. It 
is recognized that implementing evidence-based guidelines and changing established 
patterns of care requires multi-strategy approaches, acknowledging potential barriers and 
facilitators on different levels of healthcare.
One of these levels is that of the individual physicians. Cabana et al. proposed a model, 
describing in detail the barriers of individual physicians that result in their non-adherence 
to evidence-based guidelines.16 These barriers can reflect physicians’ knowledge (lack of 
awareness or lack of familiarity) or attitude (lack of agreement, lack of self-efficacy, lack of 
outcome expectancy or so-called “ inertia of previous practice” (i.e. habit and routines)). 
Besides, external barriers, such as patient factors and environmental factors, can influence 
physicians’ actual behavior. Cabana’s model has been used successfully in different studies 
to explore physicians’ barriers to adhere to guidelines.17, 18 Physicians’ facilitators, their 
decision to change, are often the opposites of potential barriers.
In addition, May et al. proposed a general theory of implementation, describing the 
incorporation of the intervention into clinical practice and the social system, which 
requires workable interventions and individual and collective commitment of healthcare 
professionals and patients as well as their sustainable investments in operationalizing the 
required actions.19
Summarizing, detailed knowledge on physicians’ barriers and facilitators for change is 
thought to be essential for designing an effective intervention to improve implementation 
of evidence-based recommendations.20 Similarly, further understanding of physicians’ 
barriers and facilitators for accepting pharmacists’ interventions is important to improve 
clinical pharmacy services. Therefore, the objectives of this study were to explore physi-
cians’ barriers and facilitators for acceptance of pharmacists’ interventions in hospital care.
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methoDs
design and setting
This study was designed as an explorative questionnaire study and was performed in a uni-
versity hospital in the Netherlands. In this hospital, medication is prescribed using a com-
puterized physician order entry system (Medicator®, CSC-Isoft, Leiden, The Netherlands) 
combined with a basic clinical decision support system, based on the Dutch national drug 
database G-standard® (Z-Index, The Hague, The Netherlands). During prescribing this 
system generates intrusive alerts (pop-ups) for overdosing, allergies, contra-indications, 
duplicate therapy and drug-drug interactions, which are nevertheless often ignored by 
physicians.21 Reviewing ignored alerts for drug-drug interactions is part of the daily 
routine of clinical pharmacist in the central pharmacy. In addition, a clinical rule is used 
to assess drug dosing in patients with renal failure. For relevant drug-related problems 
detected by these alerts and the clinical rule that require a change in pharmacotherapy 
or additional monitoring, the clinical pharmacist intervenes and gives recommendations 
to the responsible physician, usually a resident, by telephone. All these interventions are 
recorded in a special form of the electronic medical patient record.
data collection and physicians
Data were collected by telephone interviews with individual physicians using an open-
ended questionnaire. Interviews were performed between July 2013 and June 2014 by 
pharmacists or pharmacy interns with randomly selected residents and attending specialists 
from medical and surgical wards. The questions were open-ended and dealt with the fol-
lowing topics: acceptance, barriers and facilitators and physicians’ opinion on pharmacists’ 
interventions (table 1). Answers to the questions were noted during the interview.
Derived from a previous study, showing that data saturation occurs within 12 in-depth 
interviews for qualitative research 22, we included 12 medical residents, 12 medical special-
ists, 12 surgical residents and 12 surgeons. Participating physicians were asked for the 
Table 1: Questionnaire on physicians’ experiences and opinions of pharmacists’ interventions
Topic Question
Acceptance, barriers and 
facilitators
1 Could you estimate which percentage of pharmacists’ 
interventions you accept?
2 What are your reasons for not accepting an intervention?
3 What are your reasons to accept an intervention?
Content 4 What’s your general opinion on the pharmacists’ interventions?
5 Do you think the interventions are relevant?
6 Are the interventions clear?
7 Are the interventions feasible?
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following characteristics: gender, medical specialty (medical versus surgical) and status 
(resident versus specialist).
Classification of barriers and facilitators
Reported barriers for acceptance (question 2) were classified by two reviewers until 
consensus was reached according to the model proposed by Cabana et al., which we 
adapted slightly to fit with pharmacists’ interventions.16 Similarly, physicians’ facilitators 
for acceptance (question 3) were defined by rewording the barriers. The adapted model is 
presented in table 2.
Table 2: Barriers and facilitators for acceptance of pharmacists’ interventions (based on the model 
of Cabana et al.16)
Level Sublevel Barrier Facilitator
Knowledge Familiarity - Lack of familiarity - Familiarity or aware of own 
lack of familiarity
Awareness - Lack of awareness - Awareness or aware of own 
lack of knowledge
Attitude Agreement with specific 
intervention
- Lack of agreement with 
interpretation of evidence
- Inapplicable to patient
- Lack of confidence in 
pharmacist
- Agreement with 
interpretation of evidence
- Applicable to patient
- Confidence in pharmacist
Agreement with 
interventions in general
- Too rigid to apply
- Not practical
- Challenge to autonomy
- Not too rigid to apply
- Practical
- No challenge to autonomy
Outcome expectancy - Physician believes that 
recommendation will not lead 
to desired outcome
- Physician believes that 
intervention will lead to 
desired outcome
Self-efficacy - Physician believes he/
she cannot perform the 
recommendation
- Physicians believes that he/
she can perform intervention
Motivation-Inertia of 
previous practice
- Habit/Routines - Not hampered by habit/
routines
Behavior Patient factors - Inability to reconcile patient 
preferences with intervention
- Patient preferences can be 
reconciled with intervention
Intervention factors - Intervention characteristics
- Presence of contradictory 
recommendations
- Intervention characteristics
- No contradictory 
recommendations
Environmental factors - Lack of time
- Lack of resources
- Organizational constraints
- Lack of reimbursement
- Perceived increase in 
malpractice liability
- Sufficient time
- Sufficient resources
- No organizational 
constraints
- No financial constraints
- No perceived increase in 
liability
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Answers to questions on general opinion about the interventions (question 4), the relevance 
(question 5), the clearness (questions 6) and the feasibility (questions 7) of interventions 
were classified as positive, neutral or negative by the same two reviewers until consensus was 
reached. The proportion of physicians with a positive opinion was calculated.
data analysis
The mean self-reported acceptance rate with 95% confidence intervals (question 1) was 
calculated, using SPSS version 21. Mann–Whitney U tests were used to compare these 
reported rates between medical physicians and surgeons and between residents and spe-
cialists. A p-value of 0.025 (after using Bonferroni correction for multiple testing) was 
considered as statistically significant.
Results
Forty-eight physicians were interviewed as planned, namely 12 medical residents, 12 
medical specialists, 12 surgical residents and 12 surgeons. One interview of a medical spe-
cialist was excluded, because the specialist did not have any experience with pharmacists’ 
interventions in our hospital. Characteristics of the physicians are presented in table 3.
self-reported acceptance rate
In total 41 physicians estimated their own acceptance rate. Some physicians, mostly 
specialists, did not answer to this question, because they had too little experience with 
the pharmacist interventions themselves. Mean self-reported acceptance rate was 88.3% 
Table 3: Characteristics of physicians
Medical specialties Surgical specialties
Residents
(n=12)
Specialists
(n=11)
Residents
(n=12)
Specialists
(n=12)
Gender
Male 5 (41.7) 5 (45.5) 7 (58.3) 12 (100)
Female 7 (58.3) 6 (54.5) 5 (41.7) 0 (0)
Medical Specialty
Internal medicine 5 (41.7) 2 (18.2)
Neurology 4 (33.3) 4 (36.4)
Cardiology 3 (25.0) 2 (18.2)
Pulmonology 0 (0) 2 (18.2)
Gastroenterology and 
hepatology
0 (0) 1 (9.1)
General surgery 5 (41.7) 8 (66.7)
Orthopedic surgery 3 (25.0) 3 (25.0)
Neurosurgery 2 (16.7) 1 (8.3)
Plastic surgery 2 (16.7) 0 (0)
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(95% confidence interval (CI) 83.9-92.7). Details are presented in table 4. The reported 
acceptance rate differed statistically significantly between medical physicians and surgical 
physicians (81.3% versus 96.4%, p<0.001), but not between residents and specialists 
(89.6% versus 86.6%, p=0.718).
barriers and facilitators
Thirty-three physicians reported one or more barriers, resulting in 47 barriers. In total 
40 facilitators for acceptance were mentioned by 36 physicians. Two barriers and two 
facilitators were excluded from analysis, since they were not interpretable.
Medical physicians reported more barriers and facilitators than surgical physicians: 34 
versus 11 barriers and 24 versus 14 barriers. Most barriers reported (n=37) were related 
to physicians’ attitude, with inapplicability to the individual patient (n=20) and lack of 
motivation due to habit and routines (n=8) as most frequently reported barriers. Facilita-
tors were mostly related to physicians’ attitude as well (n=28), including confidence in 
the pharmacist (n=16), followed by the level of knowledge (n=7). Details on barriers, 
facilitators and illustrative examples are presented in table 5.
opinion on pharmacists’ interventions
Some physicians, mainly attending specialists, couldn’t give their opinion on pharma-
cists’ interventions, because they had too little experience themselves. In total 38 of 47 
physicians (80.9%) had a positive general opinion on the interventions. Forty physicians 
(85.1%) confirmed that the interventions are relevant; 39 physicians (83.0%) confirmed 
that the interventions are clear and 38 (80.9%) of the physicians found the interventions 
feasible. On each question only one physician responded negatively. Details on physicians’ 
opinions on pharmacists’ interventions are shown in table 4.
Table 4: Physicians’ experiences on pharmacists’ interventions
Medical specialties Surgical specialties
Total
(n=47)
Residents
(n=12)
Specialists
(n=11)
Residents
(n=12)
Specialists
(n=12)
Self-reported acceptance rate (mean, 95% CI) 82.9
(74.0-91.9)
79.3
(67.4-91.2)c
96.9
(94.3-99.6)c
95.6
(88.8-102.5)d
88.3
(83.9-92.7)
Number of physicians with a positive opinion (n, %)
Pharmacists’ interventions in generale 12 (100) 7a (63.6) 12 (100) 7b (58.3) 38 (80.9)
Relevance of interventionse 12 (100) 9c (81.8) 12 (100) 7b (58.3) 40 (85.1)
Clearness of interventionsf 11 (100) 10c (90.9) 11c (91.7) 7b (58.3) 39 (83.0)
Feasibility of interventionsg 11c (91.7) 10c (90.9) 10c (83.3) 7b (58.3) 38 (80.9)
a Two physicians in this group could not answer this question
b Five physicians in this group could not answer this question
c One physician in this group could not answer this question
d Four physicians in this group could not answer this question
e One medical specialist responded negatively and one medical specialist had a neutral opinion
f One medical resident responded negatively
g One surgical resident responded negatively
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Table 5: Physicians’ barriers and facilitators for acceptance of pharmacist interventions
Barrier M-R M-S S-R S Total
Attitude Lack of agreement with interpretation of evidence 3 2 0 0 5
Examples:
“I have a different opinion”(M-R)
“The interaction is not clinically relevant (to me)” (M-S)
Inapplicable to patient 7 8 3 2 20
Examples:
“There are no other options ”(M-S)
“I do not agree with the recommendation, because the pharmacist doesn’t 
know the clinically condition.”(M-S)
Not practical 1 0 0 0 1
Physician believes that recommendation will not lead to desired outcome 1 1 0 0 2
Example:
“(I decline recommendations when they result in) suboptimal treatment” (M-R)
Physician believes he/she cannot perform the recommendation 1 0 0 0 1
Habit/Routines 1 5 2 0 8
Example:
“I have knowledge on the drug I prescribe”(M-S)
“I have experience with certain drug-drug interactions” (M-S)
Behavior Intervention characteristics 4 0 0 0 4
Example:
“(I decline recommendations) when the recommendations are not strict” (M-R)
“(I decline recommendations for) drug dosing in renal failure” (M-R)
Presence of contradictory recommendations 0 0 3 0 3
Example:
“(I decline a) recommendation for an anti-infective agent that is conflicting 
with the microbiologists’ advice” (S-R)
Organizational constraints 0 0 1 0 1
Total 18 16 9 2 45
Facilitator
Knowledge Familiarity or aware of own lack of familiarity 0 1 0 0 1
Awareness or aware of own lack of knowledge 3 2 1 0 6
Examples:
“(I accept interventions) for relevant problems I wasn’t aware of” (M-S)
“Our lack of knowledge is a reason to accept interventions” (S-R)
Attitude Agreement with interpretation of evidence 2 5 1 0 8
Examples:
“(I accept interventions) when the pharmacists holds strong argumentation” (M-S)
“(I accepted interventions) when my prescriptions differ from guidelines” (M-S)
“(I accept interventions) for relevant interactions that are clinically relevant” (M-R)
Applicable to patient 1 0 0 0 1
Confidence in pharmacist 5 1 6 4 16
Example:
“You (the pharmacists) are the experts” (M-R, M-S, S)
“You (the pharmacists) have more knowledge” (M-R, M-S, S-R, S)
Practical 1 0 0 0 1
Physician believes that intervention will lead to desired outcome 0 1 0 0 1
Not hampered by habit/routines 0 1 0 0 1
Example:
“I don’t have experience that differs from the recommendation” (M-S)
Behavior Intervention characteristics 1 0 1 1 3
Example:
“(I accept interventions for) drug-drug interactions with risk of QT-prolongation” (M-R)
Total 13 11 9 5 38
Abbreviations: M-R Medical resident; M-S Medical specialist; S-R Surgical resident; S Surgical specialist
Text between brackets was added by the author to clarify the statements.
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DisCussion
Physicians estimated their own acceptance rate of pharmacists’ interventions at 88.3% in 
this study. This self-reported acceptance rate was significantly higher for surgical physi-
cians compared to medical physicians, but there were no differences between residents 
and specialists.
The self-reported acceptance rate we found is comparable to actual established ac-
ceptance rates in previous studies, and some studies indeed showed differences in ac-
ceptance rates between different medical specialties.3, 15 The differences between surgical 
and medical physicians could probably be explained by the differences in nature of their 
professions. Medical physicians could have more knowledge on pharmacotherapy as well 
as wider experience with prescribing.23 This could result in a more balanced risk-benefit 
analysis for their patients. Indeed medical physicians mentioned the inapplicability of 
a recommendation for their patient and their own habit and routines more often as a 
barrier than surgical specialists. On the other hand, surgical physicians focus on surgical 
interventions and rarely initiate drugs outside their area of expertise.23 As a result, they 
might easier accept a pharmacists’ intervention for these drugs, relying on the expertise of 
the pharmacist.
We had expected to find a difference between residents and specialists, since residents 
often are not independent decision makers, which has been identified as a barrier for 
adherence to antimicrobial guidelines.24 In our study residents reported an acceptance 
rate comparable to the acceptance rate of their supervisors, possibly because supervisors 
trained their residents how to deal with pharmacists’ interventions.
Most reported barriers for acceptance of interventions were related to physicians’ attitude. 
The most frequently reported barriers, inapplicability to the patient and inertia to previous 
practice, stress the importance of an assessment of the clinical relevance for the individual 
patient by the pharmacists and knowledge on local protocols.
In a previous study on non-adherence to non-steroidal anti-inflammatory drug 
guidelines, limited applicability to a specific patient and inertia to previous practice were 
important barriers as well.17 The model of Cabana et al. has also been used in a study on 
health care professionals’ barriers to optimal antibiotic treatment for community-acquired 
pneumonia in hospitals.18 Again, inapplicability to the patient was frequently mentioned 
as a barrier for non-adherence to guidelines on prescribing empirical antibiotic regimens. 
Habit and routines were also mentioned, but these were not the most important barriers. 
However, more barriers on the level of knowledge were reported, with lack of awareness 
being the main barrier for dosage adjustments in renal failure. Besides, social context, 
such as social pressure, was an important barrier for adherence to almost all specific rec-
ommendations, including prescribing empirical antibiotic regimens, timely initiation of 
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therapy and switching therapy from intravenous to oral. These barriers were less important 
in our study. However, when physicians consider an intervention as not applicable to their 
patient, this may be partly caused by a lack of awareness or other barriers influencing their 
behavior.
Reported facilitators were mostly related to physicians’ attitude as well, with confidence 
in the expertise and knowledge of the pharmacist reported most frequently. Almost all 
physicians had a positive general opinion on pharmacists’ interventions and more specific 
about the relevance, clearness and feasibility of the interventions. Apparently, pharmacists 
in our hospital clearly showed their knowledge and expertise and gained confidence from 
physicians.
Our study has some limitations. First, we used short questionnaires, whereas semi-struc-
tured in-depth interviews would yield more detailed information on physicians’ barriers 
and facilitators. For example, when physicians mention inapplicability to their patient 
as reason for non-acceptance, this may in fact be due to a lack of awareness, inertia to 
previous practice or social pressure. Second, we made notes during the interviews, where 
it would have been better to audiotape the interviews to be able to transcribe physicians’ 
answers verbatim. Third, it is possible that physicians gave professionally or socially ac-
ceptable answers. For example, physicians’ barriers and facilitators may be different in real 
practice. Fourth, since barriers and facilitators probably differ between settings, our results 
cannot be extrapolated as such to other settings.16
Still, our study is one of the first to explore barriers and facilitators for accepting phar-
macists’ interventions in general. In order to get detailed information on these barriers 
and facilitators, a prospective study is recommended, using in-depth semi-structured in-
terviews by an independent interviewer on physicians’ argumentation to accept or decline 
an intervention.
To improve the acceptance rate in routine clinical practice, the identified barriers should 
be addressed. Therefore, we recommend integrating specialized pharmacists in the medical 
team on the ward, which could probably result in a more accurate assessment of the 
clinical relevance of a potential drug-related problem for an individual patient, taking into 
account habits and routines on the ward. The finding that confidence in the knowledge 
and expertise of the pharmacist was the main facilitator for acceptance seems a good 
starting point for this integration, especially on surgical wards. Physicians’ confidence in 
the knowledge of the pharmacists also stresses the importance of continuing education of 
clinical pharmacists, to maintain and update their professional knowledge.
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Based on the results of our study, we conclude that most physicians are positive about 
pharmacists’ interventions in general and that they intend to accept the majority of inter-
ventions. Most barriers and facilitators for acceptance were related to physicians’ attitude, 
with inapplicability for the individual patient as most important barrier and confidence 
in the pharmacist as most important facilitator for acceptance. Apparently, pharmacists 
gained this confidence from physicians by clearly demonstrating their expertise. To op-
timize physicians’ acceptance rate with the ultimate goal to improve pharmacotherapy, 
physicians’ main barriers and facilitators need to be addressed by clinical pharmacists.
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During drug treatment, which is an essential aspect of medical treatment, drug-related 
problems occur frequently in hospitalized patients.1 These drug-related problems include 
both medication errors and adverse drug events. Adverse drug events, in turn, are divided 
into preventable adverse drug events, i.e. patient harm caused by medication errors, and 
adverse drug reactions, caused by the intrinsic toxicity of drugs during normal use.
Previous studies identified numerous risk factors for drug-related problems on the level 
of the organization, the patient and the specific drug. This contributed to the identifica-
tion of specific patients groups at risk of drug-related problems, such as patients with renal 
failure. However, an overall risk stratification approach or prediction model to identify 
patients with a high probability of developing drug-related problems still needs to be 
developed. Since it would be efficient for clinical pharmacists to target their efforts to these 
high-risk patients and to detect adverse drug events in an early stage, additional studies on 
these topics are presented in this thesis.
Individuals with an intellectual disability may be especially at risk for drug-related 
problems, since a number of risk factors, including polypharmacy, extensive use of drugs 
acting on the central nervous system and impaired cognition are pertinent in this popula-
tion. However, the scope of these problems and interventions to reduce them are largely 
unknown in this population. Our studies in these vulnerable patients are among the first 
studies addressing these issues.
The absence of a risk stratification approach partly explains why studied interventions 
to reduce drug-related problems are mainly targeted at the organizational level. These 
interventions include optimization of the pharmaceutical care process by implementing 
computerized physician order entry in combination with (advanced) clinical decision 
support (CPOE/CDSS), integrating clinical pharmacists in medical teams and perform-
ing medication reconciliation and medication reviews. Whereas a combination of these 
strategies is operated in daily clinical practice, the evidence on the effect of them is usually 
derived from single intervention studies. Therefore, we compared the detection of drug-
related problems by medication review with computerized alerts, generated by CPOE/
CDSS in a setting where both interventions are combined.
Both CPOE/CDSS and medication review result in the detection of drug-related 
problems for individual patients, followed by recommendations to the responsible physi-
cian to resolve these problems. To optimize the effect of these interventions on quality of 
patient care, detailed knowledge on physicians’ acceptance rate of these interventions is 
important. The studies presented in part II of this thesis contribute to this knowledge.
The main objectives of this thesis were to identify determinants for medication errors 
and patients at risk for adverse drug events (part I) and to evaluate the effect of clinical 
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pharmacists’ interventions to optimize pharmacotherapy (part II) in both hospitalized 
patients and individuals with an intellectual disability.
Part I of this thesis focused on identifying determinants for medication errors and patients 
at risk for adverse drug events. We showed that in hospitalized patients medication errors 
resulting in preventable adverse drug events and medication errors without patient harm 
have some determinants in common, namely hospital, ward and anti-infective agents 
(chapter 2). This indicates that these drug-related problems share the same origin to some 
extent, mainly at the organizational level, justifying organizational interventions to reduce 
medication errors and subsequent adverse drug events.
In older individuals with an intellectual disability we found a prevalence of prescribing 
errors of 47.5%. Higher age, less severe intellectual disability, higher body mass index 
(BMI), higher frailty index, polypharmacy and drugs acting on the central nervous system 
were identified as determinants for these errors (chapter 3).
We did not find an association between adverse drug events and the number of bio-
chemical tests performed before the occurrence of adverse drug events (chapter 4), so the 
number of biochemical tests cannot be used as an alert to detect adverse drug events before 
they become manifest.
In part II of this thesis the effect of clinical pharmacists’ interventions to optimize phar-
macotherapy in both hospitalized patients and individuals with an intellectual disability 
was evaluated.
First, we showed that weekly medication review in hospitalized patients performed by 
a clinical pharmacist followed by a discussion with the treating physician on the ward, re-
sults in the detection of clinically relevant drug-related problems in hospitalized patients, 
of which only 8% are identified by CPOE/CDSS (chapter 5). In addition, CPOE/CDSS 
generates a significant number of irrelevant alerts.
Our pilot study in adults with an intellectual disability demonstrated that structured 
medication review could be used to identify drug-related problems in this specific popula-
tion (chapter 6). Drug-related problems were identified in all included adults (n=27), 
but the actual implementation of recommendations to resolve drug-related problems by 
physicians was only 15.7%.
This is in contrast with the acceptance rate of 71.2%, which we found for pharmacists’ 
interventions in hospitalized patients, based on CPOE/CDSS alerts and a clinical rule 
for dosing in renal failure. The probability for acceptance increases for patients with an 
increasing number of medication orders and for clinically relevant problems. Interven-
tions regarding continued pre-admission treatment were less likely to be accepted (chapter 
7). Our exploration of physicians’ barriers and facilitators for acceptance of pharmacists’ 
interventions (chapter 8) showed that both are mainly related to physicians’ attitude. Inap-
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plicability of the intervention to the individual patient was the most frequent mentioned 
barrier, whereas confidence in the pharmacist, which they gained by clearly demonstrating 
their expertise and knowledge, was the main facilitator for acceptance.
In this final chapter our main results are critically reviewed in a wider perspective in 
relation to the main objectives of this thesis.
Drug-relateD Problems: DeFinitions anD stuDy methoDs
In medication safety literature, different definitions for the different types of drug-related 
problems and their mutual relationship are being used, which complicates comparison of 
results between studies. In 2005 Yu et al. found as much as 119 different definitions for 
25 safety terms, including 11 definitions for adverse drug reactions, 10 definitions for 
adverse drug events and 7 for medication errors, on websites of organizations involved in 
medication safety. These definitions were not only worded differently, but also had differ-
ent functional meanings.2 For example, we used the term medication error for all errors in 
the medication process, irrespective of their outcome whereas others referred to incidents 
without harm or errors that were intercepted before reaching the patient as “near misses”.
The assessment of the causal association between drug treatment and patient harm is a 
second issue in research on adverse drug events, since it shows high inter-rater variability, 
even among experts in pharmacovigilance.3, 4 Methods that are being used for causality 
assessment are generally based on probabilistic theories derived from Bayes’ theorem, 
algorithms or expert judgment.5 However, these methods, including the Yale algorithm 
we used in our studies, are designed for pharmacovigilance and focus on adverse drug 
reactions.6 Therefore, we previously developed an algorithm, based on the simplified Yale 
algorithm, for the structured assessment of the association between medication errors and 
preventable adverse drug events, including the (potential) severity of the error.7 However, 
agreement between pharmacists and physicians on the presence of preventable adverse 
drug events and the severity of these events was only fair to moderate. And even more 
striking, physicians did not regard almost one third of the errors identified by pharmacists 
as errors at all. We hypothesized before, that physicians may assess errors from a different 
perspective given their profession, looking at the patient and his current condition first, 
followed by an assessment of the clinical relevance of an error, whereas pharmacists are 
focused on the drug and the medication process itself.7
Due to such differences between professionals, causality assessment should be a con-
sensual process, in which both physicians and pharmacists are involved, in particular for 
research purposes. In daily clinical practice (potentially) relevant drug-related problems 
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are usually discussed with a physician, who can decide to accept or decline a recommenda-
tion for an individual patient, as we showed in part II of this thesis.
Third, the method of data collection influences the detection of drug-related problems. 
For example, spontaneous reporting is prone to under-reporting and biased reporting. To 
cover all prescribing errors, including those that did not result in patient harm, a process-
based approach is recommended, for example by reviewing medication orders, retrospec-
tively or prospectively.8 The clinical context of a patient, such as renal function and other 
comorbid conditions should always be taken into account for an accurate detection of 
errors. For example, a drug-drug interaction that is well managed in an individual patient 
by measuring biochemical parameters or serum drug levels should not be considered as a 
prescribing error.
Detecting adverse drug events usually requires an outcome-based approach, such as 
more intensive and time-consuming chart review. Computerized trigger tools might be 
more efficient in identifying adverse drug events. However, Jha et al. showed that chart 
review detects more events than computerized monitoring and that the overlap between 
the methods was very small; only 12% of detected adverse drug events were identified by 
both methods.9
As a result of these different data collection methods for medication errors and adverse 
drug events, the information on drug-related problems is fragmented, since most studies 
focused either on medication errors and estimated subsequent harm (without actually 
assessing the actual occurrence of harm), or on adverse drug events with an assessment on 
the preventability of the events. To get a complete picture of drug-related problems, all 
these events should be studied together, using a combination of process-based data col-
lection methods with outcome-based data collection methods, in prospective multicenter 
studies, preferably on a national level.
Given these difficulties in medication safety research, reported rates for the different 
types of drug-related problems vary to a substantial degree.1, 10 It seems evident that clear 
and unambiguous definitions, reliable causality assessment and a uniform combination of 
process-based and outcome-based data collection methods is needed. This may seem un-
realistic, given the fact that several definitions and classifications have been proposed11-13 
that have not been uniformly adopted in patient safety research yet. Even in this thesis, 
we used different classifications for drug-related problems. In chapters 2 and 3, focusing 
on prescribing and transcribing errors, we used a process-based classification, whereas in 
chapter 5 and 7 we used a broader classification for both errors and adverse drug events.
The terminology, causality assessment and taxonomy of adverse drug reactions of the 
World Health Organization (WHO)14 is being applied worldwide in the field of phar-
macovigilance, from clinical trials to drug registration and post-marketing surveillance. 
Therefore, we believe that a comparable framework could work for drug-related problems 
as well. This framework could build on WHO’s adverse drug reaction taxonomy, expanded 
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with a definition and classification for medication errors and a procedure for assessing the 
causal relationship between a medication error and preventable adverse drug events, as we 
used in chapter 2 and 4.
Patients at risk For aDverse Drug events
As stated before, a comprehensive approach to identify high-risk patients in hospitals and 
target interventions to these patients has not been developed yet. This may be explained 
by several factors.
First, age and the number of drugs (or polypharmacy) have been most frequently as-
sociated with the occurrence of drug-related problems.1, 10, 15 Since a large proportion of 
hospitalized patients are older than 65 years and use more than five drugs, these risk fac-
tors are too unspecific for an effective risk stratification approach in hospitalized patients.
Second, the number of comorbid conditions has been frequently identified as a risk 
factor as well.16-18 This information is mainly recorded as free text in the electronic medical 
patient record, in particular in hospitalized patients. As a result, it is complicated to use 
this information to detect high-risk patients. For the same reason, we could not address the 
number of comorbid conditions in our studies. When this information would be coded 
in the electronic medical patient record, comparable to the documentation of diseases and 
intolerances by general practitioners and community pharmacists19, it would be easier to 
use in daily clinical practice, for clinical rules and for research purposes.
Third, it is possible that the studied risk factors are not specific enough to identify 
patients that will develop adverse drug events. Almost fifteen years ago, Bates et al. tried 
to develop a patient risk stratification strategy. They concluded that adverse drug events 
occur relatively randomly across hospitalized patients and that preventable adverse drug 
events are mostly the result of organizational problems.20 Possibly, a combination of single 
risk factors into one prediction model could increase the specificity to identify patients 
at risk.
To develop such a prediction model, lessons could be learned from the development of 
early warning scores, designed to identify hospitalized patients at risk of sudden cardiac 
arrest or transfer to an intensive care unit (ICU) using vital signs (e.g. blood pressure, 
heart rate, temperature, oxygen saturation, respiratory rate and level of consciousness). 
In a recent review, it was demonstrated that aggregate weighted scoring systems have the 
highest accuracy to predict cardiac arrest, ICU transfers and mortality.21 These aggregated 
scoring systems categorize parameters into different degrees, and assign point values for 
the different categories, that are summed to obtain the total risk score. The variables used 
in such a score should be easily available from the electronic medical patient record or 
medication records and could include among others ward type, presence of renal failure 
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and certain pharmacotherapeutic groups. Subsequently, the accuracy (sensitivity and 
specificity) of the tool needs to be determined and eventually the validated tool should 
preferably be completely automated and integrated in the electronic medical record.
inDiviDuals with an intelleCtual Disability: a PoPulation 
at risk
The studies we performed in individuals with an intellectual disability are among the 
first studies on drug-related problems in this population. Given the risk factors pertinent 
in this population, it is not surprising that we found a high prevalence of drug-related 
problems, often related to drugs acting on the central nervous system.
The evidence of the contribution of pharmacists to patient care in this population is 
scarce.22 This “absence of evidence” is probably not “evidence of absence” of pharmacists’ 
services in this population, as Bell et al. stated in their editorial on this topic.23 However, 
practice-based research on potentially effective interventions to reduce drug-related prob-
lems in these vulnerable patients needs to be encouraged. Structured medication review 
is one of these possible interventions, but a tool needs to be designed to detect drug-
related problems that are common in this population, including a risk-benefit analysis of 
psychotropic drugs and the possibility of withdrawal of unnecessary drugs. Furthermore, 
research is necessary to explore means to involve individuals with an intellectual disability 
in the identification of drug-related problems during structured medication review. Al-
though these patients have shown to have less understanding of their drug therapy, almost 
all patients included in a descriptive study said they wanted an understandable leaflet 
with information on their drugs, which should include the indication and side effects.43 
Physicians and pharmacists could compose these leaflets together to inform clients on 
pharmacotherapy in an understandable manner, such as Unwin and Deb did in the UK.44
oPtimizing PharmaCy serviCes to reDuCe Drug-relateD 
Problems
We showed that a clinical pharmacist can detect drug-related problems in addition to 
basic CDSS (chapter 5). A number of these drug-related problems, identified by medica-
tion review, could be detected by more advanced clinical decision support, as presented 
in table 1. Actually, the same holds for the START/STOPP-criteria used in the structured 
medication review in individuals with an intellectual disability (chapter 6). Integrating 
these problems into CPOE/CDSS could also result in earlier detection of the problems, 
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Table 1: Detecting drug-related problems using advanced clinical decision support
Class Subclass
Advanced 
CDSS 
possible? System requirements
Indication Additional drug 
therapy required
Partly For drug therapy indicated to prevent adverse drug events: 
Linking use of a drug with lacking of a drug to prevent adverse 
drug events.
For other START-criteria: Linking a drug to coded information 
on comorbid conditions or to a drug specific for a comorbid 
condition (requires coding of all comorbid conditions)
Unnecessary 
drug therapy
Partly For STOPP-criteria: Linking a drug to the absence of a 
specific comorbid condition (requires coding of all comorbid 
conditions).
Effectiveness Ineffective drug 
therapy
Partly Linking of a drug to the reason for prescribing and, where 
relevant, the duration of therapy.
For anti-infective agents drugs: linking to microbiological tests 
results.
Dosage too low Yes Integrated in basic CDSS.
Linking to age and body weight could increase the specificity 
of alerts.
Safety Adverse drug 
event
Partly Linking abnormal biochemical results with certain drugs.
Linking initiation of an antidote to use of a drug.
Linking initiation of a drug to treat an adverse drug event 
(misinterpreted as a new condition, i.e. the prescribing cascade) 
to use of a drug.
Dosage too high Yes Integrated in basic CDSS.
For dose-checking in renal failure: Linking to laboratory results.
Linking to age and body weight would increase the specificity 
of alerts, especially in pediatric and older patients.
Drug use Drug use 
problem
Partly Information of the patient is required to detect these problems.
Use of an enteral feeding tube, documented as coded 
information, could be detected by CDSS.
Pharmaceutical 
care
Monitoring Partly Linking test results, such as biochemical parameters, 
electrocardiogram recordings, blood pressure measurements, 
to initiation and use of a drug.
Drug-drug 
interaction
Yes Integrated in basic CDSS.
Linking with laboratory results and patient characteristics (age) 
could increase the specificity of alerts.
Contra-indicated 
drug
Partly Depending on coded documentation of comorbid conditions, 
allergies and intolerances in the electronic medical patient 
record. This includes some STOPP-criteria.
Lifestyle No Information of the patient is required to obtain this information
Duplicate therapy Yes Integrated in basic CDSS.
Discrepancy with 
pre-admission 
pharmacotherapy
Partly Linking of prescription data between healthcare settings, e.g. a 
national electronic patient record.
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namely during or immediately after prescribing, leaving room for tailoring pharmaco-
therapy to patients’ preferences during a medication review.24
In addition, advanced CDSS can also reduce the number of clinically irrelevant alerts of 
basic CDSS. As shown by Helmons et al. this can result in a significant reduction of the 
number of alerts and time spent on checking of alerts for drug-drug interactions.25
Still, for other drug-related problems, such as the identification of unnecessary drugs 
and the detection of certain adverse drug events, a clinical pharmacist integrated in the 
medical team, who can perform medication reviews, is recommended. This pharmacist 
could combine the computer-based alerts and additional problems, to prioritize the prob-
lems and to compose a pharmaceutical care plan.
Pharmacy services could be optimized further by improving the acceptance rate of 
pharmacists’ interventions for individual patients. Physicians may have valid arguments 
to neglect pharmacists’ recommendations, since prescribing the right drug to the right 
patients includes balancing the potential benefits and risks of a treatment. Besides, pa-
tients’ preferences and costs should be taken into account.26 This implies that pharmacists 
should include this information, obtained from the physician, nurse and the patient or the 
electronic medical patient record, in their assessment of the clinical relevance in order to 
increase the acceptance rate of their advices.
In chapter 5, the acceptance rate of pharmacists’ interventions after medication review 
was only 56%. However, when we look at the interventions that were considered clini-
cally relevant by the physicians, the acceptance rate was 86% (247 of 286 interventions). 
This indicates that an accurate assessment of the clinical relevance by pharmacists could 
increase the acceptance rate, which we indeed showed in chapter 7.
The assessment of drug-related problems in daily practice usually requires detailed in-
formation on a patients’ medical history and current conditions and thus depends largely 
on the available documentation in the electronic medical record. As a result, it can be 
time-consuming to retrieve the required information from these records. During the study 
described in chapter 5, we learned that it is more efficient to discuss the identified po-
tential drug-related problems with the attending physician, explaining the relatively large 
number of irrelevant alerts. However, an increasing number of irrelevant interventions 
could compromise physicians’ confidence in the knowledge and skills of pharmacists.
Besides, most drug-related problems in the study presented in chapter 5 were potentially 
unnecessary drugs. Recommendations to withdraw a drug could be more difficult to ac-
cept, especially regarding medication initiated before admission by another physician. 
This is supported by our finding in chapter 7 that interventions regarding medication 
initiated before admission are less likely to be accepted. This was confirmed in a recent 
study by Poots et al, showing that junior doctors find it difficult to stop medication during 
a medication review at hospital admission and considered it as a responsibility of the 
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general practitioner or certified specialist.27 Remarkably, physicians did not report that 
they believed they were unable to change medication initiated by another physician at all 
in our study (chapter 8). Apparently this is not the first barrier that crosses their minds.
Case management
The difficulties with medication initiated before admission raise the question who is 
responsible for chronic pharmacotherapy in patients treated by more than one physician. 
Therefore, every patient needs a case manager, regularly reviewing all pharmacotherapy. In 
primary care, the general practitioner fulfills this role and in organizations for individuals 
with an intellectual disability, the physician specialized for individuals with an intellectual 
disability is this case manager. Medication reviews should be performed by the desig-
nated case manager in close collaboration with the patients’ pharmacists. During hospital 
admission, clinical pharmacists integrated in the medical team, could partly fulfill the 
role of pharmacotherapeutic case manager. We suggest that they discuss the most urgent 
interventions with the responsible resident or attending physician. However, non-urgent 
interventions could be discussed with the designated case manager in primary care. Of 
course, in all settings prescribers who initiated the therapy should be consulted when 
necessary and should be informed about any changes in therapy.
Crossing barriers to reDuCe Drug-relateD Problems: 
PharmaCist PresCribing
Physicians’ most important facilitator for actually accepting pharmacists’ interventions is 
their confidence in the knowledge and skills of the pharmacists. The desire to make greater 
use of these skills and specialization of pharmacists was the main argument for authoriz-
ing pharmacists for prescribing in the United Kingdom.28 Therefore, the confidence of 
physicians could be a good starting point for exploring pharmacist prescribing in the 
Netherlands, which could partly cross the barriers of physicians’ acceptance, including the 
reluctance of physicians to change medication initiated by another physician. In addition, 
it could be seen as a natural extension of the pharmacist’s role in advising physicians in 
good prescribing.
Pharmacist prescribing is currently allowed in Canada, the United States and the United 
Kingdom (UK).29 Since most experience with pharmacist prescribing is reported from the 
UK, we will discuss the two British models for pharmacist prescribing, supplementary 
prescribing and independent prescribing, in more detail.
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Pharmacist supplementary prescribing (or dependent prescribing) was permitted in the 
UK since 2003. Supplementary prescribing is defined as “a voluntary partnership between 
the responsible independent prescriber (a physician or a dentist) and a supplementary 
prescriber, to implement an agreed patient specific clinical management plan with the 
patient’s agreement particularly, but not only, in relation to prescribing for a specific 
non-acute medical condition or health need affecting the patient.”28 The clinical manage-
ment plan must mention the pharmacotherapeutic groups that may be prescribed by the 
pharmacist. To acquire prescribing rights a course needs to be completed, which includes 
a period of learning in practice, supervised by a mentor, who is usually the independent 
prescriber with whom the dependent prescriber will form a prescribing relationship.29
Subsequently, independent prescribing was introduced in 2006. An independent 
prescriber is defined as a practitioner responsible for the assessment of patients with 
undiagnosed or diagnosed conditions and for decisions about the clinical management 
required, including prescribing.28
In their review on prescribing pharmacist activities in the UK, published in 2007, Tonna 
et al. state that especially the practice of hospital pharmacists, who are part of a multi-
disciplinary patient team and have access to medical records, lends itself for pharmacist 
prescribing. However, the impact of pharmacist prescribing on the quality of patient care 
has not been well established.28
Especially within specific protocols pharmacist prescribing could be useful, for example: 
dosage adjustments based on therapeutic drug monitoring, dosage adjustments in patients 
with renal failure, clinical nutrition, medication reconciliation, discharge planning and 
adherence to guidelines.30-32
Barriers for implementing pharmacist prescribing were identified in different studies 
and included financial and organizational problems, general lack of awareness of the 
pharmacists role, and fear of pharmacists’ vulnerability to conflicts of interests with phar-
maceutical companies.28, 29, 33 These barriers need to be addressed before implementing 
pharmacist prescribing. For example, prescribing pharmacists should not be involved in 
drug purchasing and negotiations with companies to prevent conflicts of interests.
Besides, medical staff members expressed their concerns on pharmacists’ limited patient 
contact and limited diagnostic skills, compared to nurses, to ensure safe prescribing.28 
This is an important concern, especially in Dutch hospital settings, where the integration 
of clinical pharmacists on the wards is progressing slowly. On the other hand, a recent 
study in the UK showed that prescribing error rates for pharmacist prescribers did not 
significantly differ from certified specialists.34
In the Netherlands, prescribing is a reserved act for physicians, dentists and midwives. 
Since 2014, nurse practitioners and physician assistants are authorized to prescribe low 
risk medication, within their field of expertise and according to current guidelines. 
This model could be extended to clinical pharmacists. There are some examples from 
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the Netherlands, where pharmacists already have a role in continuing medication in the 
medication reconciliation process at admission and prescribing upon discharge, actually 
acting as dependent prescribers.30-32
However, to ensure safe prescribing detailed knowledge on the patient, his current 
conditions and medical history and his preferences are essential. Besides, to be able to pre-
scribe in concordance with the patient, patient contact is required. Therefore, additional 
training in communication with patients, clinical judgment and decision making would 
be required. Last but not least, patients’ perspectives on pharmacist prescribing need to be 
taken into account.
eFFeCts oF interventions on morbiDity, mortality anD 
healthCare Costs
Although, improving clinical pharmacy services can result in the detection and reduction 
of drug-related problems and is likely to benefit the patients, the impact on clinically 
relevant end points, including morbidity, hospitalizations and mortality, as well as the 
cost-effectiveness has not been unambiguously demonstrated.
For example, integrating pharmacists in the medical team on hospital wards did result 
in shorter length of stay and a reduction in costs in some studies.35 However, in a recent 
Dutch multicenter randomized trial, the effect of a ward-based pharmacy team, perform-
ing medication reconciliation and regular medication reviews, did not result in a reduction 
of length of stay and number of complications in surgical patients.36 Actually the same 
holds for medication review, of which the effect on mortality and hospital admissions in 
both hospitalized patients and primary care setting remain uncertain.37, 38
To give some possible explanations for these conflicting results we would like to refer 
to the gold standard to show the efficacy of a new drug: comparison of the new drug to 
the current standard of care in double-blind controlled randomized trials. In our field 
of research, blinding patients and healthcare professionals to pharmacists’ interventions 
is impossible, which could lead to bias in the interpretation of the results of performed 
studies. Randomization on the level of wards or hospitals, in case of multicenter studies, is 
possible. However, differences in settings, such as the CPOE/CDSS used, could interfere 
with the studied intervention. This is why pre-post interventions designs are often used. 
However, this method has its own limitation, namely that other changes in the care process 
or the introduction of new treatments could influence the outcomes.
More important, patients included in drug-efficacy trials need to comply with strict 
inclusion criteria to obtain a homogeneous sample and the study protocol controls all 
important variables so only the intervention can impact the outcomes. However, pharma-
cists’ interventions, which are heterogeneous themselves, are targeted to a heterogeneous 
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population, since for example age, the current condition, comorbid conditions and drug 
use differs between patients. And, although pharmacotherapy is an important part of 
medical treatment, patients undergo many other types of interventions, especially during 
hospital admissions, such as surgery or renal replacement therapy, that probably have a 
larger impact on morbidity and mortality than pharmacists’ interventions to optimize 
pharmacotherapy.
other interventions to reDuCe Drug-relateD Problems
In this thesis we focused on improving clinical pharmacy services to optimize pharmaco-
therapy. In addition, other organizational measures and national policies could contribute 
to reduction of drug-related problems. Some examples will be discussed briefly below.
patient participation in medication safety
Involving patients and their relatives in their own safety could contribute to reduce drug-
related problems and optimize pharmacotherapy, since they are the one constant factor 
within the entire care process. This requires patient empowerment, defined as the process 
by which patients gain more control over their health and health care.39 Empowered 
patients understand their health conditions and the need for lifestyle changes, can partici-
pate in decision-making, can make informed choices, are able to ask questions, take their 
responsibility for their health and make use of available information.40
For involvement in patient safety, patients should at least be aware of their responsibil-
ity to keep track of their current pharmacotherapy, history of allergies and experienced 
adverse drug reactions. This is especially important for medication reconciliation at transi-
tions between care settings, to which patients can add essential information.41
Besides, patients should be made aware that they should ask questions whenever they 
have doubts on their medication, such as dose omissions or discrepancies with pre-admis-
sion treatment during hospitalization. Clinical pharmacists could play a role in supporting 
patients to ask questions on their pharmacotherapy.42
education of healthcare professionals
Since lack of information on drugs, insufficient pharmacological knowledge and insuf-
ficient training are identified as risk factors for medication errors and preventable adverse 
drug events, education of healthcare professionals on good prescribing and reducing drug-
related problems is extremely important. 1, 45 46 47, 48 Recently, Ashcroft et al. showed that 
error rates are higher for all physicians during their post-graduate or specialty training pro-
gram compared to certified specialists. On the other hand, certified specialists made more 
serious prescribing errors.34 Therefore, undergraduate education, postgraduate training 
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and continuous professional development is required to improve prescribing skills. First, 
practical prescribing skills need to be assessed before graduating, comparable to the UK, 
where a national assessment of prescribing competence has been introduced for all stu-
dents.49 After graduation, academic detailing (face-to-face education by trained healthcare 
professionals) has been shown to have a positive effect on the quality of prescribing.50, 51 In 
addition, formally discussing and providing constructive feedback on errors can improve 
learning from these errors.52 Clinical pharmacists, integrated in medical teams, could play 
a role in this continuing education of physicians and nurses.
Physicians referred to clinical pharmacists as experts in knowledge on drugs and the 
medication process our study. However, the postgraduate residency program for clinical 
pharmacists in the Netherlands should focus more on the patient and collaboration with 
other professionals to improve their clinical skills.
Summarizing, our results show that it is difficult to select patients at risk of adverse drug 
events, but there are opportunities for clinical pharmacists to improve their services to 
detect drug-related problems and improve pharmacotherapy. This leads us to the following 
recommendation for patient care.
reCommenDations For Patient Care
To optimize pharmacotherapy in daily patient care, we have the following recommenda-
tions:
- Clinical decision support and clinical rules should be optimized to detect drug-related 
problems and to reduce the number of irrelevant alerts.
- Clinical pharmacists should be integrated with medical teams to focus on drug-related 
problems and adverse drug events in particular, using medication review, in both 
hospitalized patients and individuals with an intellectual disability. These pharmacists 
could also contribute to patient empowerment and education of physicians and nurses.
- Pharmacists should be aware of physicians’ barriers for acceptance of pharmacists’ in-
terventions in daily routine, including an accurate assessment of the clinical relevance 
for the individual patient.
As in all research, our studies leave many questions unanswered which future research 
should look into.
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reCommenDations For Future researCh
To solve the remaining issues on drug-related problems and the effects of interventions:
- A taxonomy for drug-related problems, including definitions and assessment methods 
should be developed and implemented on a worldwide level to obtain comparable 
results from medication safety studies.
- Studying the effect of interventions to optimize pharmacotherapy in individuals with 
an intellectual disability, including structured medication review designed to detect 
common drug-related problems in this vulnerable population, should be stimulated.
- The possibilities for pharmacist prescribing within their field of expertise and accord-
ing to specific protocols, should be explored.
ConClusions
Summarizing, we conclude that it is difficult to detect patients at risk for drug-related 
problems, especially for adverse drug events. Until better prediction models are devel-
oped, interventions to optimize pharmacotherapy should be targeted at the organizational 
level. These interventions include optimization of computerized physician order entry 
combined with advanced clinical decision support and integration of pharmacists in the 
medical team. These pharmacists can perform medication reviews to detect drug-related 
problems, both in hospitalized patients and individuals with an intellectual disability.
Both computerized physician order entry with clinical decision support and medication 
review result in patient-specific recommendations to optimize pharmacotherapy. Physi-
cians’ acceptance of these interventions could be improved, taking physicians’ barriers into 
account. Extension of pharmacists’ role to prescribing pharmacotherapy is an interesting 
opportunity to optimize pharmacotherapy that should be explored.
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Geneesmiddelen zijn onmisbaar bij de behandeling van ziektes, het verlichten van sympto-
men en het voorkomen van toekomstige complicaties. Behandeling met geneesmiddelen, 
oftewel farmacotherapie, heeft helaas een keerzijde; er kunnen zogenaamde geneesmiddel-
gerelateerde problemen optreden. Deze problemen omvatten enerzijds medicatiefouten, 
die gemaakt worden in het proces van voorschrijven tot toedienen en waarvan naar schat-
ting maximaal 10% tot vermijdbare schade bij de patiënt leidt. Anderzijds kunnen bij juist 
gebruik van geneesmiddelen bijwerkingen optreden. Deze bijwerkingen en vermijdbare 
schade worden samen geneesmiddelgerelateerde schade genoemd.
Geneesmiddelgerelateerde problemen komen frequent voor bij patiënten opgenomen 
in ziekenhuizen. In eerdere onderzoeken zijn verschillende risicofactoren geïdentificeerd 
voor het optreden van dergelijke problemen. Dit heeft bijgedragen aan de identificatie van 
patiënten met een verhoogd risico, maar er is nog geen predictiemodel voorhanden om 
patiënten met het hoogste totale risico te identificeren. Een dergelijk predictiemodel zou 
apothekers kunnen helpen hun aandacht te richten op patiënten met de meeste kans op 
geneesmiddelgerelateerde problemen. Daarom hebben wij een aantal aanvullende onder-
zoeken gedaan naar risicofactoren voor geneesmiddelgerelateerde problemen bij patiënten 
in het ziekenhuis.
Een aantal risicofactoren voor geneesmiddelgerelateerde problemen, zoals polyfarmacie 
(het gebruik van vijf of meer geneesmiddelen), een verminderd denkvermogen en het 
gebruik van geneesmiddelen werkend op het zenuwstelsel, komen frequent voor bij 
mensen met een verstandelijke beperking. De frequentie van geneesmiddelgerelateerde 
problemen in deze patiëntengroep is echter niet goed onderzocht en daarom wordt daar in 
dit proefschrift aandacht aan besteed.
Interventies om geneesmiddelgerelateerde problemen te voorkomen zijn tot op heden 
voornamelijk gericht op optimalisatie van het medicatieproces. Een voorbeeld daarvan 
is de implementatie van elektronische voorschrijfsystemen met beslissingsondersteuning. 
Deze beslissingsondersteuning genereert signalen tijdens het voorschrijven van genees-
middelen die mogelijk een probleem kunnen zijn bij de betreffende patiënt, bijvoorbeeld 
in geval van overdosering, een allergie of een wisselwerking met een ander geneesmiddel.
Daarnaast kan het integreren van apothekers in medische behandelteams op ver-
pleegafdelingen en het uitvoeren van medicatiereviews bijdragen aan het detecteren en 
verminderen van geneesmiddelgerelateerde problemen. Hoewel elektronische voorschrijf-
systemen en het integreren van apothekers in behandelteams in de praktijk naast elkaar 
worden toegepast, is het effect van deze organisatorische maatregelen veelal vastgesteld in 
onderzoeken gericht op een afzonderlijke maatregel. Daarom hebben wij een onderzoek 
uitgevoerd om de detectie van geneesmiddelgerelateerde problemen met behulp van medi-
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catiereview door een ziekenhuisapotheker, die nauw betrokken is bij het behandelteam, te 
vergelijken met de automatische signalen afkomstig van beslissingsondersteuning.
Zowel beslissingsondersteuning als medicatiereview resulteert in detectie van geneesmid-
delgerelateerde problemen voor individuele patiënten, resulterend in een advies van een 
apotheker aan de behandelend arts. Om het effect van deze interventies van apothekers 
te optimaliseren is het van belang om inzicht te krijgen in de mate waarin artsen deze 
interventies daadwerkelijk accepteren en hun argumentatie daarvoor.
In dit proefschrift richten wij ons op patiënten opgenomen in ziekenhuizen en mensen 
met een verstandelijke beperking. Ons eerste doel is het identificeren van risicofactoren 
voor medicatiefouten en patiënten met risico op geneesmiddelgerelateerde schade (deel I). 
Daarnaast evalueren we interventies van apothekers om farmacotherapie te optimaliseren 
(deel II).
Deel i risiCoFaCtoren voor meDiCatieFouten en 
geneesmiDDelgerelateerDe sChaDe
In hoofdstuk 2 hebben we aangetoond dat medicatiefouten die niet tot schade leiden en 
medicatiefouten die resulteren in schade bij opgenomen patiënten een aantal dezelfde 
risicofactoren hebben, namelijk: het ziekenhuis, de verpleegafdeling en middelen tegen 
infecties. Dit geeft aan dat deze problemen gedeeltelijk dezelfde oorsprong hebben en 
rechtvaardigt organisatorische maatregelen voor de reductie van medicatiefouten en 
schade die daar uit voort kan vloeien.
Bij personen met een verstandelijke beperking hebben we een prevalentie van voor-
schrijffouten van bijna 48% gevonden (hoofdstuk 3), vergelijkbaar met ouderen in de 
algemene populatie. Een hogere leeftijd, een minder ernstige verstandelijke beperking, een 
hogere body mass index, een hogere mate van kwetsbaarheid, gebruik van geneesmiddelen 
werkend op het zenuwstelsel en polyfarmacie verhogen de kans op voorschrijffouten.
In de dagelijkse praktijk wordt geneesmiddelgerelateerde schade niet altijd herkend. 
De arts zou wel een vermoeden kunnen hebben dat er iets met de patiënt aan de hand is 
en dit ‘niet-pluisgevoel’ leidt doorgaans tot extra diagnostiek. In hoofdstuk 4 hebben we 
daarom onderzocht of er een verband is tussen het aantal uitgevoerde klinisch chemische 
bepalingen en het optreden van geneesmiddelgerelateerde schade bij opgenomen patiën-
ten. Wij hebben dit verband niet kunnen aantonen en daarom kan het aantal uitgevoerde 
bepalingen niet worden gebruikt om geneesmiddelgerelateerde schade vroegtijdig op te 
sporen.
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Deel ii interventies van aPothekers om FarmaCotheraPie 
te oPtimaliseren
In hoofdstuk 5 hebben we laten zien dat apothekers die wekelijks een medicatiereview 
uitvoeren bij opgenomen patiënten geneesmiddelgerelateerde problemen kunnen identi-
ficeren. Slechts 8% van deze problemen wordt door de huidige beslissingsondersteuning 
gedetecteerd. Bovendien genereert de beslissingsondersteuning meldingen die niet relevant 
zijn.
Ons pilot-onderzoek bij mensen met een verstandelijke beperking (hoofdstuk 6) laat 
zien dat een medicatiereview ook bij deze patiënten kan worden gebruikt om geneesmid-
delgerelateerde problemen te identificeren. Bij alle 27 onderzochte patiënten vonden wij 
tenminste één probleem. In dit onderzoek werd niet meer dan 16% van de aanbevelingen 
ter verbetering van de problemen door de arts geaccepteerd. Dit is waarschijnlijk te verkla-
ren doordat de artsen niet direct bij het review-proces betrokken waren.
Bij opgenomen patiënten blijkt de acceptatiegraad van interventies van apothekers, 
naar aanleiding van beslissingsondersteuning en een klinische beslisregel voor patiënten 
met een nierfunctiestoornis, aanzienlijk hoger, namelijk meer dan 70% (hoofdstuk 7). 
De kans op acceptatie neemt toe bij een toenemend aantal gebruikte geneesmiddelen 
en is groter voor klinisch relevante problemen. Interventies die betrekking hebben op 
medicatie die reeds voor opname gebruikt wordt, worden minder snel geaccepteerd. Om 
meer inzicht te krijgen in de argumenten van artsen om interventies van apothekers al dan 
niet te accepteren zijn 48 artsen geïnterviewd over dit onderwerp (hoofdstuk 8). Hieruit 
blijkt dat zowel barrières als faciliterende factoren voor acceptatie gerelateerd zijn aan de 
attitude van de arts. Het niet van toepassing zijn van een interventie op een individuele 
patiënt werd het meest genoemd door artsen als reden om een interventie niet te ac-
cepteren. Vertrouwen in kennis en kunde van de apotheker was de meest genoemde reden 
om interventies daadwerkelijk te accepteren. Dit vertrouwen kan dienen als basis voor 
verdergaande samenwerking tussen artsen en apothekers om geneesmiddelgerelateerde 
problemen te voorkomen.
aanbevelingen
Op basis van de resultaten van de onderzoeken in dit proefschrift, hebben wij de volgende 
aanbevelingen voor de patiëntenzorg:
- Beslissingsondersteuning en klinische beslisregels moeten worden geoptimaliseerd om 
geneesmiddelgerelateerde problemen te detecteren, met zo min mogelijk irrelevante 
meldingen.
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- Apothekers, met aandacht voor geneesmiddelgerelateerde problemen en bijwerkingen 
in het bijzonder, moeten meer worden geïntegreerd in medische behandelteams, zowel 
in ziekenhuizen als instellingen voor mensen met een verstandelijke beperking. Medi-
catiereview kan daarbij gebruikt worden voor het detecteren van problemen.
- Apothekers moeten zich bewust zijn van de argumenten van artsen om interventies 
al dan niet te accepteren. Dit betekent onder andere dat de klinische relevantie voor 
de individuele patiënt goed moet worden ingeschat door de apotheker, voordat de 
interventie aan de arts wordt voorgelegd.
Natuurlijk roept ons onderzoek nieuwe vragen op en blijven er vragen onbeantwoord, 
resulterend in de volgende suggesties voor vervolgonderzoek:
- Er moet een wereldwijde taxonomie voor geneesmiddelgerelateerde problemen ont-
wikkeld worden om resultaten van verschillende onderzoeken te kunnen vergelijken. 
Deze taxonomie moet de definities van de verschillende begrippen bevatten plus een 
methode om de relatie tussen schade en een geneesmiddel te kunnen beoordelen.
- Onderzoek naar effectieve interventies om farmacotherapie te optimaliseren bij men-
sen met een verstandelijke beperking, moet worden gestimuleerd.
- De mogelijkheden voor beperkte voorschrijfbevoegdheid voor apothekers moeten 
onderzocht worden. Een dergelijke voorschrijfbevoegdheid, vergelijkbaar met de 
bevoegdheid voor verpleegkundig specialisten en physician assistants, is een logische 
uitbreiding van de rol van apothekers in het adviseren van voorschrijvers over farma-
cotherapie.
ConClusies
Ondanks dat wij onafhankelijke risicofactoren voor geneesmiddelgerelateerde proble-
men gevonden hebben, blijft het moeilijk de patiënten met het hoogste totaal risico op 
geneesmiddelgerelateerde problemen te selecteren. Totdat een effectief predictiemodel 
beschikbaar is, zijn interventies op organisatorisch vlak nodig om farmacotherapie te 
optimaliseren. Deze maatregelen omvatten verbetering van de elektronische voorschrijf-
systemen met beslissingsondersteuning en integratie van apothekers in behandelteams die 
medicatiereviews uitvoeren, zowel in ziekenhuizen als instellingen voor mensen met een 
verstandelijke beperking.
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De acceptatie van interventies om geneesmiddelgerelateerde problemen te verbeteren 
bij individuele patiënten kan worden verbeterd, rekening houdend met de barrières voor 
acceptatie van artsen. Daarnaast is een beperkte voorschrijfbevoegdheid voor apothekers 
een interessante mogelijkheid voor het optimaliseren van farmacotherapie.
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Tilburg heb ik met heel veel plezier met je samengewerkt. Het laatste jaar heb je me op 
de juiste momenten gemotiveerd of juist afgeremd. Ik heb grote bewondering voor jouw 
efficiëntie en parate kennis; ik leer nog iedere dag van je. Dank voor je inspiratie, je humor, 
snelle en scherpe commentaren en vooral voor alle kansen die je me gegeven hebt. Ik had 
me geen betere copromotor kunnen wensen.
Arnold, jouw blik op het grote geheel is bijzonder waardevol geweest. Onze maandelijkse 
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openheid en eerlijkheid daarin en ben je enorm dankbaar voor je vertrouwen en je steun.
Beste Floor, na een overleg met jou had ik meestal meer vragen dan daarvoor. Maar juist 
daarom, door jouw andere invalshoek, heb je een bijzondere bijdrage geleverd aan mijn 
onderzoek; heel erg bedankt daarvoor. En onze toevallige ontmoeting in Parijs is onver-
getelijk.
Beste Peter, enorm bedankt voor de kans die je me hebt gegeven om naast mijn baan als 
ziekenhuisapotheker dit onderzoek uit te kunnen voeren en voor je steun en begrip, met 
name in het laatste jaar.
Prof.dr. P.A.E. Sillevis Smitt, prof.dr. T. van Gelder, prof.dr. B.D. Franklin, prof.dr. H.M. 
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thank you all for your time and critical assessment of this thesis.
Annemieke en Edwin, bedankt voor jullie enorme inzet en het werk dat jullie hebben 
afgeleverd. Ik heb jullie met heel veel plezier begeleid.
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Ryan, wat een klus was het, die labtesten. Heel erg bedankt voor je tomeloze inzet hiervoor 
en alle gezelligheid. Louise, dank voor je bijdrage aan de interviews; het heeft naast een 
hoofdstuk hele waardevolle informatie opgeleverd voor onze dagelijkse praktijk.
Beste Heleen, Mirka, Susan en Bart, heel erg bedankt voor de fijne samenwerking. Jullie 
hebben mijn ogen geopend voor de bijzondere populatie van mensen met een verstan-
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Ik wil graag alle medeauteurs bedanken voor hun bijdrage en waardevolle commentaren.
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theker, ben ik een aantal personen meer dan dankbaar.
Beste Toine, jij bent een grote bron van inspiratie voor me als onderzoeker en als zieken-
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je aansporing in het dankwoord van jouw proefschrift, die me aan het denken heeft gezet.
Alle artsen en verpleegkundigen van de afdelingen Geriatrie en Interne Geneeskunde 
(in Waalwijk) van het TweeSteden ziekenhuis: bedankt voor jullie medewerking en jullie 
warme welkom. Ik heb zo veel bewondering voor jullie toewijding. De tijd die ik als 
jonge onderzoeker bij jullie heb doorgebracht is, zonder dat ik het toen door had, van 
onschatbare waarde geweest voor mijn klinische ervaring.
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